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ABSTRACT 
 
JARROD S. JOHNSON:  Virion Components and Subcellular Parameters that Impact 
Trafficking, Nuclear Targeting, and Infection of Adeno-Associated Virus 
(Under the direction of R. Jude Samulski) 
 
 
Adeno-associated virus (AAV) is an attractive vehicle for gene therapy.  Serotypes of 
this non-pathogenic parvovirus exhibit both diversity in cellular tropism and long-term 
transgene expression; however, their medical application has been limited due to inefficient 
transduction of target tissues.  In this dissertation we have explored how virion components 
and host factors at the subcellular level help determine whether a vector can transduce a 
target cell. Transduction is only successful when virions attach to host cell receptors, 
internalize into an endosome, escape from a subcellular compartment, traffic through the 
cytosol, target the nucleus, and release their genomes during favorable conditions.  Prior to 
this work, it was unclear if capsids could enter the nucleus intact during infection.  
Additionally, specific mutations in the two larger capsid proteins, VP1 and VP2, were known 
to reduce AAV infectivity.  These proteins possess unique N-termini that contain a putative 
phospholipase A2 domain and potential nuclear localization signals, but their roles in 
directing subcellular trafficking have not been well defined. Moreover, induction of cellular 
stress by genotoxic agents, heat shock, or proteasome inhibition, dramatically increases the 
transduction efficiency of AAV, although the mechanisms responsible for this effect remain 
unknown.  Therefore, we set out to build upon this foundation of AAV subcellular biology 
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and hypothesized that AAV virions preferentially transduce during conditions of cellular 
stress.  With this work, we have elucidated that: 1) AAV capsids are capable of entering the 
nucleus as an infectious virion; 2) basic regions near the N-terminus of VP1 direct steps in 
subcellular trafficking and may play a role in uncoating; and 3) AAV exploits conditions of 
cellular stress related to expression of misfolded proteins, which may be a generalized 
phenomenon having positive implications for targeting diseased cells with these vectors.  
With its focus on how AAV navigates the subcellular environment, this work intersects areas 
of cell biology, virology, and gene delivery.  Ultimately, by analyzing how capsid 
composition and host parameters influence infection we have addressed central concepts at 
the level of subcellular trafficking that help advance the design of viral vectors for gene 
therapy. 
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CHAPTER 1 
INTRODUCTION TO AAV BIOLOGY 
 
Origins and physical characteristics of the virus 
Adeno-associated virus (AAV) was discovered over forty years ago as a contaminant 
of adenovirus (Ad) preparations (Atchison et al., 1965; Hoggan et al., 1966) and has since 
been termed a dependovirus because it requires the presence of a helper virus, such as Ad or 
herpes virus, in order to enter into a productive lytic cycle (Berns and Giraud, 1996).  As key 
principles of AAV biology have been uncovered it has become clear the virus exhibits a 
number of properties that make it a promising vector for gene delivery.  The most highly 
characterized serotype, AAV2, has been classified as non-pathogenic, and has never been 
associated with disease in humans or animals.  All viral coding sequences can be removed 
from the viral genome when producing recombinant vectors, minimizing risks that could be 
brought on through host production of the virus (Samulski, 1999).  Additionally, sustained, 
long-term transgene expression has been documented in a wide variety of tissues such as the 
brain, liver, muscle, retina, and vasculature (Samulski, 1999).  Thus, enthusiasm for using 
AAV as a gene therapy vector has been infectious, and over the last few years research on its 
clinical potential and basic biology have been expanding at a rapid pace.  
AAV is a member of the parvovirus family and one of the smallest known DNA 
viruses.  An icosahedral particle roughly 20-25nm in diameter, the AAV virion is non-
enveloped and comprised of only protein and DNA.  Thus, compared to other viruses, all of 
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the molecular components required to navigate extracellular and subcellular environments 
are contained in a simple and compact structure.  AAV packages a single-stranded DNA 
genome of 4,679 bases in length (Srivastava et al., 1983).  The viral genome is flanked by 
two inverted terminal repeats (ITRs) of 145 bases (Lusby et al., 1980), which are the only 
sequences required for packaging.  Two genes are found between the ITRs (Fig 1), one 
coding for proteins involved in replication (rep) and one coding for proteins that form the 
capsid (cap).  There are four Rep proteins that play integral roles in the AAV life cycle.  
Rep78 and Rep68 are the two larger proteins that originate from the p5 promoter as splice 
variants.  These proteins are multifunctional and operate during transcription of viral mRNA, 
replication of viral DNA, and site-specific integration of DNA into human chromosome 19.  
Transcripts for the smaller proteins involved in replication, Rep52 and Rep40, are driven 
from the p19 promoter.  Rep52 and Rep40 are important for genome packaging during 
assembly of the virion in the nucleus.    
Much of this dissertation focuses on understanding functional elements of the capsid 
proteins. The three capsid proteins (VP1, VP2, and VP3) are encoded in the second 
overlapping reading frame of the AAV genome, each beginning with a different start codon 
but sharing a common C-terminus and stop codon (Fig. 1).  Transcripts for these proteins are 
driven by the p40 promoter.  VP1 is the largest capsid protein and is translated from a minor 
splice variant. The major splice variant yields translation of VP2 from an alternative start 
codon (ACG), and translation of VP3 from as many as three separate start codons 
(Warrington et al., 2004).  AAV capsids self-assemble from 60 capsid proteins with VP1,  
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Fig 1. Genomic map of AAV. Two genes code for proteins involved in replication or capsid 
composition.  The p5 promoter initiates transcripts for Rep78 (when unspliced) and Rep 68 
(spliced). The p19 promoter initiates transcripts for Rep 52 (unspliced) and Rep 40 (spliced). 
Both Rep 52 and 40 products are in-frame with the Rep 78 and 68 products.  Capsid 
transcripts are driven from the p40 promoter, which produces a minor splice variant for 
coding VP1 and a major splice variant for coding VP2 and VP3.  mRNAs.  All three capsid 
proteins exist in an overlapping reading frame with a common C-terminal stop codon. 
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VP2, and VP3 in a ratio of approximately 1:1:10, respectively (Buller and Rose, 1978; 
Muzyczka, 1992).  VP1 contains a 137 amino acid extension at its N-terminus not found in 
VP2 or VP3 (Trempe and Carter, 1988).  Though its role in infection is not well understood, 
the N-terminus of VP1 is critical for successful subcellular trafficking of AAV.  To some 
extent the capsid will tolerate deletions or insertions at the N-terminus of VP2, but mutating 
key basic residues has been shown to negatively impact infection (Wu et al., 2000; Grieger et 
al., 2006; Sonntag et al., 2006). 
 
Structural and functional diversity of AAV serotypes 
In the mid 1950’s James Watson and Francis Crick first hypothesized that viral capsid 
structures were based on repeating subunits arranged with cubic symmetry (Crick and 
Watson, 1956).  This idea stemmed from the observation that the genetic makeup of viruses 
was too small to code for a diverse repertoire of capsid subunits.   Soon after, Donald Caspar 
and Aaron Klug provided experimental evidence from tomato bushy stunt virus (BSV) and 
turnip yellow mosaic virus (TYMV) that supported this model (Caspar, 1956) and suggested 
viruses are ‘spherical structures’ formed from identical subunits bonded together in ‘quasi-
equivalent’ ways  (Caspar and Klug, 1962).  Years later we find almost all viruses adhere to 
these principles of frugality, and AAV is no exception.  The 20-sided icosahedral capsid can 
be parsed into six 5-fold axes, ten 3-fold axes, and fifteen 2-fold axes of symmetry.  AAV2 
was crystallized in 2002 (Xie et al., 2002) and other serotypes have soon followed (Kaludov 
et al., 2003; Walters et al., 2004; Miller et al., 2006; Nam et al., 2007; Quesada et al., 2007; 
Mitchell et al., 2009).   
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Fig 2. Structure of the 25nm diameter capsid.  A. Cartoon ribbon representation of a VP3 
subunit of AAV2.  The orientations of the 2-, 3-, and 5-fold axes of symmetry are marked.  
The beta-barrel motif that forms the core framework of the capsid can be seen at the bottom 
of the diagram.  A trimer (B, 3-fold axis) and a pentamer (C, 5-fold axis) of VP3 subunits is 
displayed to highlight how one single subunit (red) intertwines with adjacent subunits.  D.  
The 25nm icosahedral capsid is shown with a pentamer superimposed enface in black. 
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At the core of the VP3 capsid subunit is a β-barrel motif, and looped regions extend 
to intertwine with adjacent subunits and serve as receptor binding sites (Fig 2).  The most 
prominent features of the AAV2 capsid are the spikes protruding at the 3-fold axis of 
symmetry.  While AAV8 shares similarly striking protrusions at the 3-fold axis, the other 
serotypes are somewhat blunted in these regions.  The significance of these differences is not 
yet known, but the distinctions in surface topology and electrostatics are thought to determine 
receptor binding preferences.  AAV2 infects a wide variety of tissues, but other serotypes 
display distinct infectious advantages (Fig 3).  In muscle for example, AAV1 is roughly 100-
fold more infectious than AAV2 (Gao et al., 2004).  In lung tissue AAV9 is 100-fold more 
infectious than AAV2.  AAV1 and AAV5 are 10-fold more infectious than AAV2 in the 
hippocampus (Burger et al., 2004).  In liver tissue, AAV8 is also 200-fold more infectious 
than AAV2 (Gao et al., 2004), yet in cultured hepatocytes, AAV8 is not infectious 
(unpublished data). indicating that in vitro observations will not always emulate in vivo 
characteristics.  
Twelve natural AAV serotypes have been described in the literature (Schmidt et al., 
2008), numerous variants have been identified through work at the University of 
Pennsylvania (Gao et al., 2002; Gao et al., 2003; Gao et al., 2004), and several new mosaic 
and chimeric virions have been engineered (Bowles et al., 2003; Hauck et al., 2003; Opie et 
al., 2003; Rabinowitz et al., 2004).  One of the most significant advances in vector design in 
recent years has been the application of directed molecular evolution to generate enormously 
diverse capsid libraries (Maheshri et al., 2006; Perabo et al., 2006; Grimm et al., 2008; Li et 
al., 2008).  In this strategy, DNA sequences that code for the capsid proteins of different 
serotypes are amplified and subjected to limited DNase digestion, then rejoined though  
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Fig 3. Tissue tropisms of AAV serotypes 1-9.  Known primary receptors, coreceptors, and 
tissue tropisms for natural AAV isolates 1-9 are listed.  HS (heparin sulphate), SA (sialic 
acid), PDGFR (platelet derived growth factor receptor), HGFR (hepatocyte growth factor 
receptor-1), FGFR (fibroblast growth factor receptor-1), LamR (laminin receptor). 
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homologous recombination.  The resulting ‘shuffled’ DNA is then amplified again through 
PCR, sometimes with an error-prone polymerase to introduce mutations not found in the 
natural capsid sequences (Koerber et al., 2006).  Essentially this process creates a plasmid 
library after subcloning into a parent construct, which can subsequently be used to produce a 
virus library with a diversity of over 106 unique clones.  Virus particles that display attractive 
properties, such as the ability to avoid neutralizing antibodies, avoid unwanted interactions 
with complement or off-target cell surfaces, and display enhanced delivery to specific tissues 
can be selected through screening steps and amplified with adenovirus.   
Directed evolution is only as good as the selective pressures applied on the system.  
This method does not take into consideration the relationship between the genome and the  
capsid, as has been seen with the ordered nucleic acid of canine parvovirus (CPV) and 
minute virus of mice (MVM) (Chapman and Rossmann, 1995; Reguera et al., 2005).  While 
no definitive relationship has been established between the DNA and capsid structure of 
AAV, Mavis Agbandje-McKenna and colleagues have shown that there is an ordered density 
in the capsid interior that could correspond to DNA (Levy et al., 2009). It is noteworthy to 
mention we have observed that different transgenes have markedly different particle to 
infectivity ratios, with wild type AAV2 packaging the AAV2 genome maintaining the 
highest efficiency (personal communication with Michael Linden).  It would not be 
surprising if future research efforts were focused on identifying the best combination of 
genome sequence and capsid for a given therapeutic target.  Despite limitations of directed 
evolution, and the fact that selection and amplification in humans will be logistically difficult 
to achieve, this strategy represents a powerful step forward in optimizing vectors for gene 
therapy, and may enable valuable ad hoc analysis of structure/function relationships in the 
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virion.  However, the capsid composition is not the only determinant of transduction since 
many host cell factors are also necessary for binding, uptake, and transgene stabilization. 
 
Clinical successes and shortcomings of rAAV vectors 
Gene therapy can be defined as a medical technology that aims to treat and potentially 
cure diseases with a known genetic locus by introducing new genes into an individuals cells 
or tissues.  Although this technology is in its infancy, recent strides have been made in 
research with both viral and non-viral mechanisms of gene transfer.  AAV vectors represent 
some of the most promising gene delivery tools since they are non-pathogenic, infect 
dividing and non-dividing cells, display long-term expression profiles, and do not require that 
viral genes be packaged along side the therapeutic gene.  Other systems currently being 
studied for gene therapy will not be discussed here, but include retroviral vectors, lentiviral 
vectors, adenoviral vectors, non-viral delivery systems such as lipoplex & polyplex vectors, 
and naked DNA.  Gene therapy with these systems has focused on four strategies: 1) 
introducing a new gene in a non-specific location in the host genome to replace a non-
functional gene, 2) introducing a new gene that specifically substitutes in place of a non-
functional gene through homologous recombination, 3) repairing an existing gene by targeted 
reverse mutation, and 4) regulation of an existing gene to increase or decrease its expression 
level.  The majority of research has historically focused on the first strategy, but this may 
change as other approaches become feasible.  In this vein, preclinical research and clinical 
trials have been centered around monogenic disorders such as cystic fibrosis, hemophilia, and 
muscular dystrophy. 
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To date, over 40 clinical trials have now been completed with AAV-based gene 
therapy vectors and many more remain ongoing (Mueller and Flotte, 2008).  In addition to 
those disorders listed above, AAV vectors have been tested in paradigms that include 
prostate and melanoma cancers, Canavan’s disease, amyotrophic lateral sclerosis, alpha 1-
antitrypsin deficiency, Alzheimer’s disease, Parkinson’s disease, rheumatoid arthritis, 
Leber’s congenital amaurosis, epilepsy, cardiac failure, and vaccines targeting HIV.  The first 
clinical trial using recombinant AAV (rAAV) as a vector was initiated 15 years ago by Dr. 
Terry Flotte for cystic fibrosis (Flotte et al., 1996).  As described later (see Chapter 4), cystic 
fibrosis is a progressive hereditary disorder resulting from the loss of CFTR protein at the 
mucosal surface of airway epithelium, which leads to mucus accumulation, inflammation, 
and the inability to clear pathogens.  The clinical studies employed vector delivery to the 
airway by nasal, endobronchial, sinus and aerosol inhalation.  Subsequent cell culture 
analysis suggested a positive correlation between the presence of vector DNA sequences, 
mRNA expression and electrophysiologic correction of cAMP-activated chloride transport 
(Flotte et al., 2005).  While no significant correction was observed, there was a trend toward 
improved biological function for the first 60 days after vector administration.  The major 
outcome of this study was that AAV2 vectors were well-tolerated in patients over a 7-log 
order dosing. 
Other significant results have come from clinical trials for hemophilia B, a blood 
clotting disorder resulting from a deficiency in Factor IX (FIX) protein.  Similar to trials with 
cystic fibrosis, data from preclinical animal studies were incredibly promising for 
hemophilia.  After AAV2-FIX vector was found to be tolerated after intra-muscular injection 
in an initial study (Kay et al., 2000; Manno et al., 2003), a second clinical trial was 
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performed where AAV2-FIX was delivered intrahepatically (Manno et al., 2006).  In these 
studies there was evidence of in vivo gene expression and correction of bleeding time, 
although effects were only transient.   Most significantly, the second trial demonstrated that 
cell-mediated immune responses were generated following transgene expression.  Liver 
transaminases became elevated, but clinically significant liver dysfunction was not apparent 
(Manno et al., 2006).  It is generally assumed that the cell-immune responses are directed 
against the AAV2 capsid and are responsible for eliminating transduced liver cells; however, 
one publication has suggested the immune response could be directed towards alternative 
transcripts expressed from cryptic start sites in the transgene (Li et al., 2009a).  Nonetheless, 
it has become clear from these studies that in order for AAV-mediated gene therapy to be 
successful we must discover how to circumvent the immune response and increase the 
efficiency of vector transduction. 
Extremely encouraging results have emerged from a recent clinical trial for Leber’s 
congenital amaurosis (Maguire et al., 2008).  This disease is a form of retinal degeneration 
and 15% of these cases stem from a mutation in the retinal pigment epithelium-specific 65kD 
protein gene (RPE65), which plays a role in the retinoid cycle.  Patients with Leber’s 
congenital amaurosis rapidly progresses to blindness by 10 years of age.  Three patients who 
enrolled in the trial were treated with rAAV2 packaging RPE65 by a single subretinal 
injection between September 2007 and January 2008 in their most affected eye.  As an 
outstanding example of how gene therapy technology is advancing, all three patients have 
reported improved vision accompanied with physiological changes in responsiveness to light 
as tested by pupillometry diagnostics (Maguire et al., 2008).  These changes became apparent 
starting 2 weeks after vector administration, reached maximum postoperative effects at 3 
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months, and since then have persisted unchanged for at least 1 year (Cideciyan et al., 2008).  
Other promising news has been filtering in from clinical trials on Parkinson’s disease and 
Canavan’s disease, but substantial progress has yet to be made with AAV-mediated gene 
therapy in targets outside of immuno-privileged regions such as the eye and brain.  
 
Subcellular events required for infection 
AAV transduction depends on serotype- and cell type-specific factors that include the 
availability of receptors on the plasma membrane, the activation of endocytosis, and the 
efficiency of subcellular processing (Muzyczka and Warrington, 2005).  Understanding the 
basic biological principles that control infection is vital to being able to target specific tissues 
with gene therapy vehicles while minimizing transduction in non-target tissues.  At the 
cellular level, completion of the infectious process depends on the virus overcoming a 
number of physiological barriers.  The initial step in AAV infection, binding to the cell 
surface, is specified by residues in VP3 and is dependent upon the expression of receptors 
that these residues target (Summerford and Samulski, 1998; Qing et al., 1999; Summerford et 
al., 1999).  For AAV2 the primary receptor is heparin sulfate proteoglycan (Summerford and 
Samulski, 1998) (referred to as heparin), which is distributed in a wide variety of tissues.  
This broad distribution of heparin is thought to contribute to AAV2’s breadth of tissue 
tropism, but the low infectivity of the virus indicates receptor availability is not the only 
determinant of infection.  Proposed coreceptors for AAV2 include αvβ5 integrin 
(Summerford et al., 1999), α5β1 integrin (Asokan et al., 2006), hepatocyte growth factor 
receptor (Kashiwakura et al., 2005), fibroblast growth factor receptor type 1 (Qing et al., 
1999), and the laminin receptor (Akache et al., 2006). The receptors for the other natural 
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AAV serotypes have not all been identified, but it is assumed that serotype-specific 
differences in tissue tropism are partially due to variations in receptor preference (Fig 3).  
After binding receptors on the host cell plasma membrane, AAV2 is endocytosed from the 
cell surface in a clathrin- and dynamin-dependent process (Duan et al., 1999; Bartlett et al., 
2000; Bantel-Schaal et al., 2002), and then must escape from the endosome (Fig 4). 
Following endocytosis, many AAV particles accumulate in late-endosomes or lysosomes and 
do not deliver their genome to the nucleus (Duan et al., 2000; Hansen et al., 2000; Douar et 
al., 2001; Ding et al., 2005).  This impediment to gene delivery is exacerbated when particles 
lack VP1 or contain specific mutations in the N-terminus (Girod et al., 2002).  The vast 
majority of internalized particles remain outside the nuclear membrane, and although recent 
evidence suggests successful infection occurs only when the capsid uncoats inside the 
nucleus, it is still controversial whether AAV can enter the nucleus as an intact capsid (Fig. 
4).  The last steps of infection require that the single-stranded viral genome undergoes second 
strand synthesis by host cell factors or anneals with a complementary genome.  As genomes 
convert to stable double-stranded forms, gene expression can persist (Wang et al., 2007).  
A consortium of structural elements on the capsid surface and interior must work in 
concert in order for transduction to take place.  Residues in VP3 make up the framework of 
the capsid, and their crystal structure depicts a beta barrel core surrounded by peptide loops 
that provide subunits with interfacial interactions and present receptor binding domains on 
the capsid surface.  The N-termini of VP1 and VP2 are more flexible than the beta barrel core 
and have not been crystallized.  VP1 and VP2 are not required for virus assembly, packaging 
of the genome, cell attachment, or internalization.  While AAV can maintain some infectivity 
in the absence of VP2, VP1 is critical for infection and viruses that lack this protein are  
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Fig 4. Stages of AAV infection. Infection of wt AAV or transduction of AAV vectors can be 
demarcated into several steps: 1) cell attachment through receptor and coreceptor binding, 2) 
internalization into an endosomal compartment, 3) endosomal acidification and endosomal 
processing, 4) potential conformational change that exposes VP1/2 N-termini, 5) endosomal 
escape, 6) and nuclear targeting.  Subsequent steps are less clear, but are surmised to include 
nuclear entry, genome release (uncoating), conversion of the single-stranded genome to a 
double stranded intermediate, and stabilization of the double stranded transgene. 
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crippled, presumably at subcellular steps of infection.  It is thought the N-termini of VP1 and 
VP2 reside within the capsid interior and are likely exposed to cellular membranes while the 
virus is within the acidic environment of the endosome (Fig 5).  Cytoplasmic microinjection 
of AAV2 and other parvoviruses does not lead to transgene expression, so subcellular 
processing of the virus within the endosome is thought to be required for successful infection 
(Vihinen-Ranta et al., 1998; Ding et al., 2005).  Indeed, acidification of the endosome is 
known to be necessary for AAV infection in several cell types (Hansen et al., 2001a; 
Pajusola et al., 2002), and exposure of VP1 has been stimulated by mild heat-shock or urea 
treatment in vitro (Bleker et al., 2005; Kronenberg et al., 2005).  
In the last few years, two functional elements of the capsid, a phospholipase A2 
(PLA2) domain and putative nuclear localization signals (NLS), have been identified on 
AAV2 (Fig 6).  Almost all parvoviruses contain a sequence of about 70 amino acids in VP1, 
being highly homologous to the catalytic domain of secretory PLA2, comprised of histidine 
and aspartic acid residues (75HD) (Zadori et al., 2001).  Mutating these residues to alanine 
and asparagine (75HD/AN) does not affect cell surface attachment or endocytosis, but 
strongly inhibits PLA2 activity and viral infectivity (Zadori et al., 2001). In the literature it is 
surmised that PLA2 activity mediates endosomal membrane permeabilization, permitting 
escape of AAV into the cytosol, but this has not been directly demonstrated.  It is also 
possible that the PLA2 domain could act at the nuclear membrane instead or in addition to 
the endosomal membrane.  In fact, MVM has been reported to disrupt the nuclear envelope 
during infection, as assessed by indirect immunofluorescence and electron microscopy 
(Cohen et al., 2006).  If parvoviruses enter the nucleus by directly disrupting the nuclear 
membrane, the phospholipase would make for an appropriate tool.  
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Fig 5. N-terminal regions of VP1/2 become exposed through the 5-fold pore.  A. An 
equatorial slice of the capsid atomic model with 2-, 3-, and 5-fold axes of symmetry. B. 3D 
image reconstruction of a portion of the AAV2 capsid where the unique N-terminus of VP1 
is predicted to fold.  C. Partial unfolding of VP1 after a capsid conformational change allows 
its exposure through a channel at a 5-fold axis.  D. A model of VP1up exposure through the 
5-fold axis (residues 1 to 185 become accessible). (Adapted from Kronenberg et al., 2005) 
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Typically, macromolecular trafficking across the nuclear membrane is an ATP-
dependent process and is directed by soluble factors in the cytoplasm like Ran-1, that interact 
with specific NLSs on target proteins (Nigg, 1997; Gorlich and Kutay, 1999).  As with many 
cellular functions, viruses have found a way to usurp host machinery involved in nuclear 
trafficking to suit their own needs.  NLSs have been identified on VP1 from various 
parvoviruses that are integral to nuclear targeting (Vihinen-Ranta et al., 1997; Lombardo et 
al., 2000; Lombardo et al., 2002).  Namely, the first 10 residues of VP1 in CPV and many 
other parvoviruses is defined as a robust NLS (Vihinen-Ranta et al., 1997), yet these residues 
are not conserved in AAV (Fig 6).  Several conserved, hydrophilic, basic regions have been 
identified in AAV2 capsid proteins, termed BR1, BR2, and BR3.  Mutating these regions 
results in a graduated loss of infectivity compared to recombinant AAV2: 1-log order for 
BR1 (120QAKKR/QANNR), 2-log orders for BR2 (140PGKKR/PGNNR), and 3-log orders for 
BR3 (168PARKR/PANNR) (Wu et al., 2000).  Thus far, no thorough study has been 
undertaken concerning how mutations in either the PLA2 domain or NLS basic regions affect 
trafficking of virions; with this dissertation we attempt to address this deficiency in Chapter 
3.   
 
Overcoming subcellular barriers to transduction 
Results have been encouraging from recent clinical trials, yet AAV’s success as a 
gene therapy vector has been limited in many tissues because high viral titers must be 
administered to overcome barriers to transduction (Samulski, 1999; Goncalves, 2005).  
Several systems in the host are in place to inhibit delivery of foreign genetic material.  One of 
these barriers to gene delivery is the immune response, and a significant percentage of adults  
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Fig 6. Homology between serotypes in VP1. Sequence alignment of N-terminal residues in 
VP1 from AAV serotypes 2, 1, 5, 8, canine parvovirus (CPV), minute virus of mice (MVM), 
and porcine parvovirus (PPV).  Start sites for VP1, VP2, and VP3 in AAV serotypes are 
marked with arrows.  Amino acids that share sequence homology with a cytosolic PLA2 are 
indicated with a black line.  Similarly, residues identified as putative NLS regions are also 
shown.  Catalytic residues (HD), or basic amino acids (K or R) critical to the function of 
these domains are marked with red lines. 
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are sero-positive for neutralizing antibodies against AAV2 (Blacklow et al., 1968; Chirmule 
et al., 1999; Erles et al., 1999; Moskalenko et al., 2000).  Specificity of cell binding and 
internalization also limit infection (Sanlioglu et al., 2001), although many serotypes such as 
AAV2 display broad cellular tropism.  As of late, researchers are becoming increasingly 
aware that subcellular processing is a significant barrier to infection (Vihinen-Ranta et al., 
1998; Bartlett et al., 2000; Duan et al., 2000; Vihinen-Ranta et al., 2000; Hansen et al., 
2001a; Sanlioglu et al., 2001; Ros et al., 2002; Ding et al., 2003; Hauck et al., 2004).  
Subcellular processing encompasses those steps outlined in the previous section (Fig 4), and 
include endosomal escape, subcellular trafficking, nuclear delivery, and uncoating. 
Interactions between the capsid and cellular proteins and membranes are inevitable as 
the virus traverses the subcellular milieu.  At every node of interaction the cell has an 
opportunity to block subsequent steps of infection.  A common subcellular trafficking 
pathway sorts foreign particles and pathogens after endocytosis to a perinuclear area near the 
microtubule organizing center (MTOC) (Leopold and Pfister, 2006; Wileman, 2007).  
Microtubules provide a lattice for organizing the vesicles and organelles that AAV has been 
associated with, such as endosomes, lysosomes, the Golgi apparatus, and the nucleus 
(Cuschieri et al., 2007).  AAV capsids immunoprecipitate with the microtubule minus-end 
directed motor protein, dynein, which is the primary mover of microtubule traffic toward the 
MTOC (Kelkar et al., 2006).  Many degradative components are found in high concentration 
near the MTOC, such as proteasomes (Badano et al., 2005), lysosomes, and many associated 
chaperones and enzymes.  Sorting viruses and bacteria to the MTOC would thus place these 
foreign invaders in proximity to an arsenal of components the cell could use to remove them.  
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Microtubules not only serve as highways to traffic viruses, bacteria, and cellular 
vesicles, but also to traffic misfolded proteins that originate from within the cell (Garcia-
Mata et al., 2002).  During subcellular stress, the microtubule trafficking network could be 
saturated with misfolded proteins and the capacity of degradation at the MTOC can be 
exceeded.  Consequences manifest as proteasome dysfunction, accumulation of protein 
aggregates, formation of aggresomes, expansion of the secretory pathway, and activation of 
the unfolded protein response (UPR) (Bernales et al., 2006).  It has previously been 
demonstrated that AAV virions exhibit dose-dependent sorting within the endosomal 
network (Ding et al., 2006).  Using high multiplicities of infection (MOIs) that potentially 
saturate the lysosome, or following siRNA-mediated knockdown of Rab7 lysosomal sorting, 
AAV trafficking can be shunted through recycling endosomes which are thought to yield 
enhanced transduction.  
Several treatments that affect proteolytic degradation and catabolism have been 
shown to enhance AAV transduction.  For example, proteasome inhibitors and heatshock can 
potentiate transduction in a cell-type specific manner by up to several hundred fold (Duan et 
al., 2000; Hansen et al., 2000; Ding et al., 2003; Hauck et al., 2004).  Thus, we hypothesize 
that AAV virions are processed by the cell in a manner similar to misfolded proteins, and 
following pharmacological interference or saturation of these pathways, the virus is able to 
exploit the subsequent conditions of subcellular stress. The proteasome, lysosome, and 
autophagosome degradation machinery at MTOC likely represent significant subcellular 
barriers that virions must bypass in order to deliver their transgenes to the nucleus.  With this 
dissertation we have continued to explore how overcoming subcellular barriers to infection 
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using physical and pharmacological stressors will lead to enhanced transduction of AAV 
vectors.   
 
 
  
 
CHAPTER 2 
ENHANCEMENT OF AAV INFECTION BY MOBILIZING VIRIONS INTO AND OUT 
OF THE NUCLEOLUS 
 
Abstract 
Adeno-associated virus (AAV) serotypes are being tailored for numerous therapeutic 
applications, but the parameters governing the subcellular fate of even the most highly 
characterized serotype, AAV2, remain unclear.  To understand how cellular conditions 
control capsid trafficking, we have tracked the subcellular fate of recombinant AAV2 
(rAAV2) vectors using confocal immunofluorescence, three-dimensional infection analysis, 
and subcellular fractionation.  Here we report that a population of rAAV2 virions enters the 
nucleus and accumulates in the nucleolus after infection, whereas empty capsids are excluded 
from nuclear entry. Remarkably, after subcellular fractionation, virions accumulating in 
nucleoli were found to retain infectivity in secondary infections.  Proteasome inhibitors 
known to enhance transduction were found to potentiate nucleolar accumulation.  In contrast, 
hydroxyurea, which also increases transduction, mobilized virions into the nucleoplasm, 
suggesting two separate pathways influence vector delivery in the nucleus.  Using an siRNA 
approach, we then evaluated if nucleolar proteins B23/nucleophosmin and nucleolin, 
previously shown to interact with AAV2 capsids, impact trafficking and transduction 
efficiency.  Similar to effects observed with proteasome inhibition, siRNA-mediated 
knockdown of nucleophosmin potentiated nucleolar accumulation and increased transduction 
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5- to 15-fold.  Parallel to effects from hydroxyurea, knockdown of nucleolin mobilized 
capsids to the nucleoplasm and increased transduction 10- to 30-fold. Moreover, affecting 
both pathways simultaneously using drug and siRNA combinations was synergistic and 
increased transduction over 50-fold.  Taken together these results support the hypothesis that 
rAAV2 virions enter the nucleus intact and can be sequestered in the nucleolus in stable 
form.  Mobilization from the nucleolus to nucleoplasmic sites likely permits uncoating and 
subsequent gene expression or genome degradation.  In summary, with these studies we have 
refined our understanding of AAV2 trafficking dynamics and have identified cellular 
parameters that mobilize virions in the nucleus and significantly influence AAV infection. 
 
Introduction 
Adeno-associated virus (AAV) is classified as a dependovirus because it requires the 
presence of a helper virus, such as adenovirus or herpes virus, in order to enter into a 
productive lytic cycle (Berns and Giraud, 1996).  Because of its non-pathogenicity, and 
ability to promote sustained, long-term transgene expression in a wide variety of tissues such 
as the brain, liver, muscle, retina, and vasculature (Samulski, 1999), several recombinant 
AAV serotypes (rAAVs) are emerging as attractive vectors for gene therapy.  Despite many 
advances in AAV vector design, barriers including pre-existing immune response and off-
target binding have necessitated administration of high viral titers to achieve efficient 
transduction (Samulski, 1999; Goncalves, 2005).  
Beyond the barriers of the immune response (Blacklow et al., 1968; Moskalenko et 
al., 2000) and cell surface targeting (Sanlioglu et al., 2001), researchers are becoming 
increasingly aware that subcellular processing is a significant barrier to infection (Sanlioglu 
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et al., 2001; Ding et al., 2003; Hauck et al., 2004).  Subcellular processing may include 
conformational changes within the endosome or similar compartments, endosomal escape, 
nuclear targeting, and uncoating, but the factors that control these events are not well 
defined.  Understanding how cellular conditions impact subcellular processing of virions will 
lead to improved gene delivery through exploitation of these parameters and promote better 
vector design.  
Given that the virion is an icosahedral particle only 25nm in diameter, rAAV must 
contain all of the molecular components required to navigate through the subcellular 
environment in a remarkably small structure.  Wild-type AAV is a non-enveloped parvovirus 
that packages a single-stranded DNA genome of approximately 4.7 kb in length.  The viral 
genome is flanked by two inverted terminal repeats and contains two open reading frames, 
one that codes for replication proteins and another for capsid proteins.  Three capsid proteins 
(VP1, VP2, and VP3) are encoded in the second overlapping reading frame, each beginning 
with a different start codon but sharing a common C-terminus and stop codon.  Capsids are 
comprised of 60 copies of V1, VP2, and VP3 in a ratio of approximately 1:1:10, respectively 
(Buller and Rose, 1978; Muzyczka, 1992).  During production, AAV capsids are known to 
assemble at early time points in the nucleolus (Wistuba et al., 1997), a subdomain of the 
nucleus and one of the oldest known cellular structures.  Intact capsids have been shown to 
interact with nucleolar proteins such as nucleolin (NCL) and B23/nucleophosmin (NPM1) in 
the context of assembly (Qiu and Brown, 1999; Bevington et al., 2007), but how these 
proteins impact infection or vector delivery is currently unknown. 
Initial cell surface binding of AAV capsids is mediated by expression of glycoprotein 
receptors and specified by residues in VP3 (Summerford and Samulski, 1998; Qing et al., 
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1999; Summerford et al., 1999).  After binding receptors on the host cell plasma membrane, 
AAV2 is endocytosed from the cell surface in a clathrin- and dynamin-dependent process 
(Duan et al., 1999; Bartlett et al., 2000; Bantel-Schaal et al., 2002).  Following endocytosis, 
many AAV particles accumulate in late-endosomes, lysosomes, or other compartments, and 
do not deliver their genome to the nucleus (Ding et al., 2005).  This impediment to gene 
delivery is exacerbated when particles lack VP1 or contain specific mutations in the unique 
N-terminus of VP1 (Girod et al., 2002).  The N-terminus of VP1 is normally folded inside 
the capsid, harboring a phospholipase domain and putative nuclear localization signals 
necessary for infection (Zadori et al., 2001; Girod et al., 2002; Canaan et al., 2004).  These 
regions of VP1 are thought to translocate to the capsid exterior during subcellular processing 
of the virus (Bleker et al., 2005; Kronenberg et al., 2005; Sonntag et al., 2006).  Even with 
proper capsid composition, the vast majority of internalized particles remain clearly outside 
the nuclear membrane, and although recent evidence suggests successful infection occurs 
when the capsid uncoats inside the nucleus (Thomas et al., 2004; Sonntag et al., 2006), it is 
still vehemently debated whether AAV can enter the nucleus as an intact capsid.   
In general, it has proven difficult to discern whether infectious particles truly cross 
the nuclear membrane, due to the limitations of fluorescent microscopy (Bartlett et al., 2000; 
Xiao et al., 2002).  In an in vitro setting it has been demonstrated that unmodified AAV 
capsids are capable of entering purified nuclei (Hansen et al., 2001b), yet these conditions do 
not accurately represent what occurs physiologically since virus directly microinjected into 
cytoplasm will not enter the nucleus nor efficiently transduce the cell (Ding et al., 2005; 
Sonntag et al., 2006). In one instance, single-particle tracking of AAV has been used to 
follow capsids in a live-cell imaging paradigm and has found that they can be quickly and 
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directly transported to the nucleus (Seisenberger et al., 2001).  However, another recent study 
has parsed confocal images of GFP-tagged AAV2 particles during infection and has reported 
that few, if any particles enter the nucleus during infection (Lux et al., 2005).   
Although it is unclear whether capsids enter the nucleus intact, it has been well 
established that nuclear delivery of the genome is highly inefficient and significantly limits 
transduction.  Several studies have identified agents that surmount subcellular barriers to 
transduction (Yalkinoglu et al., 1988; Ferrari et al., 1996; Duan et al., 2000).  Two of the 
most well documented agents known to improve subcellular processing are proteasome 
inhibitors and hydroxyurea (HU); however, their mechanisms of action remain unknown.  
Therefore we set out to determine what effect, if any, these agents had on subcellular 
trafficking of rAAV2 in hopes of identifying specific cellular parameters that promote 
efficient transduction.   
Here we report that rAAV2 capsids accumulate in the nucleolus during infection. 
Proteasome inhibitors were found to potentiate nucleolar accumulation, while HU reduced 
nucleolar accumulation and appeared to mobilize capsids to the nucleoplasm.  Acting 
independently, both proteasome inhibitors and HU increased transduction and together they 
were cooperative, which suggests these treatments operate through separate pathways to 
improve gene delivery.  In addition, we found that siRNA-mediated knockdown of nucleolar 
proteins NCL and NPM1 had effects similar to proteasome inhibition or HU and increased 
transduction.  Based on our results, we have proposed a model wherein AAV virions initially 
enter the nucleus intact and can be sequestered in the nucleolus in stable form.  Disruption of 
the nucleolus subsequently mobilizes virions from the nucleolus to nucleoplasmic sites and 
likely permits uncoating.  
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Materials and Methods 
Cell culture.  HeLa cells and HEK-293 cells were maintained at 37°C and 5% CO2 
in Dulbecco’s modified Eagle’s medium (DMEM) that was supplemented with 10% heat-
inactivated fetal calf serum, 100U/ml penicillin, and 100g/ml streptomycin. 
Virus production. Virus was produced as previously described in HEK-293 cells 
(Xiao et al., 1998).  Briefly, using polyethylenimine (linear molecular weight, ~ 25,000), 
cells were triple-transfected with pXR2, the pXX6-80 helper plasmid, and pTR-CMV-
Luciferase containing the luciferase reporter transgene flanked by inverted terminal repeats.  
At 60hr post-transfection cells were harvested and virus purified by cesium chloride gradient 
density centrifugation for 5hr at 65,000 rpm or overnight at 55,000 rpm. Fractions that 
contained peak virus titers were dialyzed against 1X phosphate-buffered saline (PBS) 
supplemented with calcium and magnesium. Viral titers were determined in triplicate after 
treating dialyzed fractions with DNase, digesting the capsid with proteinase K, and purifying 
viral DNA by DNeasy column (Qiagen) according to the manufacturers protocol.  Viral DNA 
was applied via a dot-blot manifold to a Hybond-XL membrane (Amersham) and detected 
with a [γ-32P]CTP-labeled probe complementary to the luciferase transgene. Empty capsids 
were harvested from HEK-293 cells after transfection of only pXR2 and XX6-80 without a 
transgene plasmid and dialyzing from low density cesium chloride fractions that displayed 
peak Mab A20 reactivity.  For this manuscript consistent results were obtained for many 
different virus preparations and could also be reproduced when virus was purified by 
iodixanol gradient. 
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Confocal immunofluorescence microscopy.  Similar to what we have previously 
described (Grieger et al., 2007), HeLa cells (5 × 104/well) were plated on poly-L-lysine-
coated 12-mm glass coverslips (#1.5) 24hr before infection. Recombinant virions were added 
to cell media (2 × 104 vg/cell).   No virus was added to control wells.  Where indicated, HU 
was added at 10 mM for 12hr and washed off extensively prior to virus administration.  
Proteasome inhibitor (MG132, Calbiochem) was present for the duration of infection at 2 
µM, when used. At indicated time points, cells were washed three times with PBS and then 
fixed with 2% paraformaldehyde for 15min at room temperature. The cells were then 
permeabilized with 0.1% Triton X-100 in PBS for 5min at room temperature. Following four 
washes with PBS, the permeabilized cells were blocked with immunofluorescence buffer 
(IFB) (20 mM Tris, pH 7.5, 137 mM NaCl, 3 mM KCl, 1.5 mM MgCl2, 5 mg/ml bovine 
serum albumin, 0.05% Tween) for 30min at room temperature. The cells were incubated with 
primary antibody to detect intact capsids (MAb A20 (1:10), NCL (Abcam 22758, 1:1,000), 
or laminB1 (Abcam 16048, 1:750) diluted in IFB, for 1hr at 37°C or overnight at 4°C. The 
cells were then incubated in secondary antibody, diluted 1:5,000 in IFB (anti-mouse Alexa 
Fluor 488; or anti-rabbit Alexa Fluor 568, Molecular Probes), for 1hr at 37°C. After six 
washes in PBS, coverslips were mounted cell side down on glass slides with mounting 
medium (Prolong antifade Gold with DAPI [4′,6′-diamidino-2-phenylindole]; Molecular 
Probes). Images were captured on a Leica SP2 AOBS upright laser scanning confocal 
microscope and processed using Adobe Photoshop. 
3-Dimensional render of infection.  Confocal Z-stack sections of HeLa cells fixed 
16hr after infection with either rAAV2 or empty capsids in the presence of 2 µM MG132 
were processed and rendered in 3 dimensions using Volocity software (Improvision). 
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Cell fractionation and nucleolar isolation.  Nucleoli were isolated from cell 
fractionations as previously described (Mauramatsu, 1963), with minor modifications 
allowing for viral infection.  Briefly, five 15cm plates of HeLa cells at 90% confluency were 
used for each preparation.  Empty or full rAAV2 particles were incubated with cells for 16hr 
at 37°C (2,000vg/cell, empties normalized to A20 reactivity of full capsids).  Cells were 
washed 3× with ice cold PBS and harvested by centrifugation at 218g for 5min.  The cell 
pellet was resuspended in hypotonic buffer and homogenized on ice using a tight pestle to the 
point where >90% of cells were burst, and leaving nuclei intact.  The homogenate was spun 
at 218g for 5min to separate crude nuclear pellet from the post-nuclear supernatant (PNS, 
~5ml).  Nuclei were further purified from cytoplasmic contaminants by spinning through a 
0.35 M sucrose cushion to give a nuclear associated (NA) pellet.  Nuclei were lysed by 
limited sonication on ice and the nuclear suspension in 0.35 M sucrose was layered over a 
0.88 M sucrose cushion to separate nucleoli (NU, 200µl) from NA fractions (~5ml).  
Nucleoli were further purified for by another spin through sucrose and their integrity and 
purity was verified by phase-contrast microscopy and western blot.  
Transduction assays.  At least 4hr prior to infection or drug treatment, HeLa cells 
were plated in 24 well plates at a density of 105cells/well.  For drug studies, cells were 
handled as stated above.  Cells were infected with purified rAAV2 at designated vector 
genomes per cell or 5 µl of indicated samples after cell fractionation and typically harvested 
after 24hr unless otherwise noted. Luciferase activity was measured in accordance with the 
manufacturer's instructions (Promega). Luciferase activity was measured with a Tropix 
TR717 automated plate reader.  Error bars represent standard deviations from samples scored 
in triplicate.  Graphs are representative data sets from at least three independent assays. 
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Western blotting.  Samples from purified virus or cell fractionations were loaded 
onto NuPage 10% Bis-Tris gels and typically run using for 3hr at 150V in 1× NuPage MOPS 
(morpholinepropanesulfonic acid) buffer.  Electrophoresis was performed in the XCell 
SureLock Mini Cell (Invitrogen). Proteins were transferred to a Hybond ECL membrane 
utilizing the XCell II Blot module (Invitrogen) for wet transfer according to the 
manufacturer's protocol.  Membranes were blocked for at least 30min at room temperature in 
5% nonfat dry milk (NFDM) dissolved in 1× PBS/Tween(0.1%). For detection of capsid 
proteins, primary antibody (Mab B1) was diluted 1:20 with 2.5% NFDM in 1× 
PBS/Tween(0.1%) and incubated for 1 h at room temperature or overnight at 4°C. After 
washing with 1× PBS/Tween(0.1%), blots were incubated for 1hr at room temperature with 
anti-mouse HRP secondary antibody, diluted 1:5,000 in 2.5% NFDM with 1× 
PBS/Tween(0.1%).  Following multiple washes with 1× PBS/Tween(0.1%), SuperSignal 
West Femto Maximum Sensitivity Substrate (Pierce) was added to each membrane according 
to the manufacturer's protocol for developing. Each membrane was then exposed to 
Amersham Hyperfilm MP. 
Quantifying genomes by PCR.  Identical to methods stated earlier, cells were 
fractionated into PNS, NA, and NU components as previously described (Mauramatsu, 
1963).  DNA was isolated from fractions using DNeasy columns (Qiagen) according to the 
manufacturers protocol.  Quantitative PCR was performed on a LightCycler 480 using Sybr 
green (Roche) and primers designed against the firefly Luciferase transgene: (fwd) Luciferase  
5’ AAA AGC ACT CTG ATT GAC AAA TAC 3’, and (rev) 5’ CCT TCG CTT 
CAA AAA ATG GAA C 3’.  Conditions used for the reaction are as follows:  1 cycle at 95ºC 
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for 10min, 45 cycles at  95ºC for 10sec, 62ºC for 10sec, 72ºC for 10sec, 1 cycle at 95ºC for 
30sec, 65ºC for 1min, and 99ºC for acquisition. 
Genome pulse-chase.   Confluent 10cm plates of HeLa cells were pulsed with 
rAAV2 (2,000vg/cell) for 2hr at 37°C, washed with medium and harvested at 0, 12, and 24hr 
post-infection in 5 ml PBS.  DNA from 200µl of the cell suspension was purified using 
DNeasy columns and applied to a Hybond XL membrane using a dot blot manifold.  DNA 
specific to the viral genome was detected as mentioned above by hybridization of a 
radiolabeled probe created against the luciferase transgene. 
siRNA transfection.  Knockdown of NCL, NPM1, and VCP was obtained by 
transfecting validated siRNA sequences using Hiperfect (Qiagen) according to the 
manufacturers’ protocol for fast-forward transfection of adherent cells.  Briefly, 80,000 HeLa 
cells were plated into 24well plates and mixed immediately with pre-incubated DMEM, 
transfection reagent, and siRNA at a final concentration of 5nM.  Two days after 
transfection, cells were trypsinized and replated at appropriate densities for transduction 
assays or confocal immunofluorescence.  Target sequences were as follows: Hs_NPM1_7 -   
5’ AAA GGT GGT TCT CTT CCC AAA 3’, HS_NPM1_8 – 5’ AAT GTC TGT ACA GCC 
AAC GGT 3’, Hs_VCP_6 – 5’ AAG ATG GAT CTC ATT GAC CTA 3’, Hs_VCP_7 – 
AAC AGC CAT TCT CAA ACA GAA, Hs_NCL_10 – AAG GAA ATG GCC AAA CAG 
AAA, Hs_NCL_5 – AAG CTA TGG AGA CTA CAC CAG.  
 
Results 
Identifying and overcoming subcellular barriers that prevent the majority of virions 
from delivering their payload to the nucleus is critical toward developing successful vectors 
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for gene therapy applications.  As previously reported, proteasome inhibitors and genotoxic 
agents affect events of subcellular processing to enhance transduction of rAAV2 in a cell-
type and serotype-specific manner (Duan et al., 2000; Hansen et al., 2000; Ding et al., 2003; 
Hauck et al., 2004).  The proteasome inhibitor, MG132, is known to reduce the degradation 
rate of ubiquitin-conjugated proteins by the 26S complex of the proteasome.  In contrast, the 
primary target of the genotoxic agent, HU, is thought to be ribonucleotide reductase.  It is 
unclear precisely how transduction of rAAV is enhanced following these treatments but 
MG132 and HU are postulated to increase efficiency of nuclear entry (Yalkinoglu et al., 
1988; Ferrari et al., 1996; Duan et al., 2000).  Here we demonstrate that the aforementioned 
pharmacological agents can regulate accumulation and mobilization of intact AAV virions in 
the nucleus following infection using a variety of techniques. 
Pharmacological modulation of rAAV2 trafficking and transduction using 
MG132 and HU.   To establish the trafficking profile of rAAV2 we tracked the subcellular 
fate of virions by confocal immunofluorescence microscopy. Using a monoclonal antibody 
(Mab A20) that only recognizes intact capsids, we were able to identify virions within the 
nucleus by 16hr after infection when virus was continuously present in the media (Fig 7A). 
The distinct pattern of accumulation we observed for rAAV2 with no drug treatment was 
potentiated when MG132 was present (white arrows).  Capsids could be detected in the 
nucleus as early as 4hr after infection, which corresponds to the earliest time we could detect 
gene expression.  A markedly different pattern was observed during infection following HU 
pretreatment, with capsids showing a diffuse distribution in the nucleoplasm (arrow heads).   
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Fig 7. Trafficking and transduction after treatment with MG132 or HU.  A. Confocal 
immunofluorescence microscopy was used to visualize subcellular trafficking of intact 
virions in HeLa cells with monoclonal antibody A20 (yellow) with reference to the nuclear 
membrane marker lamin B1 (magenta).  rAAV2 virions (20,000vg/cell) were administered 
for the indicated times in control conditions, in the presence of MG132 (2µM), or following 
HU pretreatment (10mM, 12hr).  Nucleolar accumulation and diffuse nucleoplasmic 
localization are marked with white arrows and arrowheads, respectively.  Scale bar represents 
20µm.  B. Luciferase assays of transduction were performed to quantify efficiency of firefly 
luciferase transgene delivery.  200, 2000, or 20,000vg/cell were administered for 2hr at 37°C, 
washed 3× with cell medium, harvested at the indicated times, and scored for transduction 
after 24hr. 
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At 16 and 24hr time points MG132 and HU had clearly contrasting effects on capsid 
localization in the nucleus.  This finding was intriguing considering both MG132 and HU 
increase infection efficiency over a wide range of particle numbers (Fig 1B-D), as measured 
by luciferase assays of transduction.  HU increased transduction from 5- to 10-fold and 
MG132 increased transduction by almost 2 log orders of magnitude. 
It is noteworthy to mention that despite the need for high particle numbers 
(20,000vg/cell) in immunofluorescence studies using AAV (Xiao et al., 2002; Lux et al., 
2005; Sonntag et al., 2006), a linear relationship between transduction and dose were 
observed (Fig 7B-D).  This supports the notion that similar trafficking patterns are occurring 
at low MOI (200vg/cell), despite these doses being below the limit of visual detection.  
Nonetheless, the striking nuclear accumulation pattern we observed with proteasome 
inhibition in immunofluorescence studies prompted further exploration.  
Recombinant AAV2 virions but not empty capsids, accumulate in nucleoli.  The 
nucleolus has been termed the gateway to viral infection because of its seemingly ubiquitous 
involvement in the replication dynamics of many viruses (Hiscox, 2002).  For wild type 
AAV2, capsid assembly has been reported to occur in nucleoli (Wistuba et al., 1997; Qiu and 
Brown, 1999; Bevington et al., 2007), but the roles of the nucleolus or nucleolar proteins 
during infection of an exogenously applied vector have not been studied.  To more clearly 
determine if rAAV capsids accumulate in the nucleolus, we carried out immunofluorescence 
experiments to identify intact capsids (yellow) and the nucleolar marker, NCL (magenta) 
16hr after infection with 20,000vg/cell in the presence of MG132 (Fig 8A).  Cross-sectional 
analysis of z-stacked confocal images show that rAAV2 colocalizes with NCL in nucleoli, 
although the majority of virions remain outside the nuclear membrane.   
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Fig 8. Accumulation in the nucleolus is unique to rAAV2.  A. Confocal z-stack analysis of 
infection was used to determine if the immunofluorescent signal originated from within the 
nucleus.  Serial cross-sections were captured in the z-plane through HeLa cells infected for 
16hr in the presence of MG132 (2µM) with either rAAV2 (i, 20,000vg/cell) or empty capsids 
(ii, equivalent amount relative to A20 and B1 staining).  Intact rAAV2 virions (yellow) were 
found to colocalize with nucleolar marker NCL (magenta), and depicted within the nucleus 
(blue, DAPI).  B.  Subcellular fractionation of HeLa cells after infection (2,000vg/cell 
rAAV2 or equivalent empty capsid amount).  Capsid proteins present in cell fractions PNS 
(post-nuclear supernatant), NA (nuclear associated), and NU (nucleoli) were detected by 
western blot (Mab B1).  PNS and NA fractions were diluted 25-fold over fraction NU.  
Nucleolar isolation was verified by the presence of NPM1 by western blot and observing 
purified nucleoli as dense retractile bodies by phase contrast microscopy (not shown). C. 3-
Dimensional render of infection in panel A, as processed by Volocity software (Improvision).  
The nucleus (blue channel) was gated to reveal nucleoplasmic staining of NCL (magenta, ii 
& vi), focal nucleoli (iii & vii), and then the presence or absence of rAAV2 and empty 
capsids, respectively, within nucleoli (yellow, iv & viii). White arrows depict nucleolar 
accumulation. 
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Remarkably, in contrast to rAAV2 virions, empty capsids were not found to 
accumulate in nucleoli or colocalize with NCL, even in the presence of MG132.  Only with 
samples where DNA-containing particles were administered were we able to detect nucleolar 
accumulation (Fig 8A vs. 8B) at any time point after infection, despite similar levels of 
internalization between rAAV2 and empty capsids as indicated by A20 staining.  Nucleolar 
accumulation of rAAV2 could be also potentiated by another proteasome inhibitor ALLN 
and was demonstrated in HEK-293 cells (data not shown), suggesting this phenomenon is not 
unique to one cell type. 
Additionally, we were able to explore nucleolar accumulation of rAAV2 in three 
dimensions by rendering z-stacked images acquired by confocal microscopy using Volocity 
software (Fig 8C).  This enabled us to digitally subtract the nucleus by channel gating (blue 
channel) to reveal more precisely the localization of capsids in its interior.  Detection of NCL 
(magenta) was observed diffusely in the nucleoplasm (Fig 8C, ii & vi) and when the channel 
was gated to show only intense staining was found confined to nucleoli (iii & vii).  After 
completely subtracting the magenta channel, a collection of virions localized to the nucleolar 
interior could be clearly seen (yellow) for rAAV2 (Fig 8C, iv), yet empty capsids were 
absent from these regions (viii). 
Capsid proteins are found in nucleolar fractions.  To further support the evidence 
from immunostaining that rAAV2 virions are capable of accumulating in the nucleolus, we 
infected cells and attempted to isolate nucleoli containing virus by subcellular fractionation.  
To this end we infected HeLa cells with 2,000vg/cell rAAV2 or  an equivalent amount of 
empty capsids for 16hr in the presence of MG132.  Cells were fractionated into post nuclear 
supernatants (PNS) that contained mostly cytoplasmic material, nuclear associated fraction 
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(NA) that may have included material attached to the outside of the nuclear membrane, and a 
fraction enriched with highly purified nucleoli (NU).  When analyzed by western blot, capsid 
proteins from rAAV2 and empty capsids were represented at similar levels in NA fractions 
(diluted 25-fold over fraction NU, Fig 8B).  Identical to what was found with 
immunostaining, a population of capsids or capsid proteins were detected in NU fractions 
after rAAV2 infection, but not after empty capsid infection.  The fact that empty capsids 
could not be detected in nucleoli by immunostaining or subcellular fractionation, suggests 
accumulation of rAAV2 in the nucleus is not an artifact, but rather represents a property 
unique to genome-containing rAAV2 that is not demonstrated by empty capsids (see 
Discussion section). 
Since the localization of intact capsids or capsid protein may not reflect the 
localization of genomes if virions have already uncoated, we chose to quantify relative 
amounts of capsid proteins and genomes after subcellular fractionation.  We have also 
analyzed whether proteasome inhibition or HU treatment affect capsid and genome 
localization using subcellular fractionation since these treatments appear to have different 
effects as observed by immunofluorescence.  It has been reported that uncoating is a slow 
and inefficient process for rAAV2 (Thomas et al., 2004; Zhong et al., 2004a; Sipo et al., 
2007), so we predicted the amount of genomes in nucleolar fractions should roughly 
correspond to the amount of capsid protein detected in those fractions if the majority of 
virions have not released their DNA.  As expected, MG132 increased the amount of capsid 
protein associated with fraction NA and NU (Fig 9A, lanes 7 & 11).  In contrast, HU reduced 
the amount of capsid protein most notably in fraction NU (lane 12), relative to untreated 
control infection (lane 10).  These findings further support our immunofluorescence data that  
  38 
 
Fig 9. Detection of capsid proteins and viral genomes in nucleoli after subcellular 
fractionation. A. Subcellular fractionation of HeLa cells after no infection (sample lanes 1,5, 
& 9), infection with rAAV2 at 2,000vg/cell (lanes 2,6, & 10), rAAV2 with Mg132 (lanes 3,7, 
& 11), or rAAV2 after HU treatment (lanes 4,8, & 12).  Cells were fractionated after 16hr 
into PNS, NA, and Nuc.  Capsid proteins in fractions were detected by western blot (Mab 
B1).  Nucleolar isolation is indicated by presence of NPM1 in fraction NU.  B.  
Quantification of viral genomes present in cell fractions after infection by qPCR (same 
sample order as above).  Amplification was performed using SYBR Green with primers 
designed for the luciferase transgene. 
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suggest proteasome inhibitors increase nucleolar accumulation of capsids whereas HU 
mobilizes capsids into the nucleoplasm, away from the nucleolus. 
Vector genomes can be detected in isolated nucleoli.  Quantifying the number of 
genomes in these locations is just as important in analyzing capsid distribution, since capsids 
could have released their genomes prior to this point in trafficking.  The nucleolus may either 
be a site where potentially infectious virions are sequestered given certain cellular conditions 
or represent a site for depositing empty capsids after genome release that would have no 
bearing on transduction efficiency.  To determine if genomes could be detected in fractions 
PNS, NA, or NU, we purified DNA from these fractions after infecting cells, and submitted 
the samples to quantitative PCR.  The trends observed for genome copy number (Fig 9B) 
closely follow those observed for capsid protein, with more genomes detected in fraction NU 
following proteasome inhibition (Fig 9B, lane 11) and less detected after HU treatment (lane 
12), compared to an untreated control infection (lane 10).  It should be noted that fraction NU 
contains highly purified nucleoli and during the isolation is concentrated roughly 25-fold 
over fractions PNS and NA.  Thus, it is important to realize that the majority of capsids and 
genomes in the cell do not enter the nucleolus.  Since most virions are likely associated with 
the outside of the nuclear membrane, nuclear entry is an inefficient process even in the 
presence of proteasome inhibitors. 
Virions accumulating in nucleoli remain infectious entities.  Detecting viral 
capsids and viral genomes in the same subcellular compartment does not necessitate the 
former still carry the latter.  When these are observed to accumulate in the nucleolus, the 
capsid could have remained intact after already releasing its genome or the capsid could still 
contain the genome if the virus has not yet completed infection.  To test whether vector 
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genomes detected in the nucleolus were protected in intact capsids or had been released 
during capsid uncoating, we assayed if virions isolated from nucleoli after infection could 
successfully transduce cells in secondary infections (Fig 10A).  In one condition, rAAV2 
(2000vg/cell) was spiked into HeLa cell media for roughly 1min.  This short incubation 
period is not long enough for the majority of virions to bind and internalize into cells.  As 
shown in Fig 10A, condition 1 serves as an internal control to verify the procedure is not 
vulnerable to contamination from infectious particles in the media, during wash steps and 
nucleolar fractionation.  Conditions 2 and 3 were 16hr infections (2,000vg/cell) with rAAV2 
or rAAV2 +MG132, respectively.  This time interval was chosen based on the 
immunofluorescence evidence that prominent nucleolar accumulation is seen by 16hr after 
infection (Fig 7A). 
After the primary infection under the conditions listed above, HeLa cells were 
fractionated into PNS, NA, and NU compartments (Fig 10A).  To determine if virions 
accumulating in these fractions remained infectious, small volumes of these fractions were 
administered to fresh HeLa cells and transduction was scored 24hr later by luciferase assay.  
When compared to purified rAAV2 (10,000vg/cell), negligible levels of transduction were 
observed from fraction PNS for all conditions, from fraction NA for condition 1, or fraction 
NU from condition 1 (Fig 10B).  Low transduction is observed in fraction NA for conditions 
2 and 3, and moderate transduction was detected with fraction NU for conditions 2 and 3.  
When these samples for conditions 2 and 3 from fraction NU were heated to 70°C for 10min 
to disassemble capsids, transduction levels dropped to baseline as they did for heat-treated 
purified rAAV2.  These data strongly suggest that capsids accumulating in nucleoli during 
infection still contain their genome and remain infectious entities. 
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Fig 10. Secondary infection after nucleolar fractionation.  A. Experimental schematic  
representing three conditions of infection: 1) control with virus only present for 1min in the 
cell media, 2) 16hr infection with rAAV2 (2,000vg/cell), and 3) 16hr infection in the 
presence of MG132 (2µM).  Cells treated in this manner were processed to separate PNS, 
NA, and NU fractions.  B. To determine if virions accumulating in these fractions remained 
infectious, a luciferase assay of transduction was performed 24hr after 5µl aliquots from the 
designated fractions were administered to fresh HeLa cells. Particle numbers in samples NU-
2 and NU-3 were determined to be similar to purified rAAV2 (first column, 10,000vg/cell), 
with NU-3 being slightly higher than NU-2.  As a control, purified rAAV2 (10,000vg/cell) 
and samples NU-2 and NU-3 were submitted to heat treatment (70°C, 10min) to destroy 
capsid integrity. 
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Separate pathways can be exploited to enhance transduction.  The central tenet 
that inefficient subcellular processing of rAAV significantly reduces transduction has driven 
research toward discovering ways to enhance processing and subcellular trafficking of the 
virus.  To date, no effect on capsid degradation has been observed during proteasome 
inhibition, despite capsid ubiquitination being demonstrated in vitro (Duan et al., 2000; Yan 
et al., 2002).  Additionally, knowing the total amount of virion accumulation in cells treated 
with MG132 or HU would establish a baseline for comparing the effects of each treatment.  
To determine if proteasome inhibitors or genotoxic agents affect the amount of vector 
genomes internalized and to follow how these drugs affect the persistence of rAAV2 DNA, 
we performed a viral genome pulse-chase to compare control, MG132, and HU conditions.  
Cells were infected for 2hr at 37°C, washed with medium and harvested at 0, 12, and 24hr 
post-infection.  The remaining viral genomes were purified and detected by dot blot 
hybridization (Fig 11A).  As previously documented for AAV2 (Douar et al., 2001), 
proteasome inhibition slows clearance of viral genomes compared to untreated control 
samples, though the mechanism of action remains unknown.  Degradation of viral genomes 
is not impeded in samples pretreated with HU, as the pattern of genome disappearance 
closely matches that of controls. 
Both MG132 and HU are pluripotent agents and have numerous downstream effects, 
but since these drugs are thought to act through different pharmacological mechanisms, we 
hypothesized that together they may act synergistically to increase rAAV transduction.  Thus, 
we performed a luciferase assay of transduction comparing the effects of MG132, HU, or the 
combination of the two to determine if they operate through separate pathways.  As expected, 
when combined, MG132 and HU enhance transduction more than either one independently  
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Fig 11. MG132 and HU increase transduction through different mechanisms. A. 
Genome pulse-chase experiments were performed to determine whether MG132 or HU 
influence total levels of vector genome accumulation and to examine the effects of these 
drugs on genome degradation.  Cells were pulsed with rAAV2 (2,000vg/cell) for 2hr at 37°C, 
washed with medium and harvested at 0, 12, and 24hr post-infection.  Viral DNA was 
purified from the cell suspensions and detected by dot blot hybridization using a radiolabeled 
probe created against the luciferase transgene. B. A luciferase assay of transduction with 
rAAV2 (2,000vg/cell) was performed to test for synergistic transduction enhancement of 
MG132 and HU.  Cells were either treated with HU (10mM), MG132 (1µM), or a 
combination of the two and tested for luciferase activity 24hr post infection. 
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(Fig 11B).  It should be noted that in these experiments the concentration of MG132 was 
reduced 2-fold compared to concentrations used in earlier assays since some toxicity was 
observed when combined with HU.  These results further corroborate the ability of MG132 
and HU to act through independent mechanisms that manifest as enhanced nucleolar 
accumulation and nucleoplasmic mobilization of AAV capsids, respectively. 
Influence of nucleolar proteins on rAAV transduction and localization. The fact 
that AAV capsids are known to assemble in the nucleolus during replication has important 
ramifications when considering steps leading to nucleolar accumulation during infection 
(Wistuba et al., 1997). Two reports have identified nucleolar proteins that colocalize and 
immunoprecipitate with intact capsids (Qiu and Brown, 1999; Bevington et al., 2007).  These 
proteins, nucleolin (NCL) and B23/nucleophosmin (NPM1), are predominant components of 
the nucleolus.  While traditionally known for their roles in ribosome assembly, they have also 
been found to exist outside of the nucleolus, having roles as chaperone proteins and are 
known to relocate in response to stresses such as HU.  It is clear that NCL and NPM1 are 
implicated in the life cycles of many viruses in addition to AAV, including HIV , herpes 
simplex virus, and coronavirus (Hiscox, 2002).  Yet, the impact of such proteins on AAV 
infection has not been established. 
To test whether NCL and NPM1, which bind the AAV capsid during assembly, can 
also sequester virions in the nucleolus after nuclear entry post-infection, we knocked-down 
NCL and NPM1 by transfection of corresponding siRNA in HeLa cells.  Significant 
reduction of targeted protein levels were verified by Western blot analysis relative to β-actin 
loading controls (Fig 12A).  When transduction efficiency was compared for controls, mock 
transfected cells, scrambled non-targeted siRNA, and targeted siRNAs, we observed  
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Fig 12. Impact of nucleolar proteins on rAAV2 transduction and trafficking.  siRNAs 
targeting nucleolin (NCL), and nucleophosmin (NPM1), nucleolar proteins known to bind 
AAV capsids, were transfected into HeLa cells at a final concentration of 5nM in parallel 
with mock transfected cells, treated with transfection reagent only, a scrambled siRNA 
transfection, or siRNA targeting a non-related protein, VCP.  A.  Western blots of cell lysates 
taken 4 days after siRNA transfection detecting loss of targeted protein relative to β-actin 
controls.  B.  Luciferase assay of transduction in HeLa cells transfected with siRNAs 
targeting NCL, NPM1, or VCP.  Cells were split to equal cell densities 48hr after transfection 
and infected with rAAV2 (2,000vg/cell).  Transduction was scored 24hr after infection. C. 
Immunofluorescence of rAAV2 in HeLa cells 16hr post-infection using Mab A20 to detect 
intact capsids (green) with nuclear membranes outlined relative to DAPI stain (not shown).  
Patterns of localization were compared between samples treated with MG132 and NPM1-
siRNA, or samples treated with HU and NCL-siRNA.  Arrows and arrowheads indicate 
nucleolar accumulation and diffuse nucleoplasmic staining, respectively.  D. Western blots of 
total cell protein from control samples or following MG132 or HU administration for 2, 6, or 
24hr.  Levels of NCL or NPM1 remain relatively unaffected after drug treatments compared 
to β-actin controls.  E. Immunofluorescence localization of NCL (i, ii, iii) or NPM1 (iv, v, vi) 
is shown in red in untreated cells compared to drug treated cells after 24hr (MG132: ii & v - 
HU: iii & vi).  Arrowheads indicate a shift toward nucleoplasmic localization of NCL 
following HU treatment (iii). 
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significant increases in samples with NCL or NPM1 knocked-down (Fig 12B).  Samples that 
were treated with siRNAs targeting a protein unrelated to nucleolar function, vallosin 
containing protein (VCP) showed a slight decrease in transduction.  No discernable change in 
capsid localization was apparent in mock transfected samples, cells transfected with 
scrambled-siRNA, or with VCP-siRNA when compared to controls (data not shown).  
Remarkably, the localization of capsids in samples treated with NCL-siRNA was 
dramatically altered and appeared similar to samples treated with HU (Fig 12C).  In contrast, 
samples treated with NPM1-siRNA had prominent nucleolar accumulation of capsids, similar 
to what is observed during proteasome inhibition. 
Many agents that augment AAV infection, such as adenovirus, herpes virus, and 
genotoxic agents, are  known to redistribute nucleolar proteins away from the nucleolus 
(Matthews, 2001; Rubbi and Milner, 2003; Lopez et al., 2008).  By changing the localization 
of NCL or NPM1, these treatments might essentially be analogous to siRNA-mediated 
protein depletion if the primary function of these proteins in the AAV life-cycle is associated 
with the nucleolus.  Although expression levels are relatively unaffected by MG132 or HU 
up to 24hr after administration (Fig 12D), HU treatment resulted in partial redistribution of 
NCL from the nucleolus to the nucleoplasm (Fig 12E, iii).  Because capsid localization 
appears similar between HU and NCL-siRNA samples we expect these treatments to operate 
through the same pathway.  Since both NCL-siRNA and NPM1-siRNA treatments increase 
transduction but have different effects on capsid localization, we hypothesized that at least 
two nuclear-associated pathways can be exploited to increase transduction of rAAV2.  
To test whether MG132 or HU will synergistically increase transduction in NCL-
siRNA or NPM1-siRNA samples, we performed luciferase assays of transduction following  
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Fig 13. Specific combinations of drugs and siRNAs enhance transduction.  HeLa cells 
transfected with siRNAs targeting NCL, NPM1, or VCP were split to equal cell densities 
48hr after transfection and infected with rAAV2, rAAV2 + MG132, or rAAV2  + HU.  
Transduction efficiency was scored by luciferase assay 24hr later.  Asterisks indicate 
mitigated effectiveness of MG132 in NPM1 siRNA samples and double asterisks highlight a 
pronounced reduction in sensitivity to HU in NCL siRNA samples. 
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various combination treatments (Fig 13).  In support of our hypothesis, HU was found to 
have reduced efficacy of increasing transduction in NCL-siRNA cells, suggesting both 
treatments influence the same pathway.  Similarly, the efficacy of MG132 appeared to 
decrease in NPM1-siRNA samples.  Synergy was observed in samples treated with MG132 
and NCL-siRNA or samples treated with HU and NPM1-siRNA, which supports these 
treatments operate through separate pathways in the nucleus to enhance transduction.  It is 
noteworthy to mention that a linear relationship between transduction efficiency and dose 
was observed across MOI ranging from 200 to 20,000vg/cell (Fig 13A-C).    
 
Discussion 
With these experiments we have sought to elucidate steps during subcellular 
trafficking as rAAV2 traverses from the cell surface to the nucleus.  We have demonstrated 
that rAAV2 virions enter the nucleus intact and have explored through confocal 
immunofluorescence and biochemical fractionation how changing cellular parameters 
influences nucleolar accumulation.  Our results suggest virions that accumulate in nucleoli 
remain infectious and are sequestered there in stable form.  These data prompt us to speculate 
that mobilization from the nucleolus to nucleoplasmic sites enables capsid transition from a 
stable environment to one where uncoating and subsequent gene expression or genome 
degradation can occur (Fig 14).  This model is particularly striking in light of the helper-
dependent nature of AAV, as the virus has likely evolved to utilize nucleolar proteins for 
sequestration in a stable compartment and exploit nucleolar disruption during mitosis, 
genotoxic stress, or coinfection to trigger genome release under favorable conditions. 
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Fig 14. Illustrated model of two nuclear trafficking paradigms.  Virions entering 
the nucleus are subject to an accumulation pathway (A) and a mobilization pathway (B). Low 
or negligible transduction occurs when virions do not enter nuclei at high efficiency. If high 
particle numbers are administered, virions can accumulate in the nucleolus in stable form (A) 
and favorable conditions may permit vector mobilization within the nucleus to sites that 
promote uncoating in the nucleoplasm (B). Transduction can be increased by manipulating 
either pathway independently; however transduction is dramatically potentiated if more than 
one pathway is engaged as exemplified by the cooperative effects of MG132 and HU (Fig 
5B). 
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In these studies we employed multiple techniques to substantiate our conclusions.  
Initially with immunofluorescence experiments, we examined the subcellular trafficking 
profile of rAAV2 and detected accumulation of intact capsids in the nucleolus.  We also 
show through secondary infections that rAAV virions isolated from nucleoli retain 
infectivity.  Moreover, disruption of nucleoli by genotoxic agents or siRNA-knockdown of 
nucleolar proteins mobilizes virions and increases transduction.  Our  trafficking studies, like 
all immunofluorescence experiments, were subject to limitations with respect to detection 
sensitivity, as high particle numbers are required for visualization.  However, we are able to 
detect capsid proteins in nucleoli post-infection at 10-fold lower doses by biochemical 
analyses.  Our conclusions are also supported by the fact that transduction assays display a 
linear trend between 200 and 20,000vg/cell in control, drug treatment, and siRNA studies 
(Fig 7 and 13).  Although we cannot empirically visualize rAAV2 in nucleoli at 200vg/cell, 
transduction studies strongly argue for identical effects on nucleolar accumulation and 
nucleoplasmic mobilization that the aforementioned treatments would have at lower MOI.   
Along with documenting accumulation of rAAV in the nucleus, a significant finding 
from these studies shows empty capsids are internalized into cells but cannot be detected in 
the nucleus, even in the presence of proteasome inhibitors (Fig 8).  This observation suggests 
the phenotype of nuclear accumulation is linked to infectious particles, or virions that can at 
least pass beyond the nuclear membrane.  A potential reason for the distinct trafficking 
patterns observed between empty and full virions is that empty capsids fail to expose the N-
terminus of VP1 during infection (data not shown).  Indeed, Kronenberg et al., have 
demonstrated similar results after limited heat treatment and show full and empty capsids 
display different cryo-electron microscopy profiles (Kronenberg et al., 2005).  These studies 
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in conjunction with our observations, suggest that empty capsids are unable to expose the 
phospholipase domain in VP1 that is thought to be required for endosomal escape or 
subsequent steps during infection.  In addition to the implications regarding cell entry 
mechanisms, this finding poses an interesting caveat concerning vector preparations for 
clinical use.  High numbers of empty particles in vector preps may compete with genome-
containing particles for cell attachment and uptake, effectively reducing the chances of gene 
delivery to the nucleus.  Other effects, such as the potential for empty particles to trigger 
cellular recycling or degradation pathways, or the possibility that empty particles saturate 
extracellular and/or subcellular binding sites, in turn, could either inhibit or augment 
transduction.  Thus, care must be taken to control the level of empty capsids in vector preps 
and understand their effects in laboratory and clinical studies. 
Although unlikely, capsids detected in the nucleolus during infection could represent 
reassembled particles.  This could occur if capsids disassembled in the cytoplasm during 
entry and subunits were transported into the nucleolus for assembly.  Similar examples of 
this concept have been found in cellular systems such as with the nuclear pore complex, 
which disassembles in the cytoplasm and reassembles in the nuclear membrane over the 
course of mitosis (Kiseleva et al., 2001).  However, it is unlikely the virus is subject to this 
system for several reasons.  During replication AAV monomers and subunits can be readily 
detected in cytoplasm and nuclei by antibody B1 (Wistuba et al., 1995; Wistuba et al., 1997), 
but in our studies and others, researches have failed to detect significant B1 staining during 
infection {data not shown,(Lux et al., 2005; Sonntag et al., 2006)}.  Thus, the supply of free 
monomers and subunits would likely not be great enough to support reassembly during 
infection.  Moreover, after isolating nucleoli from cells infected with rAAV2, we found 
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particles in these fractions to retain infectivity (Fig 11).  These particles could not have 
reassembled during infection, since replication proteins are needed for re-packaging of the 
genome, and these proteins are absent from current vectors.  For these reasons it is unlikely 
that capsids detected in the nucleus represent a reassembly artifact.  More importantly, the 
most striking observation in this study is that infectious virions are sequestered in nucleoli, 
supporting the existence of an ‘accumulation pathway’ for rAAV in the nucleus (Fig 8A). 
Roughly 40 years ago, AAV serotypes were first shown to accumulate in nucleolar 
structures in the context of replication (Atchison et al., 1966; Henry et al., 1972).  Our results 
highlight the apparent paradox of how AAV could assemble and disassemble in the same 
cellular location.  The process of uncoating can be defined as the separation of the genome 
from the capsid and might not require complete disassembly of the particle.  But even in this 
light, the prospect of virions uncoating in the nucleus during infection seems perplexing.  
Why wouldn’t all newly assembled capsids be driven to uncoat during production?  There are 
at least two plausible explanations for this paradox.  One possibility is that during production 
capsids will in fact uncoat as they are assembled.  Since these processes obey principles of 
hysteresis (Singh and Zlotnick, 2003), uncoating is likely to occur slower than assembly, 
because an external impetus is needed to overcome the collective contact energies of the 
subunits.  A few groups have suggested that uncoating is not a rapid process for AAV2 
(Thomas et al., 2004; Zhong et al., 2004a; Sipo et al., 2007).  As progeny virions are 
assembled and packaged a certain number may always be uncoating, albeit at a slower rate.  
Although this would explain how virions could assemble and disassemble in the nucleus, it 
would not be efficient from an evolutionary perspective since unnecessary energy would be 
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expended during replication and slow uncoating during infection would place limits on viral 
survival.   
A second possible explanation for this paradox has been suggested by Sonntag et al. 
(Sonntag et al., 2006), relying on the premise that incoming virions undergo modifications 
during infection that promote uncoating.  These modifications may include conformational 
changes, such as the extrusion of the N-terminus of VP1/2 from capsid interior to its exterior 
(Kronenberg et al., 2005; Sonntag et al., 2006), partial proteolytic cleavage (Van Vliet et al., 
2006; Akache et al., 2007), ubiquitination, or phosphorylation.  Considering that these 
changes may confer some instability to the capsid we could expect the AAV genome to 
become more accessible to the cell as the virion matures during entry.  Indeed, with 
parvoviruses minute virus of mice and B19, viral genomes are found to be exposed during 
infection but prior to capsid disassembly (Cotmore et al., 1999; Mani et al., 2006).  It remains 
to be seen whether AAV genomes become more accessible after VP1 exposure or during 
subcellular processing; however, in such a scenario the cell could distinguish between a 
virion assembled in the nucleus and one entering from outside.   
Exploring how drug treatments influence rAAV virions in the nucleus became a 
major focus of this study.  Proteasome inhibitors have repeatedly been shown to increase 
transduction efficiency in a cell-type and tissue-specific manner (Ding et al., 2005).  
Fittingly, when proteasomal degradation is inhibited we see an increase in capsid 
accumulation in the nucleolus (Fig 7 & 9) and a decrease in the rate of genome degradation 
(Fig 11A).  In one report, rAAV capsids were shown to accumulate in nucleoli after 
microinjection into the nucleus in the presence of proteasome inhibitors (Sonntag et al., 
2006).  It is unlikely that capsid degradation is occurring in the nucleolus since no 
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proteasome activity has been detected there (Hugle et al., 1983; Reits et al., 1997; Rivett, 
1998).  However, proteasome activity in the nucleoplasm could indirectly influence 
processing of AAV genomes and retard their degradation.  An increase in genome 
availability would serve to enhance transduction intensity and also lead to more rapid 
transgene expression.  Studies in addition to ours have demonstrated prolonged genome 
persistence following administration of proteasome inhibitors (Douar et al., 2001), several 
reports provide evidence that interfering with proteasomal degradation primarily increases 
AAV transduction by improving nuclear uptake of genomes (Ding et al., 2003; Yan et al., 
2004).  Certainly, both subcellular trafficking and the kinetics of transduction are positively 
influenced by proteasome inhibitors (Fig 1B-D).  In broad terms these results lend credence 
to the hypothesis that a nuclear accumulation pathway can be exploited to increase rAAV 
transduction (Fig 14A), but we cannot assume accumulation is due to inhibition of capsid 
degradation.  While it is tempting to speculate that proteasome inhibitors block degradation 
of AAV capsids, results from these studies, or in fact, from any other report to date, do not 
support the conclusion that proteasomes directly operate on intact capsids in the context of 
infection.   
Since AAV2 is known to assemble in the nucleolus and interact with nucleolar 
proteins (Qiu and Brown, 1999; Bevington et al., 2007), it is intriguing that recombinant 
virions can be detected in this compartment after exogenous administration.  In addition to 
being involved in AAV replication, from this study we have demonstrated NCL and NPM1 
are involved in pathways that influence rAAV2 trafficking and transduction.  We found these 
pathways to intersect with accumulation and mobilization pathways that are influenced by 
proteasome inhibitors and HU, respectively.  Studies on minute virus of mice, a parvovirus 
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related to AAV, have discovered NCL interacts directly with the viral genome during 
infection (Barrijal et al., 1992).  Although we see effects on capsid localization following 
knockdown of NCL and NPM1 we cannot discount the possibility that these pathways affect 
the genome as well.  Both NCL and NPM1 display single-stranded DNA and RNA binding 
capability (Liu and Yung, 1999; Yang et al., 2002), in the context of transcription (Ying et 
al., 2000), DNA attachment to the nuclear matrix, or chromatin decondensation (Erard et al., 
1990).  NCL and NPM1 also have roles in the DNA damage response (Yang et al., 2002; 
Kim et al., 2005; Takagi et al., 2005).  Recent work from Cervelli et al., indicates that rAAV 
genome single-strand to double-strand conversion can be detected at nuclear foci where DNA 
damage response components, the MRN complex or MDC1 protein, are recruited (Cervelli et 
al., 2008).  It has been demonstrated that DNA damage or genotoxic stress agents like HU 
reduce the associations between rAAV genomes and these components, suggesting 
machinery involved in the DNA damage response negatively impacts genome processing 
(Schwartz et al., 2007; Cervelli et al., 2008), which would be consistent with our results.  
Understanding why some cells are readily transduced by viruses while other cells are 
recalcitrant to infection is a cornerstone to general virology and research pertaining to viral 
vectors.  Evolutionarily speaking, it would be highly advantageous for a virus to lie dormant 
in a cellular compartment until favorable conditions arose that would promote successful 
gene delivery.  This resonates particularly well in the case of AAV, where coinfection by a 
helper virus is necessary for productive replication. Perhaps helper-dependent viruses have 
learned to exploit nucleolar proteins to sequester themselves in the nucleolus and use 
nucleolar disruption during mitosis, genotoxic stress, or coinfection as a trigger to release of 
their genetic contents into the nucleoplasm.  In support of this view, a common theme 
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emerges when studying agents that augment rAAV infection and affect the nucleolus.  
Components of adenovirus bind nucleolar proteins (Samad et al., 2007), and adenovirus 
protein V induces the redistribution of NCL and NPM1 from the nucleolus to the cytoplasm 
(Matthews, 2001).  Herpes virus, another AAV helper, also modulates the spatial distribution 
of NCL (Bertrand and Pearson, 2008; Calle et al., 2008; Lopez et al., 2008).  Additionally, 
inactivation of NCL and NPM1 by siRNA results in nucleolar disruption and cell cycle arrest 
(Grisendi et al., 2005; Ugrinova et al., 2007), and these phenotypes are remarkably similar to 
those caused by genotoxic agents such as HU (Rubbi and Milner, 2003).  This information 
corroborates our hypothesis that rAAV2 virions, initially sequestered in the nucleolus, are 
subject to a ‘mobilization pathway’ (Fig 14B), whereby capsids are released from a stable, 
protective environment to one where the genome becomes accessible. 
In summary, our results support a model wherein at least two pathways are in play to 
influence AAV trafficking and transduction in the nucleus, an accumulation pathway and a 
mobilization pathway (Fig 14).  In cases where negligible or low transduction is observed we 
expect few, if any virions reach the nucleus, and those that do may be sequestered in the 
nucleolus in a dormant state.  This may help explain why some investigators observe a 
threshold effect with AAV vectors following in vivo administration (Nakai et al., 2002; Wu 
et al., 2008).  Favorable conditions may be created during cell division or cell stress that 
would permit virus or vector mobilization within the nucleus to sites that promote uncoating 
in the nucleoplasm (Fig 14B). Externally, these conditions can be manipulated using physical 
or pharmacological treatments to force virions to adopt productive infectious pathways.  
Transduction is most dramatically potentiated under conditions where more than one 
pathway is engaged to overcome subcellular barriers, such as in the case of MG132 and HU 
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cooperation or synergy (Figs 11 & 13).  It remains to be seen whether nucleolar trafficking is 
an obligatory step in the cascade of infectious events, yet it is clear that by disrupting the 
integrity of the nucleolus using genotoxic agents or by affecting the expression and 
localization of nucleolar proteins, transduction can be improved.  In summary, with these 
studies we have refined our understanding of AAV2 trafficking dynamics, separating two 
pathways that accumulate or mobilize virions in the nucleus and significantly enhance AAV 
infection. 
  
 
CHAPTER 3 
BASIC RESIDUES NEAR THE N-TERMINUS OF VP1 DIRECT SUBCELLULAR 
TRAFFICKING OF AAV2 AND REGULATE UNCOATING 
 
Abstract 
Several adeno-associated virus (AAV) serotypes are emerging as popular tools for 
gene therapy, yet the virion components that modulate their subcellular trafficking profiles 
have not been well defined.  Successful infection depends on the capsid actively directing 
and enduring a cascade of subcellular events that include internalization into an endocytic 
compartment, endosomal processing, endosomal escape, nuclear targeting, and uncoating.  
Each of these events has been reported to limit incoming virions from achieving nuclear 
delivery of the transgene.  Regions near the N-terminus of capsid protein VP1 are highly 
homologous to a phospholipase A2 (PLA2) domain and nuclear localization signals (NLSs).  
These motifs are reported to be necessary for endosomal escape and nuclear targeting, 
respectively.  Normally the N-terminus of VP1 is folded inside the capsid, but it is thought to 
translocate to the capsid exterior during infection.  To more clearly understand the trafficking 
profile of AAV2 and to explore how virion components modulate subcellular trafficking, we 
have generated capsid mutations in these regions of VP1 and examined their effect on 
subcellular trafficking using monoclonal antibodies that recognize intact capsids, exposed N-
termini, and cellular markers.  We have discovered that mutants are able to assemble into 
capsids, package DNA similar to wild type, internalize into cells, and traffic through a 
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perinuclear region in the vicinity of the Golgi apparatus.  However, these mutants display 
differences in their preferential subcellular localization.  Remarkably, one mutant (BR3+K) 
that is 10 to 100-fold less infectious than AAV2 in HEK-293 and HeLa cells is able to enter 
the nucleus and accumulates in the nucleolus in response to proteasome inhibition.  Since we 
have identified these capsids to be DNA-containing particles this implicates either the 
nucleoplasm as the site for uncoating or the extra positive charge in VP1 to prohibit DNA 
release.  Ultimately, these studies improve our understanding of how residues in VP1 
influence trafficking, provide insight into how cells process the incoming virion, and 
underscore the complexity of AAV infection at the subcellular level. 
 
Introduction 
Viruses are magnificent organisms that have discovered through evolution a myriad 
of ways to circumvent host cell defenses and transport their genetic information to the 
nucleus or cytoplasm.  Specific interest in adeno-associated virus (AAV) has been fueled by 
its enormous potential as a gene therapy tool, given that it has never been associated with 
disease, can infect a wide variety of mitotic and post-mitotic cells, and its coding elements 
can be replaced with therapeutic transgenes of up to ~5kb (Berns and Giraud, 1996)..  As a 
member of the parvovirus family, AAV is one of the most unadorned viruses.  It has a 
diameter of only 25nm, is non-enveloped, and cannot replicate on its own.  The single 
stranded wild type viral genome is flanked by two inverted terminal repeats that are the only 
elements necessary for packaging.  The three capsid proteins (VP1, VP2, and VP3) are 
encoded in an overlapping reading frame, each beginning with a different start codon but 
sharing a common C-terminus and stop codon.  Capsids are comprised of 60 proteins, with 
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V1, VP2, and VP3 in a ratio of approximately 1:1:10, respectively (Buller and Rose, 1978; 
Muzyczka, 1992).   
Although AAV has a several properties that make it an attractive vehicle for gene 
therapy, transduction is difficult to achieve in many cell types due to inefficient subcellular 
trafficking (Sanlioglu et al., 2001; Ding et al., 2003; Hauck et al., 2004).  At the cellular 
level, infection commences with receptor attachment, which is mediated by glycoproteins 
such as heparan sulphate (Summerford and Samulski, 1998; Qing et al., 1999; Summerford et 
al., 1999).  After coreceptor activation AAV2 is endocytosed from the cell surface in a 
clathrin and dynamin dependent process (Duan et al., 1999; Bartlett et al., 2000; Bantel-
Schaal et al., 2002).  Subsequently virions are reported to traffic through early endosomes 
(Bartlett et al., 2000), late-endosomes, recycling endosomes, lysosomes (Ding et al., 2006), 
and AAV2 and AAV5 have been visualized in the Golgi apparatus (Bantel-Schaal et al., 
2002; Pajusola et al., 2002).  The capsid must release its genome through an uncoating 
process, so that the genome is able to undergo second strand synthesis or can reanneal with a 
complementary single-stranded genome.  Ultimately, the transgene must be delivered to the 
nucleus, transition from a single-stranded genome to a double-stranded intermediate, and 
convert to a stable double-stranded form, before transduction is considered complete (Wang 
et al., 2007).  We have demonstrated that capsids are capable of entering the nucleus intact 
(Johnson and Samulski, 2009), but it is still debated whether that location is the site for 
uncoating.  To complete transduction, the capsid must successfully deliver the genome to the 
nucleus, but the vast majority of genomes remain outside the nuclear membrane (Ding et al., 
2003; Hauck et al., 2004).  
Domains that are necessary for subcellular steps in infection are harbored in the N-
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terminus of VP1 and VP2 (Zadori et al., 2001; Girod et al., 2002; Canaan et al., 2004).  
These regions of VP1 and VP2 are thought to translocate to the capsid exterior during a 
conformational change that occurs in the capsid at some point after receptor binding but prior 
to endosomal escape (Bleker et al., 2005; Kronenberg et al., 2005; Sonntag et al., 2006).  
Two functional elements of the capsid, a phospholipase A2 (PLA2) domain and putative 
nuclear localization signals (NLS), have been identified in unique N-terminal regions of VP1 
and VP2.  These elements are conserved in almost all parvoviruses  (Canaan et al., 2004) 
with a sequence of about 70 amino acids in VP1, being highly homologous to the catalytic 
domain of secretory PLA2.  Mutating the histidine and aspartic acid catalytic dyad of the 
PLA2 to alanine and asparagine (75HD/AN) does not affect cell surface attachment or 
endocytosis of the virus, but strongly inhibits PLA2 activity and ablates viral infectivity 
(Zadori et al., 2001). Though it has not been directly demonstrated, the PLA2 activity of 
AAV is surmised to mediate endosomal membrane permeabilization, permitting escape of 
into the cytosol. 
Transport of macromolecules such as parvoviruses across the nuclear membrane is an 
ATP-dependent process and is mediated by soluble cytosolic factors like Ran-1, that interact 
with specific NLSs on target proteins (Nigg, 1997; Gorlich and Kutay, 1999). NLSs have 
been identified on VP1 from various parvoviruses that are integral to nuclear targeting 
(Vihinen-Ranta et al., 1997; Lombardo et al., 2000; Lombardo et al., 2002).  The first ten 
residues of VP1 in canine parvovirus has been identified as an NLS (Vihinen-Ranta et al., 
1997) and minute virus of mice is known to have a bipartite NLS (Lombardo et al., 2002), 
and yet these residues are not conserved in AAV.    Several patches of hydrophilic, basic 
regions have been identified in AAV2 capsid proteins (Fig. 15A), termed BR1 (only in VP1), 
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BR2, and BR3 (in VP1 and VP2) (Grieger et al., 2006).  Mutating these regions results in a 
graduated loss of infectivity compared to recombinant AAV2: 1-log order for BR1 
(120QAKKR/QANNR), 2-log orders for BR2 (140PGKKR/PGNNR), and 3-log orders for BR3 
(168PARKR/PANNR) (Wu et al., 2000).  While it is known that these mutations negatively 
impact the infectivity of AAV2, their influence on subcellular trafficking in the context of the 
virion has not been studied in depth.   
Evidence from one of the most robust and well-studied NLSs, found in the large T-
antigen of SV40, suggests that the number of positive charges in an NLS correlates to the 
strength of its function (Kalderon et al., 1984; Kalderon and Smith, 1984).  Since the putative 
NLS regions in AAV are not extensive and nuclear targeting of AAV capsids is not efficient, 
we attempted to see if the BR2 and BR3 regions could be manipulated to, 1) tolerate 
additional positive charge, and 2) mediate enhanced nuclear targeting and transduction.  
Thus, for these studies we have engineered mutations into the N-termini of VP1 and VP2 to 
explore their affects on subcellular trafficking and transduction.  Here we report that these 
mutants display differences in their trafficking profiles: in contrast to recombinant AAV2 
(rAAV2), the majority of the mutants cannot be detected in the nucleus.  The BR1- mutant  
targets mainly to the Golgi, whereas BR2- and BR3- display a slightly more diffuse 
localization, distal from the nucleus.  Remarkably, we have generated one mutant, that 
contains a lysine for alanine substitution in BR3 (168PARKR/PKRKR, BR3+K) is 10 to 100-
fold less infectious than AAV2 in HEK-293 and HeLa cells, but is able to enter the nucleus.  
Our results implicate this mutant is defective at uncoating and suggest residues in VP1 play a 
role in genome release.  With this work we have generated a capsid toolkit which will aid in 
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dissecting the specific events in subcellular trafficking that lead to infection and will advance 
the design of AAV-based vectors. 
 
Materials and Methods 
Cell culture.  HeLa cells and HEK-293 cells were maintained at 37°C and 5% CO2 
in Dulbecco’s modified Eagle’s medium (DMEM) that was supplemented with 10% heat-
inactivated fetal calf serum, 100U/ml penicillin, and 100g/ml streptomycin. 
PCR site-directed mutagenesis. Capsid mutations were generated as previously 
described in the pXR2 backbone (Grieger et al., 2006), with minor modifications.  PCR was 
performed with the Expand Long Template PCR kit from Roche, but according to cycle 
guidelines listed in the manual for QuickChange site-directed mutagenesis (Stratagene). PCR 
products were digested with DpnI and transformed into DH10B bacteria, which were 
selected on ampicillin-containing agar plates.  Single colonies were picked and grown in 
liquid cultures overnight, and plasmids were isolated by QIAGEN Miniprep kits.  Mutations 
were verified by sequencing of the plasmids utilizing the UNC-CH Automated DNA 
Sequencing Facility on a 3100 Genetic Analyzer (Applied Biosystems).  
Virus production. Virus was produced in HEK-293 cells as previously described 
(Xiao et al., 1998).  Briefly, polyethylenimine (linear molecular weight, ~ 25,000) was used 
to for triple transfection of the pXR2 cap and rep plasmid, the pXX6-80 helper plasmid, and 
pTR-Luciferase or TR-eGFP reporter plasmids containing either luciferase or enhanced green 
fluorescent protein (eGFP) transgenes flanked by inverted terminal repeats.  Between 48 and 
72hr post-transfection cells were harvested and virus was purified by cesium chloride 
gradient density centrifugation.  After identifying peak fractions by dot blot hybridization, 
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virus was dialyzed into 1X phosphate-buffered saline (PBS).  Titers were calculated by qPCR 
according to established procedures (Johnson and Samulski, 2009) using a LightCycler 480 
using Sybr green (Roche) and primers designed against the firefly Luciferase transgene: 
(fwd) Luciferase 5’ AAA AGC ACT CTG ATT GAC AAA TAC 3’, and (rev) 5’ CCT TCG 
CTT CAA AAA ATG GAA C 3’.  Conditions used for the reaction were as follows:  1 cycle 
at 95ºC for 10min, 45 cycles at  95ºC for 10sec, 62ºC for 10sec, 72ºC for 10sec, 1 cycle at 
95ºC for 30sec, 65ºC for 1min, and 99ºC for acquisition.  Adenovirus mutant stocks were 
generously provided by Pat Hearing or available in the lab, produced and purified as 
previously described (Huang and Hearing, 1989; Ferrari et al., 1996). 
Confocal immunofluorescence microscopy.  Similar to what we have previously 
described (Grieger et al., 2007), HeLa cells (5 × 104/well) were plated on poly-L-lysine-
coated 12-mm glass coverslips (#1.5) 24hr before infection. Recombinant virions were added 
to cell media (2 × 104 vg/cell).   No virus was added to control wells.  Where indicated, HU 
was added at 10 mM for 12hr and washed off extensively prior to virus administration.  
Proteasome inhibitor (MG132, Calbiochem) was present for the duration of infection at 2 
µM, when used. At indicated time points, cells were washed three times with PBS and then 
fixed with 2% paraformaldehyde for 15min at room temperature. The cells were then 
permeabilized with 0.1% Triton X-100 in PBS for 5min at room temperature. Following four 
washes with PBS, the permeabilized cells were blocked with immunofluorescence buffer 
(IFB) (20 mM Tris, pH 7.5, 137 mM NaCl, 3 mM KCl, 1.5 mM MgCl2, 5 mg/ml bovine 
serum albumin, 0.05% Tween) for 30min at room temperature. The cells were incubated with 
primary antibody to detect intact capsids (MAb A20 (1:10), NCL (Abcam 22758, 1:1,000), 
or laminB1 (Abcam 16048, 1:750) diluted in IFB, for 1hr at 37°C or overnight at 4°C. The 
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cells were then incubated in secondary antibody, diluted 1:5,000 in IFB (anti-mouse Alexa 
Fluor 488; or anti-rabbit Alexa Fluor 568, Molecular Probes), for 1hr at 37°C. After six 
washes in PBS, coverslips were mounted cell side down on glass slides with mounting 
medium (Prolong antifade Gold with DAPI [4′,6′-diamidino-2-phenylindole]; Molecular 
Probes). Images were captured on a Leica SP2 AOBS upright laser scanning confocal 
microscope and processed using Adobe Photoshop. 
3-Dimensional rendering of infection.  Confocal Z-stack sections of HeLa cells 
fixed 16hr after infection with either rAAV2 or mutant virions (20,000 vg/cell) were 
processed and rendered in 3 dimensions using Volocity software (Improvision). 
Cell fractionation and nucleolar isolation.  Nucleoli were isolated from cell 
fractionations as previously described (Mauramatsu, 1963), with minor modifications 
allowing for viral infection (Johnson and Samulski, 2009).  Briefly, five 15cm plates of HeLa 
cells at 90% confluency were used for each preparation.  rAAV2 or mutant virions were 
incubated with cells for 16hr at 37°C (2,000vg/cell).  Cells were washed 3× with ice cold 
PBS and harvested by centrifugation at 218g for 5min.  The cell pellet was resuspended in 
hypotonic buffer and homogenized on ice using a tight pestle to the point where >90% of 
cells were burst (approximately 15 strokes), and leaving nuclei intact.  The homogenate was 
spun at 218g for 5min to separate crude nuclear pellet from the post-nuclear supernatant 
(PNS, ~5ml).  Nuclei were further purified from cytoplasmic contaminants by spinning 
through a 0.35 M sucrose cushion to give a nuclear associated (NA) pellet.  Nuclei were 
lysed by limited sonication on ice and the nuclear suspension in 0.35 M sucrose was layered 
over a 0.88 M sucrose cushion to separate nucleoli (NU, 200µl) from NA fractions (~5ml).  
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Nucleoli were further purified by another spin through sucrose and their integrity and purity 
was verified by phase-contrast microscopy and western blot.  
Transduction assays.  At least 4hr prior to infection or drug treatment, HEK-293 or 
HeLa cells were plated in 24 well plates at a density of 2x105 or 105cells/well, respectively.  
For drug studies, cells were handled as stated above.  Cells were infected with purified 
rAAV2 at designated vector genomes per cell and typically harvested after 24hr unless 
otherwise noted. Luciferase activity was measured in accordance with the manufacturer's 
instructions (Promega). Luciferase activity was measured with a Wallac1420 Victor2 
automated plate reader.  Error bars represent standard deviations from samples scored in 
triplicate.  Graphs are representative data sets from at least three independent assays. 
Western blotting.  As reported (Johnson and Samulski, 2009), samples from purified 
virus or cell fractionations were loaded onto NuPage 10% Bis-Tris gels and typically run 
using for 3hr at 150V in 1× NuPage MOPS (morpholinepropanesulfonic acid) buffer.  
Electrophoresis was performed in the XCell SureLock Mini Cell (Invitrogen). Proteins were 
transferred to a Hybond ECL membrane utilizing the XCell II Blot module (Invitrogen) 
according to the manufacturer's protocol.  Membranes were blocked in 5% nonfat dry milk 
(NFDM) dissolved in 1× PBS/Tween(0.1%). For detection of capsid proteins, primary 
antibody (Mab B1) was diluted 1:20 with 2.5% NFDM in 1× PBS/Tween(0.1%) and 
incubated for 1 h at room temperature or overnight at 4°C. After washing with 1× 
PBS/Tween(0.1%), blots were incubated for 1hr at room temperature with anti-mouse HRP 
secondary antibody, diluted 1:5,000 in 2.5% NFDM with 1× PBS/Tween(0.1%).  Following 
multiple washes with 1× PBS/Tween(0.1%), SuperSignal West Femto Maximum Sensitivity 
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Substrate (Pierce) was added to each membrane according to the manufacturer's protocol for 
developing. Each membrane was then exposed to Amersham Hyperfilm MP. 
Immunoblot after limited heat treatment. To examine capsid stability and VP1 
exposure, purified virions (1x109vg/sample) were heat treated over a range of temperatures 
between 37oC and 75oC for 10min in PBS, then blotted onto a nitrocellulose membrane 
through a dot blotting apparatus. The membrane was processed as described for western 
blotting, using antibodies to detect intact capsids (monoclonal A20 - diluted 1:10), exposed 
VP1 N-termini (monoclonal A1 - diluted 1:20; polyclonal αVP1 – diluted 1:1000), 
disassembled subunits (monoclonal B1 - diluted 1:2000), and appropriate secondary 
antibodies conjugated to HRP.   
Fluorescent in situ hybridization to detect viral genomes.  HeLa cells were plated 
onto chamber slides (Nunc) coated with poly-L-lysine (25x103cells/well) 24hr prior to 
infection.  rAAV2 or BR3+K virions were administered (10,000vg/cell) for 16hr before the 
cells were washed 4X with PBS and fixed with 4% paraformaldehyde for 15min at room 
temp.  Cells were then treated with protease-K (0.5µg/ml) for 5min, washed with PBS and 
fixed again in paraformaldehyde.  Then samples were treated with triethanolamine-HCl with 
acetic anhydride for 10min at room temp, washed with PBS, and prehybridized for 2hr at 
65oC in pre-warmed hybridization buffer.   A Digoxigenin-labeled RNA probe that was not 
complementary to transcribed mRNA of the vector genome was synthesized using T7 
polymerase and spanned a 1kb fragment of the firefly luciferase transgene.  Probe was added 
to samples in hybridization buffer overnight at 65oC and after washing steps, the Digoxigenin 
label was detected using the Roche Fast Red kit for fluorescent in situ hybridization, then 
slides were coverslipped and mounted with DAPI to detect cell nuclei. 
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Results 
Mutations in VP1 and VP2 N-termini are known to reduce infectivity of AAV2 (Wu 
et al., 2000; Grieger et al., 2006; Sonntag et al., 2006), yet not much is known about how 
these components of the virion direct events in subcellular trafficking.  Discovering how 
capsid residues mediate nuclear targeting is an important step towards engineering gene 
therapy vectors that display efficient transduction in target cells.  To this end we have 
generated capsid mutations in regions that span the PLA2 domain and NLS motifs of VP1 
and VP2 and have characterized their affect on subcellular trafficking, transduction, and 
sensitivity to proteasome inhibitors. 
Mutations in VP1/2 N-termini affect transduction of rAAV.  Previously we have 
identified through software prediction mapping that there are four potential NLS regions in 
AAV2 (Grieger et al., 2006).  The first three, BR1, BR2, and BR3 were found to be 
important for transduction, but the fourth was required for capsid assembly.  Since mutating 
BR2 and BR3 was shown to have the most significant impact on transduction, we wanted to 
assess whether these regions would tolerate additional positive charge in attempt to increase 
the strength of their NLS activity, similar to what has been demonstrated for the large T-
antigen of SV40 (Kalderon et al., 1984; Kalderon and Smith, 1984; Welsh et al., 1986).  
Through PCR mutagenesis we have generated capsid mutants that lack VP1 and VP2 
(VP3only), lack PLA2 activity (75HD/AN) (Girod et al., 2002),  lack positive charges in VP1 
and VP2 (BR1-, BR2-, BR3-), or have additional lysine residues in these latter basic regions 
(BR2+K, BR3+K)  (Fig 15B).  Each of these mutants was found to assemble into capsids 
containing appropriate stoichiometric ratios of VP1, VP2, and VP3 at roughly 1:1:10,  
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Fig 15. Mutations in VP1/2 N-termini affect transduction of rAAV.  A. The AAV 
genome contains genes that code for Rep proteins involved in replication and Cap proteins 
that comprise the capsid.  The Cap proteins VP1, VP2, and VP3, exist in a 1:1:10 ratio in the 
capsid, respectively, and harbor a phospholipase domain (HD) and basic regions (+) that are 
putative nuclear localization signals. B. Capsid mutants used in this study are listed by 
sequence and amino acid changes are shown by red lettering.  C. Western of purified virus 
(5x109vg) blotted with antibody B1 that detects VP1, VP2, and VP3.  Similar to rAAV2, 
capsid proteins are in appropriate ratios for all mutants. D. Luciferase assay of transduction 
in HEK-293 cells and HeLa cells (E).  rAAV2 or mutants that package TR-CMV-Luc were 
administered (10,000vg/cell) and luciferase activity was quantified 24hr later. Error bars 
represent standard deviations from three independent samples. 
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respectively (Fig 15C).  These mutants were found to produce titers of similar magnitude to 
that of rAAV2 (data not shown), corroborating reports that VP1 and VP2 do not play a role 
in packaging (Warrington et al., 2004).  However, these mutations have striking effects on 
transduction that is mirrored in HEK-293 cells and HeLa cells (Fig 1D & E).    Mutated 
capsids VP3only, 75HD/AN, BR3-, and BR3+K seem to be the most deficient of the group 
and it is difficult to distinguish any difference from background light units (log RLUs ≤ 2 ). 
BR3+K performs slightly better in HeLa cells than in HEK-293 cells, but nonetheless, it still 
transduced between 10 and 100-fold less efficiently than rAAV2.  
Time-course of rAAV2 internalization.  To establish a point of reference for 
examining mutant localization, we first profiled subcellular trafficking of rAAV2 through a 
time course.  In attempt to track the bulk flow of particles from one stage of infection to the 
next, we sought to pulse cells with a high concentration of virus for a short time and then 
remove the supply of extracellular particles, similar to what has been done by other groups 
(Bartlett and Samulski, 1998; Leopold et al., 1998; Xiao et al., 2002).  HeLa cells were 
cooled to 4oC to inhibit endocytosis and incubated with rAAV2 virions (20,000vg/cell) for 
1hr to potentially saturate AAV-receptor interactions.  Cells were transferred to 37oC to 
initiate rapid endocytosis, after 10min unbound virus was thoroughly washed away, and 
samples were fixed and prepped for confocal immunofluorescence at the indicated time 
points (Fig 16).  The cells were returned to 37oC, and then cells were fixed and stained for 
immunofluorescence microscopy at the indicated times.  Immediately following the 10min 
pulse, the fluorescent signal from the virus appears evenly distributed throughout the cell.  
Accumulation more toward the center of the cell was observed at the 30min time point and  
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Fig 16. Time-course of rAAV2 internalization.  HeLa cells were incubated with rAAV2 
virions (20,000vg/cell) at 4oC to inhibit endocytosis.  After transferring cells to 37oC for 
10min, unbound virus was washed away, the cells were returned to 37oC, and then cells were 
fixed and stained for immunofluorescence microscopy at the indicated times.  Intact capsids 
were detected with Mab A20 (green), nuclei (blue) were detected with DAPI, and cell 
outlines are shown by differential interference contrast microscopy (DIC, panels vi-x). 
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by 2hr post-infection there was clear perinuclear clustering, as reported previously (Zadori et 
al., 2001).  Few particles remain at the distal portions of the cell by 24hr post-infection, as 
most have accumulated next to the nucleus.  From this study alone it is impossible to 
determine if any capsids have escaped from the endosome.  It is noteworthy to mention that 
the majority of virus appears excluded from the nucleus at all time points assayed.  
Localization of rAAV2 capsids compared to perinuclear cellular markers.  Two 
major cellular compartments arranged in a perinuclear fashion are the endoplasmic reticulum 
(ER) and the Golgi apparatus, which are oriented towards the microtubule organizing center 
(MTOC – see Chapter 4).  Both AAV2 and AAV5 have been shown to associated with the 
Golgi 5, 95).  AAV capsids have not been shown to enter to the ER, but other viruses such as 
SV40 will engage retrograde transport pathways from the Golgi to ER in order to undergo 
disulfide processing necessary for subsequent steps in infection (Kartenbeck et al., 1989; 
Pelkmans et al., 2001; Schelhaas et al., 2007).  Currently it is not clear if AAV particles 
require processing in either compartment during infection, but since a preponderance of 
capsids are found to accumulate perinuclearly, we asked whether they colocalized with these 
compartments.   
HeLa cells were infected for 16hr with rAAV2 and prepped for confocal 
immunofluorescence with antibodies directed toward cellular markers (red) for Golgi sorting 
components (cop-β, KDEL-R), ER-resident chaperones (BiP, calnexin, calreticulin), or 
rAAV2 capsids (green).  We detected significant colocalization with cop-β (Fig 17), a 
component of the coatomer complex that is typically associated with COPI transport in an 
retrograde direction from the Golgi to the ER (Lee et al., 2004).  Moderate colocalization was 
detected between rAAV2 and KDEL-R, a receptor that recognizes lysine-aspartate- 
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Fig 17.  Localization of rAAV2 capsids compared to perinuclear cellular markers.  
rAAV2 virions (10,000vg/cell) were administered to HeLa cells for 16hr and prepped for 
confocal immunofluorescence with antibodies directed toward cellular markers (red) for 
golgi sorting components (cop-β, KDEL-R), ER-resident chaperones (BiP, calnexin, 
calreticulin), or rAAV2 capsids (green).  Nuclei (blue) were stained with DAPI.  White 
arrows indicate moderate colocalization with cop-β and KDEL-R, whereas no obvious 
colocalization was seen with ER markers. 
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glutamate-arginine (KDEL) lumenal signal sequences at the C-terminus of proteins (Munro 
and Pelham, 1987; Pelham, 1988; Lewis and Pelham, 1992).  KDEL-R serves as an ER-
retention device for misfolded proteins and transitions between the Golgi, ER-intermediate 
compartment, and the ER (Lewis and Pelham, 1992). No obvious colocalization was found 
between rAAV capsids and traditional markers for the ER, BiP/Grp78, calnexin, or 
calreticulin (Kleizen and Braakman, 2004).  Although fluorescent signal corresponding to 
capsids emanated from the same area of the cell as BiP, calnexin, or calreticulin, these 
signals did not directly overlay with one another.  While we did find evidence of AAV2 
colocalization with the ER, the partial colocalization between rAAV2 and cop-β or KDEL-R 
(Fig 17, white arrows) is highly suggestive that an rAAV2 capsid population is subjected to 
retrograde transport from the Golgi apparatus. 
Subcellular localization of capsid mutants.  Having demonstrated that a percentage 
of rAAV2 capsids colocalize with the Golgi during trafficking, we used this area as a 
reference point for analyzing whether mutant capsids traffic differently than rAAV2.  Using 
z-stacked confocal slices of HeLa cells prepped for immunofluorescence, we were able to 
process a 3-dimensional rendering of infection with volume imaging software.  We found all 
mutants were able to bind and internalize into cells and either displayed partial or significant 
colocalization with the Golgi apparatus (Fig 18).  We observed pronounced Golgi 
localization with mutant BR1-, and less with other mutants (see Discussion). Capsid mutants 
BR2- and BR3- appear to have diffuse localization throughout the cell in addition to 
localizing to the Golgi.  This supports the idea that BR2 and BR3 are important for nuclear 
localization, but it is unclear from this work if these mutant capsids remain in endosomal 
compartments at distal regions or have escaped into the cytoplasm.  Due to the observation  
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Fig 18. Subcellular localization of capsid mutants.  Volume imaging software was used to 
process z-stacked confocal images of HeLa cells infected with capsid mutants 
(10,000vg/cell) for 16hr.  Capsids (green) are shown in relation to the golgi marker giantin 
(red) and nuclei (blue).  All mutants, along with rAAV2 display some level of colocalization 
with the golgi apparatus, with BR1- being the most intense.  Capsid mutants BR2- and BR3- 
appear to have diffuse localization throughout the cell in addition to localizing to the golgi, as 
compared to rAAV2 and other mutants. 
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that a population of even the most deficient mutants traffic to the Golgi during infection, 
namely VP3only and 75HD/AN particles, it is tempting to speculate that accumulation in the 
Golgi is a default sorting pathway taken by the virus which does not require PLA2 or NLS 
function.  However, from these experiments alone it cannot be determined if Golgi targeting 
is a requirement for infection.  
Exposure of VP1 N-termini.  Many viruses are known to experience a maturation 
process during entry into cells that is necessary for infection to progress.  Parvoviruses 
follow this paradigm, with the most striking event to date being exposure of VP1/2 N-termini 
(Kronenberg et al., 2005; Sonntag et al., 2006). Presumably, a conformational change enables 
the N-terminus of VP1/2 to translocate to the capsid exterior while the virus is in the 
endosome or other subcellular compartment.  In searching for an explanation of why 
mutations in VP1/2 render AAV2 non-infectious, it is important to establish whether VP1/2 
N-termini can be appropriately exposed in these capsids during infection.  Several antibodies 
have been generated that suit this purpose and specifically detect either intact capsids (A20), 
VP1 N-termini (A1 / αVP1), or disassembled subunits (B1) (Fig 19A) (Wobus et al., 2000).  
Extrusion of VP1/2 N-termini can be induced in vitro by limited heat treatment or urea.  
Kronenberg et al., have demonstrated that empty capsids fail to expose VP1 at temperatures 
that do expose VP1 in rAAV2 (Kronenberg et al., 2001).  We have reproduced this result by 
immunoblotting purified capsids on nitrocellulose after treating them to a range of 
temperatures, which offers an explanation of why empty capsids are defective at trafficking 
to the nucleus (Johnson and Samulski, 2009).  In contrast to empty capsids, virions with 
mutations in VP1 N-termini are able to expose VP1 similar to rAAV2 after limited heat 
treatment.  Epitopes on VP1 become exposed after incubation at 60oC (reactive to αVP1),  
  77 
 
Fig 19.  Exposure of VP1 N-termini.  A. Antibodies that specifically detect either intact 
capsids (A20), VP1 N-termini (A1 / αVP1), or disassembled subunits (B1), permit analysis 
of conformational changes in vitro in response to limited heat treatment or in cells during 
infection. B. Immunoblot showing exposure of VP1 N-termini.  rAAV2 virions or empty 
capsids were exposed to limited heat treatment after limited heat treatment at designated 
temperatures for 10min, applied to nitrocellulose membranes, incubated with antibodies 
shown, and developed after processing for chemiluminescence. Empty capsids are more 
resistant to exposing VP1.  C. Immunoblot comparing VP1 exposure among capsid mutants 
(1x109vg/well).  Capsids disassemble prior to 75oC as indicated by losing A20 reactivity and 
gaining B1 reactivity.  An intermediate conformational change exists after heating capsids to 
60oC, where VP1 epitopes are detected but capsids remain intact. D. Immunofluorescence 
microscopy demonstrating VP1 exposure during infection.  Capsids (green) display VP1 
exposure (red) in a perinuclear region.  Empty capsids, which are deficient in VP1 exposure 
and VP3only particles, which lack VP1, show no significant signal from αVP1(aa2-16).  The 
two mutants that are least infectious, 75HD/AN and BR3-, have not lost the ability to expose 
VP1 during infection, implicating dysfunction in later steps during infection as cause for lost 
transduction. 
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with capsids remaining intact as indicated by A20 reactivity and lack of B1 reactivity (Fig 
19C).   
We have also visualized VP1 exposure during infection in HeLa cells using indirect 
immunofluorescence confocal microscopy (Fig 19D).  Signal for exposed VP1 (red, αVP1) 
overlaps with signal for capsids (green, A20) in a perinuclear region that mainly corresponds 
to Golgi (data not shown).  Supporting our findings from immunoblotting capsids after heat 
treatment, we demonstrate here that we cannot detect significant exposure of VP1 N-termini 
on empty capsids.  As a negative control, VP3only particles, which lack VP1, show no 
significant signal from αVP1(aa2-16).  Additionally, we found other mutants (75HD/AN and 
BR3-, shown in Fig 19D), are still capable of exposing VP1 during entry.  Thus, we conclude 
that these mutants are deficient at later steps in infection, such as endosomal escape or 
nuclear targeting.  
Effect of proteasome inhibition on nucleolar accumulation and transduction of 
capsid mutants.  Proteasome inhibitors are known to be one of the most potent agents for 
enhancing transduction of AAV in certain cell types (Ding et al., 2005).  The mechanism by 
which these drugs act to improve transduction remains controversial, and a number of 
theories have been presented to explain their effects, including one or more of the following: 
increase nuclear delivery of AAV (Duan et al., 2000), increase ubiquitination of capsids (Yan 
et al., 2002), inhibit clearance of viral genomes (Douar et al., 2001), and potentiate 
accumulation of capsids in the nucleolus (Johnson and Samulski, 2009).  Determining if 
mutant transduction can be rescued by proteasome inhibitors will help identify where these 
mutants are defective and may shed light on how blocking proteasomal degradation increases 
AAV efficiency.  First we explored the effects of the proteasome inhibitor, MG132, on 
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capsid localization using indirect immunofluorescence (Fig 20A).  Capsids from rAAV2, 
BR2+K, and BR3+K capsids (green) are found to accumulate in the nucleus (white arrows).  
We found VP3only, 75HD/AN, and BR1-, BR2-, and BR3- mutants are mostly restricted to 
extra-nuclear regions.  We corroborated these findings by subcellular fractionation and 
detected rAAV2, BR2+K, and BR3+K capsids in nucleolar isolations (Fig 20B).  To a much 
lesser extent, VP3 protein from BR1- and BR2- mutants are detectable in these fractions as 
well.  
The effect of MG132 on transduction of mutants was also analyzed.  Remarkably, the 
pattern for transduction enhancement did not match the effect on capsid localization.  Only 
rAAV2, BR1-, and BR2+K transduction profiles were augmented by MG132 treatment, as 
determined by luciferase assay (Fig 20C).  The most perplexing discrepancy was seen with 
BR3+K, a mutant that was found to accumulate in nucleoli in response to MG132, shown by 
indirect immunofluorescence and subcellular fractionation.  Surprisingly, transduction of this 
mutant was not affected by MG132.  This finding raises important questions which we will 
attempt to address in the remainder of this chapter.  Do BR3+K capsids release their genome 
prematurely?  Are nucleolar-associated BR3+K capsids unable to release their genome?  Can 
any treatments rescue transduction of BR3+K?  What does this tell us about how proteasome 
inhibitors influence AAV infection? 
Stability of BR3+K capsids compared to rAAV.  One possible explanation for this 
discrepancy between effective nucleolar localization and low transduction is that BR3+K 
capsids have released their genomes before entering the nucleus, and thus cannot efficiently 
transduce HeLa or HEK-293 cells.   Thus we set out to determine if BR3+K capsids were 
physically different from rAAV2, in terms of their ultrastructural appearance judged by  
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Fig 20.  Effect of proteasome inhibition on nucleolar accumulation and transduction of 
capsid mutants.  MG132 (2µM) was administered to HeLa cells simultaneously with virions 
(20,000vg/cell) and after 16hrs samples were prepped for immunofluorescence microscopy.  
rAAV2, BR2+K, and BR3+K capsids (green) are found to accumulate in the nucleus (white 
arrows), and VP3only, 75HD/AN, and BR1-, BR2-, and BR3- capsids are mostly restricted to 
extranuclear regions.  B. Subcellular fractionation of nucleoli after infection.  HeLa cells 
were infected with mutant virions (1,000vg/cell) for 16hr and subjected to subcellular 
fractionation.  Capsid proteins from rAAV2, BR2+K, and BR3+K were detected in nucleolar 
fractions by western blot. C. Luciferase assay of transduction in the presence of proteasome 
inhibitor.  HEK-293 cells were infected (10,000vg/cell) for 24hr in the presence of MG132 
(2µM) and then scored for transduction efficiency.  Error bars represent standard deviations 
from three independent samples. 
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electron microscopy, capsid sensitivity to limited heat treatment, and genome sensitivity to 
DNase.  To this end we subjected purified virus preparations to uranyl-acetate negative 
staining and captured images by electron microscopy.  At this resolution, it is difficult to 
determine if there are significant structural differences between rAAV2 and BR3+K capsids 
(Fig 21A).   We also submitted these capsids to a refined heat gradient using eight 
temperatures between 37oC and 75oC.  In this assay rAAV2 and BR3+K capsids are 
comparable with respect to thermostability (Fig 21B). VP1 N-termini become exposed after 
57oC, and disassembled subunits can be detected prominently for both capsids at 65oC.  With 
this immunoblot, there was a subtle difference in B1 signal for the lower temperatures, as 
BR3+K appeared slightly more reactive.  This can be attributed to variability from prep to 
prep and could not be reliably be reproduced.  Additionally, we wanted to determine if 
differences existed with respect to genome protection, and so after heat treatment, virions 
were treated with DNase and the remaining genomes were measured by quantitative PCR.  
For both rAAV2 and BR3+K, genomes begin to become sensitive to DNase at the same 
temperatures that extrude VP1 N-termini (Fig 21C).  Again, we found no difference between 
rAAV2 and BR3+K, as their patterns of DNase sensitivity are indistinguishable.  From these 
in vitro assays, we conclude that the mutation BR3+K has no observable effects on capsid 
ultrastructure, thermostability, or DNase sensitivity.  
Fluorescent in situ hybridization depicting DNA from BR3+K is delivered to the 
nucleus during infection.  In vitro assays often fall short of reproducing complex biological 
processes in a cell or an organism.  Because the preceding tests on stability did not uncover 
any differences between rAAV2 and BR3+K, we are no closer to determining if BR3+K 
capsids release their genomes prematurely before entering the nucleus, or are unable to  
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Fig 21. Stability of BR3+K capsids compared to rAAV.  A. Purified virus preparations 
were subjected to uranyl-acetate negative staining and applied to discharged copper grids for 
electron microscopy.  Image width is approximately 150nm.  B.  Immunoblot of antibody 
reactivity after limited heat treatment (10min at designated temperatures) indicates rAAV2 
and BR3+K capsids have similar macromolecular stability.  Capsids are no longer intact at 
75oC (A20), VP1 N-termini become exposed after 57oC, and disassembled subunits can be 
detected prominently for botch capsids at 65oC.  C.  After heat treatment, virions were treated 
with DNase and submitted to qPCR to compare genome protection.  rAAV2 and BR3+K 
have indistinguishable patterns of DNase sensitivity after heat treatment.  Line graph is 
representative data from one of three experiments. 
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release their genomes once the capsid has reached the nucleolus.  Therefore, we used 
fluorescent in situ hybridization (FISH) to visualize the location of BR3+K viral genomes 
during infection.  HeLa cells were infected with rAAV2 or BR3+K (20,000vg/cell) for 16hr 
and prepped for FISH using an RNA probe that only detects single-stranded genomes of 
minus strand polarity, to avoid detection of transcribed mRNA. Similar to what we have 
found with capsid localization, the majority of genomes (red) accumulate in a perinuclear 
region (Fig 22A, panels ii and iii).  When the proteasome inhibitor, MG132, is administered 
concurrently with virus, we found genomes are delivered to the nucleus and accumulate in 
the nucleolus (Fig 22B, panels ii and iii). When uninfected cells are processed for FISH, no 
signal can be detected, indicating the probe is specific to the viral genome (Fig 22, panels Ai 
and Bi).  Differential interference contrast (DIC) microscopy was employed to display cell 
outlines (panels iv, v, and vi).  Highly refractive points of light emanate from perinuclear 
areas that correspond to virus staining and are reminiscent of vesicular or vacuolar structures 
that are readily detected with DIC .  These are likely an artifact of the protease treatment used 
during sample preparation and do not affect our interpretation of these results.  We speculate 
that since BR3+K genomes and capsids can be detected in the nucleolus, this mutant has an 
uncoating defect.  
Adenovirus, but not MG132, potentiates transduction of BR3+K.  Our attempts to 
rescue BR3+K transduction with a variety of pharmacological agents were unsuccessful, but 
here we report that Adenovirus (Ad) is capable of enhancing transduction of this mutant.  
HEK-293 cells or HeLa cells were infected with rAAV2 or BR3+K (10,000vg/cell, 
packaging TR-CMV-Luc) either alone, or in the presence of MG132 (2µM) or Ad 
(5pfu/cell), and a luciferase assay of transduction was performed 24hr later to score  
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Fig 22.  Fluorescent in situ hybridization depicting DNA from BR3+K is delivered to 
the nucleus during infection.  HeLa cells were infected with rAAV2 or BR3+K 
(20,000vg/cell) for 16hr in the absence (A) or presence of MG132 (B).  Cells were prepped 
for FISH using an RNA probe complementary to the antisense strand of the TR-Luc genome.  
No staining in control samples (panels Ai and Bi) indicates the probe does not display non-
specific binding.  Both rAAV2 (panel Bii) and BR3+K (panel Biii) genomes (red) are found 
to accumulate in the nucleus, specifically in nucleolar regions during proteasome inhibition. 
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transduction (Fig 23A and B).  For comparison, we performed identical assays in HEK-293 
and HeLa cells with vectors packaging TR-CBA-Luc, which have the chicken-beta-actin 
promoter in place of the cytomegalovirus promoter (Fig 23C and D).  In each of these 
experiments, transduction of BR3+K was at least one order of magnitude lower than that of 
rAAV2.  Similar to what we have shown earlier, proteasome inhibitors increase transduction 
of rAAV2, but not BR3+K.  Surprisingly, Ad was found to potentiate transduction of both 
rAAV2 and BR3+K at similar ratios.  Coadministration of Ad does not raise transduction of 
BR3+K to the same level as rAAV2 after enhancement; it only increases transduction to the 
same degree.  While suggesting that BR3+K carries some basal level of transduction 
capability, these results indicate that the mutant capsid is deficient compared to rAAV2 in 
these cell types. 
Ad-mediated transduction enhancement is dependent on E4 genes ORF3 and 
ORF6.  As with proteasome inhibitors, several mechanisms have been postulated for how Ad 
mediates enhanced transduction of AAV.  Two studies have focused on capsid effects, with 
one showing no effect on AAV internalization during the first 4hr of infection (Bartlett et al., 
2000), and the other indicating Ad might improve nuclear delivery of AAV (Xiao et al., 
2002).  Others put emphasis on the AAV genome and indicate that Ad genes affect the 
composition of the host cell nucleus, degrading the Mre11-Rad50-Nbs1 DNA repair complex 
(MRN) which normally is a barrier to AAV genome delivery (Schwartz et al., 2007).   Ten 
years ago, work using Ad deletion mutants demonstrated the primary helper function 
provided by Ad is to increase the efficiency of second strand synthesis (Ferrari et al., 1996; 
Fisher et al., 1996), and was dependent on E4 genes ORF3 and ORF6.  Older work has 
shown Ad mediates an effect on viral mRNA stabilization (Samulski and Shenk, 1988).   
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Fig 23. Adenovirus, but not MG132, potentiates transduction of BR3+K. A. Luciferase 
assay of transduction performed in HEK-293 cells with rAAV2 and BR3+K packaging TR-
CMV-Luc (10,000vg/cell).  Virus was administered for 24hr in the presence of Ad 
(5pfu/cell) or MG132 (2µM) and luciferase activity scored thereafter. B.  Luciferase assay in 
HeLa cells with TR-CMV-Luc vectors.  C and D. Luciferase assay of transduction using TR-
CBA-Luc vectors (1,000vg/cell) in HEK-293 and HeLa cells, respectively. 
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Here we provide evidence that E4 ORF3 and ORF6 are necessary for  Ad-mediated 
transduction enhancement of BR3+K.  Various Ad deletion mutants were coadministered 
with rAAV2 or BR3+K to HEK-293 cells or HeLa cells.  24hr later transduction of the AAV 
reporters was quantified by luciferase assay.  Deletion of the VA (dl331) or E3 (dl327, 
dl309) genes does not significantly impact transduction enhancement.  Deletion mutants 
dl312 and dl324 which lack E1a or E1a, E1b, IX, & E3 function (Fig 24A), do not enhance 
transduction of rAAV2 or BR3+K at these MOIs (5pfu/cell).  Differences between their 
effects in HEK-293 cells and HeLa cells are explained by the fact that these mutants are 
complemented by E1a transformation in HEK-293 cells.  It should be noted that E1a mutants 
have previously been shown to increase AAV transduction at high MOI (Ferrari et al., 1996).  
The mutant dl366, which lacks E4, did not increase transduction of rAAV2 or BR3+K.  By 
process of elimination, this identifies the E4 gene as providing the trans-acting factor for 
transduction enhancement.  We further narrowed our focus to the specific reading frames 
within E4 that are necessary for helper function, which are the redundant proteins in ORF3 
and ORF6.  By testing single mutants and a double mutant (Fig 10B), we have shown that the 
transduction enhancement mediated by Ad is lost only when both E4 ORF3 and ORF6 are 
deleted (Fig 24E and F). 
 
Discussion 
Studying events in AAV trafficking is becoming increasingly popular considering 
several groups have shown nuclear delivery of the genome is a major barrier to gene therapy 
(Duan et al., 2000; Hansen et al., 2000; Douar et al., 2001; Xiao et al., 2002; Zhong et al., 
2004a; Sonntag et al., 2006).  Despite efforts in this area, many of the biological principles  
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Fig 24. Ad-mediated transduction enhancement is dependent on E4 genes ORF3 and 
ORF6. A. Ad mutants lacking specific genes involved in the AAV helper effect are listed 
corresponding to their relative potential to increase AAV transduction (+).  Mutants dl312 
and dl324 will increase AAV transduction but require high MOI.  Note that HEK-293 cells 
will complement for lack of E1a (*).  B. Map of Ad E4 mutants shows dl355 is a deletion of 
ORF6, inORF3 contains an insertion of 8bp, and inORF3/dl355 is the compound mutant that 
knocks out their redundant functions.  Luciferase assays of transduction show the propensity 
of Ad mutants to enhance transduction of rAAV2 and BR3+K in HEK-293 cells (C & E) or 
HeLa cells (D & F).  Ad mutants (10pfu/cell, C & D; 2pfu/cell, E & F) were administered 
concurrently with rAAV2 or BR3+K (10,000vg/cell) for 24hr.  Ad genes E4 ORF3 and E4 
ORF6 mediate the transduction enhancement of rAAV2 and BR3+K, as indicated by the 
failure of mutants dl366 and inORF3/dl355 to increase luciferase activity. 
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that govern how AAV transitions from the cell surface to the nucleus remain unknown.  To 
more clearly understand the trafficking profile of the prototypical serotype, AAV2, and to 
explore how virion components modulate subcellular trafficking, we have generated 
mutations in the unique N-terminal regions of capsid proteins VP1 and VP2 and examined 
their effect on subcellular trafficking, transduction, and sensitivity to proteasome-mediated 
enhancement.  Here we report that these mutants are able to assemble into capsids, package 
DNA similar to wild type, internalize into cells, traffic through a perinuclear region in the 
vicinity of the Golgi apparatus, but display differences in their patterns of localization and 
transduction.  Using a variety of techniques, we show that one mutant (BR3+K) is able to 
carry its genome to the nucleus, but is 10 to 100-fold less infectious than rAAV2 in HEK-293 
and HeLa cells.  We hypothesize that the BR3+K capsid is unable to uncoat, either due to a 
high affinity to the nucleolus (which is provides a stable environment for the virion (Johnson 
and Samulski, 2009)), or to the extra positive charge prohibiting DNA release.  Our results 
highlight the role of VP1 in directing capsid trafficking, provide insight into how cells 
process the incoming virion, and underscore the complexity of AAV infection at the 
subcellular level. 
Central to this study is the finding that mutating residues in the PLA2 domain or the 
putative NLS motifs in VP1/2 will affect trafficking of capsids and directs them to different 
subcellular destinations (Fig 18).   Each of the mutant capsids appears to traffic through the 
Golgi apparatus, as has been shown for AAV2 and AAV5 (Bantel-Schaal et al., 2002; 
Pajusola et al., 2002).  It has been difficult to determine whether sorting of capsids through 
the Golgi is a necessary step during infection.  Monitoring the stages of BR2- and BR3- 
trafficking in a time-course fashion seems likely to shed light on the sequence of sorting 
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during infection, because these mutants are found to accumulate at some level in Golgi-
associated perinuclear space, but also exhibit a more evenly distributed localization pattern 
throughout the cell compared to rAAV2 and other mutants.  The necessity to follow bulk 
flow of capsids is a major limitation to our indirect immunofluorescence analysis of AAV 
infection, and has thus far prevented us from determining if Golgi accumulation is a 
preliminary step before capsids can escape to the cytoplasm or enter the nucleus.  Future 
studies using highly sensitive methods of virion detection, such as single-particle tracking 
(Seisenberger et al., 2001), should enable a more refined dissection of the infectious 
pathway. 
Concerning Golgi localization, it is interesting to note that a classical retrograde 
trafficking pathway from the Golgi to the ER depends on COPI interactions with 
cytoplasmically exposed di-lysine (KKXX) sequences on target proteins (Cosson and 
Letourneur, 1994; Letourneur et al., 1994).  Transmembrane proteins that present this 
sequence to the cytoplasm are recognized by components of the coatomer protein complex 
which then send these targets in vesicles from the Golgi toward the ER.  It seems plausible 
that rAAV2 could hijack this sorting pathway, since two di-lysine sequences are found in the 
N-terminus of VP1, and mutating one of them (BR1- 120QAKKR/QANNR) leads to an 
accumulation of capsids in the Golgi (Fig 18).  Structural modeling of VP1 predicts the N-
terminus can translocate through the 5-fold axis of symmetry in the capsid and permit 
exposure of the first 185 residues in VP1 (Kronenberg et al., 2005).  Since it only requires 
18-20 amino acids to span a phospholipid bilayer, this would be of sufficient length to allow 
presentation of the di-lysine sequences to the cytoplasm if the PLA2 domain had punctured 
through a Golgi or endosomal membrane.  
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The trigger for VP1 exposure remains elusive.  It has been postulated that the acidic 
environment of the endosome helps promote the conformational change required to expose 
VP1 through the 5-fold axis of symmetry (Bleker et al., 2005; Kronenberg et al., 2005; 
Sonntag et al., 2006), but this cannot been demonstrated in vitro through pH alone (our 
unpublished results).  Interestingly, research on canine parvovirus has demonstrated that VP1 
is exposed during endosomal trafficking even when endosomal acidification is inhibited by 
bafilomycin A1 or amiloride (Suikkanen et al., 2003).  For AAV, bafilomycin has been 
shown to reduce VP1 exposure during infection, but not completely.  Surprisingly, the 
lysosomotropic drug, chloroquine, transiently stimulated VP1 exposure  (Sonntag et al., 
2006).  The implications of these findings are two-fold; factors separate from pH are 
responsible for VP1 exposure, and events in addition to VP1 exposure are necessary for 
endosomal escape.  Dr. Mavis Agbandje-McKenna and colleagues at the University of 
Florida have shown through cryo-electron microscopy that heparin binding elicits a 
conformational change in AAV2 whereby the 5-fold pore becomes widened (Levy et al., 
2009).  Perhaps a combination of receptor binding and compartmental processing of AAV 
promotes exposure of VP1 and primes the virus for subsequent steps in infection.   
Several lines of evidence indicate the genome may play a role in VP1 exposure.  
Electron dense regions in the capsid interior change position in response to heat treatment, 
but this same change is not observed in empty capsids, according to work from 
Kleinschmidt’s group (Kronenberg et al., 2001).  DNA packaged within the capsid of a 
another parvovirus, the minute virus of mice (MVM), creates anisotropic structural 
reinforcement at several axis of symmetry, as measured by atomic force microscopy  
(Carrasco et al., 2006).  Rational mutagenesis of points along these axis of symmetry 
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negatively affects the mechanical stiffness of full capsids, but not empties (Carrasco et al., 
2008).  Its hypothesized that the DNA exerts internal pressure on the capsid shell and this 
pressure is thought to act as an impetus for genome ejection, as it does for bacteriophage  
(Smith et al., 2001; Evilevitch et al., 2003; Ivanovska et al., 2004; Ivanovska et al., 2007).  
Interestingly, genome release for MVM and the parvovirus B19 is said to occur concomitant 
with VP1 extrusion (Cotmore et al., 1999; Mani et al., 2006; Ros et al., 2006), further 
supporting a relationship between the virion DNA and propensity for conformational change 
in the capsid. 
  The concept of VP1 exposure occurring simultaneously with DNA extrusion has not 
previously been explored for AAV.  Here we present evidence that the genome becomes 
partially sensitive to DNase after limited heat treatment of the virion (Fig 21).  As epitopes 
for VP1 become exposed (~57oC) the number of genomes protected from DNase decreases.  
However, this does not conclusively demonstrate genome separation from the capsid, it only 
suggests the capsid ‘breathes’ enough to leave the genome partially accessible to digestion.  
If AAV behaves similar to MVM and B19, it would be natural for the N-terminus of VP1 to 
bring the virion DNA in tow when it translocates from the capsid interior. If the N-terminus 
of VP1 is intimately tied to genome extrusion, then mutating residues in VP1 may have 
negative repercussions on genome release and infection efficiency.  Essentially, this could 
explain what we have observed with BR3+K, since the extra positive charge provided by the 
additional lysine residue would stabilize an interaction with the negatively charged genome. 
Experiments designed to test whether VP1 is capable of binding DNA will likely improve 
our understanding of this phenomenon. 
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Alternatively, a simple hypothesis could also explain why BR3+K is less infectious 
than rAAV2, if the lysine substitution generates a stronger nucleolar localization signal.  We 
know from our previous studies that infectious virions can accumulate in the nucleolus 
(Johnson and Samulski, 2009).  Treatments that disrupt the nucleolus (such as HU or siRNA-
mediated knockdown of nucleolar proteins) result in the mobilization of capsids into the 
nucleoplasm and correlate with increases in transduction.   BR3+K displays clear nucleolar 
accumulation that may be more robust than rAAV2.  Although no consensus sequence has 
been identified for nucleolar targeting, these resemble NLS motifs (Emmott and Hiscox, 
2009).  Therefore, it is possible that the additional lysine residue in BR3 could essentially 
target and ‘trap’ the virus in the nucleolus, preventing it from uncoating in the nucleoplasm.  
This hypothesis would be consistent with the perplexing result that proteasome inhibitors do 
not increase transduction of BR3+K, despite increasing nucleolar accumulation. BR3+K 
might be terminally targeted to the nucleolus and unable to escape.  Driving more BR3+K 
capsids into the nucleus with proteasome inhibitors would only lead to more nucleolar 
accumulation.  In contrast, rAAV2 might contain weaker nucleolar localization properties, 
which could be enhanced by proteasome inhibitors, yet flexible enough to transition to the 
nucleoplasm if favorable conditions arose in the cell.  Clearly, a few BR3+K genomes are 
able to serve as templates for transgene expression since they are enhanced by 
coadministration of Ad.  It would be of interest to identify whether the presence of nucleoli 
or nucleolar proteins influences AAV infection, given that high levels of nucleolar proteins 
are found in cells that are rapidly dividing such as stem cells and cancer cells (Storck et al., 
2007).  Ultimately, the BR3+K mutant and other vectors we have generated in this study 
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should prove valuable as we continue to dissect the trafficking profile of AAV with these 
molecular tools.  
 
 
 
  
 
CHAPTER 4 
AAV EXPLOITS CONDITIONS OF SUBCELLULAR STRESS 
 
Abstract 
Several adeno-associated virus (AAV)-based vectors are emerging as attractive gene 
therapy vehicles for cystic fibrosis (CF) and other hereditary disorders; however, it remains 
difficult to efficiently transduce target tissues while minimizing transduction in off-target 
tissues.  Since heat-shock and proteasome inhibition are known to have similar cellular 
effects, potently induce a cellular stress response, and dramatically increase transduction in 
specific cell types, we hypothesized that AAV may exploit conditions during cellular stress 
to bypass subcellular barriers of infection.  To more clearly understand the biology of the 
virus in specific cellular environments, we initiated studies looking at the ability of AAV2 to 
transduce during conditions of cellular stress. Thus, we studied infection in cells 
overexpressing ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (ΔF508 
CFTR), a misfolded protein variant of wild-type CFTR that is associated with approximately 
90% of CF cases.  We have discovered that AAV2 transduces cells expressing ΔF508 CFTR, 
roughly a log order higher than cells expressing wild-type CFTR. This infectious advantage 
is observed in multiple cell lines expressing ΔF508 CFTR and has been verified with both 
luciferase and GFP reporters, suggesting this effect occurs independent of the transgene. 
When comparing control cells, CFTR cells, and ΔF508 cells, no difference was observed 
with respect to cell surface binding of virus or expression levels of a plasmid reporter after 
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transfection, which suggests the exploitation is at the level of virus trafficking or processing. 
Immunofluorescence microscopy of infection displays AAV capsids accumulate at the 
microtubule organizing center, a subcellular location considered a hotbed for misfolded 
protein proteolysis. Rescuing the misfolded ΔF508 CFTR with low temperature conditioning 
completely ablates the infectious advantage of AAV2 in these cells, suggesting AAV2 
exploits conditions of cellular stress due to misfolded proteins.  Moreover, in cultured human 
airway epithelium (HAE), infection of AAV is enhanced when physiological conditions of 
subcellular stress are modeled after stimulation from supernatant from mucopurulent material 
derived from CF lungs. We speculate AAV virions preferentially transduce during conditions 
of cellular stress and this may be a generalized phenomenon having positive implications for 
targeting diseased cells with these vectors. 
 
Introduction 
Evolutionary biology commonly speaks of survival of the fittest.  In turn, organisms 
that do not display robust fitness are typically exploited by those in a position to do so.  This 
principle is vividly apparent in virology, since many viruses have evolved to take advantage 
of hosts under stress; infection will frequently occur in a host that is unfit to defend itself on 
one or more levels.  This is true from an immunology perspective when a compromised 
immune system will put one at greater risk for disease, and it’s also true from the cell biology 
perspective if subcellular barriers to infection are broken down during conditions of cellular 
stress.  In this study we have focused on the latter concept as it applies to AAV.   
AAV is a member of the parvovirus family and is classified as a dependovirus, as it 
will not enter into a replicative state unless specific conditions are obtained in the host cell.  
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Commonly these conditions that favor replication of AAV are established during coinfection 
with a helper virus such as adenovirus (Ad) or herpes virus (Berns and Giraud, 1996).  
However, it has been shown that AAV can enter a replicative state in the absence of a helper 
virus if the host cell is in a sufficiently-stressed state, such as in the case where 
administration of certain genotoxic agents will induce amplification of AAV DNA 
(Yalkinoglu et al., 1988).   The effect of genotoxic agents on a cell can be comparable to 
helper coinfection, considering Ad and herpes activate DNA damage response pathways, the 
unfolded protein response (UPR), and upregulate chaperone expression (He, 2006; Sinclair et 
al., 2006).  
We hypothesize that transduction of recombinant AAV vectors are enhanced during 
conditions of subcellular stress.  Once wild type AAV or AAV-based vectors have attached 
to the cell surface by binding their targeted glycoprotein receptors, infection progresses 
through clathrin and dynamin-dependent internalization into an endosomal compartment 
(Duan et al., 1999; Bartlett et al., 2000; Bantel-Schaal et al., 2002).  It’s unclear if there is a 
specific compartment that AAV must enter in order to be primed for infection, but capsids 
have been detected in the early endosome, recycling endosome, late endosome, lysosome, 
and Golgi apparatus (Ding et al., 2005).  Early in infection, conformational changes in the 
AAV capsid are thought to permit exposure of a viral phospholipase domain that 
subsequently mediates endosomal escape, releasing the capsid into the cytosol (Girod et al., 
2002; Bleker et al., 2005; Kronenberg et al., 2005; Sonntag et al., 2006); however, the 
majority of capsids will never reach the nucleus (Sanlioglu et al., 2001; Ding et al., 2003; 
Hauck et al., 2004).  Identifying specific subcellular barriers to infection will be important 
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for improving vector design and for understanding how cellular parameters can be modulated 
to increase efficiency of gene delivery. 
Foreign particles and pathogens that are endocytosed into cells will typically traffic to 
a perinuclear area near the microtubule organizing center (MTOC) (Leopold and Pfister, 
2006; Wileman, 2007).  Also known as the centrosome, the MTOC is the point of origin 
from which microtubules emanate outward toward the cell periphery.  This network of 
microtubules provides a lattice for organizing the vesicles and organelles that AAV has been 
associated with, such as endosomes, lysosomes, the Golgi apparatus, and the nucleus 
(Cuschieri et al., 2007).  AAV has been shown to bind dynein, which is the primary motor 
protein responsible for anterograde movement along microtubules toward the MTOC (Kelkar 
et al., 2006).  In this central region of the cell there is a high concentration of sorting and 
degradation machinery, namely proteasomes (Badano et al., 2005), lysosomes, and many 
associated chaperones and enzymes.  It seems logical that the default dynein sorting pathway 
is designed to place viruses in close proximity to this machinery to expedite degradation and 
clearance from the cell. 
This microtubule highway not only serves to traffic viruses, bacteria, and cellular 
vesicles, but also to target misfolded proteins that originate from within the cell to the MTOC 
for degradation (Garcia-Mata et al., 2002).  During subcellular stress, the capacity of 
degradation at the MTOC can be exceeded, which can result in proteasome dysfunction, 
accumulation of protein aggregates, formation of aggresomes, expansion of the secretory 
pathway, and activation of the UPR (Bernales et al., 2006).  Several treatments that affect 
these systems have been shown to enhance AAV transduction.  For example, proteasome 
inhibitors and heatshock can potentiate transduction in a cell-type specific manner by up to 
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several hundred fold (Duan et al., 2000; Hansen et al., 2000; Ding et al., 2003; Hauck et al., 
2004).  Thus, we hypothesize that AAV virions are processed by the cell in a manner similar 
to misfolded proteins, and following pharmacological interference or saturation of these 
pathways, the virus is able to exploit the subsequent conditions of subcellular stress.  
One of the most well-known misfolded proteins associated with disease is the mutant 
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) resulting from a single 
deletion of a phenylalanine residue at position 508 (ΔF508 CFTR).  This is a misfolded 
variant of wild-type CFTR protein that is associated with approximately 90% of cystic 
fibrosis (CF), the most common lethal progressive hereditary disorder in caucasian 
populations (O'Sullivan and Freedman, 2009).  Cystic fibrosis manifests primarily in the 
lungs of afflicted individuals, plagued by mucus accumulation, airway inflammation, and 
persistent infections.  The CFTR protein is a cyclic adenosine monophosphate-activated 
chloride ion channel that primarily functions at the apical surface of airway epithelium.  The 
ΔF508 deletion disrupts the folding pathway of CFTR in the ER and renders the protein 
unable to mature, thus it is not complexly glycosylated, does not efficiently traffic to the 
plasma membrane, and is instead rapidly cleared from the cell through ER-associated 
degradation (ERAD) (Qu et al., 1997; Riordan, 2005).  Historically, degradation of misfolded 
CFTR was thought to occur primarily through the ubiquitin-proteasome system (Johnston et 
al., 1998; Gelman et al., 2002), but recent evidence suggests autophagy also plays a role (Fu 
and Sztul, 2009).  Loss of CFTR function impairs regulation of ion transport across the 
airway surface, which leads to a reduction of airway surface liquid, dehydrates airway 
mucus, decreases mucus transport, and increases the risk of infection.  While there is 
controversy over whether ΔF508 misfolding contributes to the etiology of cystic fibrosis, it 
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has been well-established that CF cells are under subcellular stress as indicated by increased 
sensitivity to Ca2+-mediated inflammation, ER-expansion, and activation of the UPR (Ribeiro 
et al., 2005a; Ribeiro et al., 2005b).  Additionally, overexpression of ΔF508 CFTR in vitro 
has been a commonly used model for studying subcellular effects of misfolded protein 
(Younger et al., 2005). 
In this report we have tested if subcellular stress and expression of misfolded proteins 
can be exploited by AAV vectors.  Here we demonstrate that AAV2 transduces cells 
expressing ΔF508 CFTR, roughly a log order higher than cells expressing wild-type CFTR. It 
is likely this effect is not due to differences in uptake or gene expression since no difference 
was observed with respect to cell surface binding of virus or expression levels of a plasmid 
reporter after transfection when comparing control cells, CFTR cells, and ΔF508 cells.  With 
supporting evidence from other misfolded proteins and experiments that rescue the 
misfolding defect of ΔF508, our results suggest the exploitation is at the level of virus 
trafficking or processing.  Moreover, we have used supernatant from mucopurulent material 
(SMM) from CF airways to stimulate physiological conditions of subcellular stress in human 
airway epithelial cultures, and demonstrate that infection of AAV is enhanced in this model. 
We speculate AAV virions preferentially transduce during conditions of cellular stress and 
this may be a generalized phenomenon having positive implications for targeting diseased 
cells with these vectors. 
 
Materials and Methods 
Cell culture.  HeLa cells were maintained at 37°C and 5% CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM) that was supplemented with 10% heat-inactivated fetal 
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calf serum, 100U/ml penicillin, and 100g/ml streptomycin.  BHK-21 cells were grown at 
37°C and 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) and Ham’s F12 
medium (50:50) that was supplemented with 5% heat-inactivated fetal calf serum, 100U/ml 
penicillin, and 100g/ml streptomycin.  BHK-21 clones expressing wt CFTR, CFTR-ΔF508, 
CFTR-G551D, CFTR-D572N, CFTR-1410X, wt MRP1, or MRP1-ΔF728  were maintained 
in selection medium containing methotrexate (250 µg/ml).  Presence or absence of 
methotrexate was not found to influence viral transduction, but nonetheless drug treatment 
was continued throughout the course of infection. 
Generation of ciliated HAE in vitro. Human tracheobronchial epithelial cells were 
isolated fresh from excess surgical specimens that were resected at lung transplantation by 
the University of North Carolina Cystic Fibrosis Center Tissue Culture Core under 
University of North Carolina institutional review board–approved protocols. As previously 
described, primary cells derived from single patient sources were expanded in tissue culture 
to generate passage 1 cells, which were plated at a density of 250,000 cells/cm2 on permeable 
membrane support (Millicells, 12mm diameter, Millipore, Corning, NY), and maintained in a 
specialty media (Fulcher et al., 2005).  Cells were differentiated under air–liquid interface 
conditions and the cultures were considered mature after 4-8weeks when found to be 
significantly ciliated (>50% ciliated cells).  Experiments were only performed with fully 
differentiated HAE cultures. 
Virus production. Virus was produced as described before in HEK-293 cells (Xiao 
et al., 1998).  Briefly, polyethylenimine (linear molecular weight, ~ 25,000) was used to for 
triple transfection of the pXR2 cap and rep plasmid, the pXX6-80 helper plasmid, and pTR-
Luciferase or TR-eGFP reporter plasmids containing either luciferase or enhanced green 
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fluorescent protein (eGFP) transgenes flanked by inverted terminal repeats.  At 60hr post-
transfection cells were harvested and virus purified by cesium chloride gradient density 
centrifugation for 5hr at 65,000 rpm or overnight at 55,000 rpm. Virus was dialyzed into 1X 
phosphate-buffered saline (PBS) to remove small molecular weight contaminants from 
fractions containing peak viral titers, which were identified by dot blot hybridization.  Titers 
were calculated by qPCR according to established procedures (Johnson and Samulski, 2009) 
using a LightCycler 480 using Sybr green (Roche) and primers designed against firefly 
Luciferase (TR-Luc) or enhanced green fluorescent protein (TR-eGFP) transgene.  
Confocal immunofluorescence microscopy.  Similar to what we have previously 
described (Grieger et al., 2007; Johnson and Samulski, 2009), HeLa cells of BHK-21 cells (5 
× 104/well) were plated on poly-L-lysine-coated 12-mm glass coverslips (#1.5) 4hr before 
infection. Recombinant virions were added to cell media at a designated MOI.  No virus was 
added to control wells.  After infection, cells were washed three times with PBS and then 
fixed with 2% paraformaldehyde for 15min at room temperature. Cells were then 
permeabilized with 0.1% Triton X-100 in PBS for 5min at room temperature, washed four 
times with PBS, and then blocked with immunofluorescence buffer (IFB) (20 mM Tris, pH 
7.5, 137 mM NaCl, 3 mM KCl, 1.5 mM MgCl2, 5 mg/ml bovine serum albumin, 0.05% 
Tween) for 30min at room temperature. The cells were incubated with primary antibody to 
detect intact capsids [(MAb A20 (1:10), anti-γ-tubulin (Abcam Ab16504 1:250), anti-CFTR-
570 (1:500)] diluted in IFB, for 1hr at 37°C or overnight at 4°C. The cells were then 
incubated in secondary antibody, diluted 1:5000 in IFB (anti-mouse Alexa Fluor 488; or anti-
rabbit Alexa Fluor 568, anti-mouse IgG3 Alexa Fluor 488, or anti-rabbit IgG1a Alexa Fluor 
568, Molecular Probes), for 1hr at 37°C. After six washes in PBS, coverslips were mounted 
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cell side down on glass slides with mounting medium (Prolong antifade Gold with DAPI 
[4′,6′-diamidino-2-phenylindole]; Molecular Probes). Images were captured on a Leica SP2 
AOBS upright laser scanning confocal microscope and processed using Adobe Photoshop. 
3-Dimensional rendering of infection.  Confocal Z-stack sections of BHK-21 cells 
immunofluorescence localization of AAV2 capsids and CFTR or ΔF508 CFTR protein were 
processed and rendered in 3 dimensions using Volocity software (Improvision). 
Transfection of BHK-21 cells with reporter plasmids. BHK-21 control cells, 
CFTR cells, or ΔF508 cells were plated at a density of  105cells/well and 4hr later were 
transfected with either TR-CBA-Luc or TR-eGFP reporter plasmids using PEI.  For each 
well 500ng DNA was mixed with 5µl PEI (1mg/ml) in 100µl of serum-free DMEM and 
incubated at room temp for 10min before adding the mixture to cell medium.  24hr after 
transfection, cells were harvested for luciferase assays or flow cytometry analysis of GFP 
expression as indicated below.  
Luciferase assay of transduction.  At least 4hr prior to infection, HeLa cells or 
BHK-21 cells were plated in 24 well plates at a density of 105cells/well.  For drug studies, 
cells were treated as indicated in the Results section. Luciferase activity was measured in 
accordance with the manufacturer’s instructions (Promega). Luciferase activity was 
measured with a Wallac1420 Victor2 automated plate reader.  Error bars represent standard 
deviations from samples scored in triplicate.  Graphs are representative data sets from at least 
three independent assays. 
GFP flow cytometry analysis of transduction or transfection.  BHK-21 cells were 
prepared for infection as stated above and plated in 24 well plates at a density of 
105cells/well.  After infection at the indicated MOI, at 24 or 48hr cells were trypsinized 
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(100µl/well), neutralized with growth media (300µl) spun down for 5min at 800g, and the 
cell pellets were resuspended in 500µl of 2% paraformaldehyde (prepared fresh in PBS). At 
least 50,000 cells were counted by flow cytometry for each sample, and three separate 
samples were recorded for each condition.  Graphs are representative data sets from one of 
three independent experiments.  
Western blotting. CFTR and MRP1 protein samples were analyzed as previously 
described (Gentzsch et al., 2007).  Briefly, cells were lysed and subjected to SDS gel 
electrophoresis on 6% polyacrylamide gels.  Proteins were transferred to nitrocellulose 
membranes and blots were probed with anti-CFTR MAb 596 or monoclonal anti-MRP1 
antibody 897.2 and visualized by enhanced chemiluminescence detection. 
Quantifying genomes by PCR. DNA was isolated from fractions using DNeasy 
columns (Qiagen) according to the manufacturers protocol.  Quantitative PCR was performed 
on a LightCycler 480 using Sybr green (Roche) and primers designed against the firefly 
Luciferase transgene: (fwd) 5’ AAA AGC ACT CTG ATT GAC AAA TAC 3’, and (rev) 5’ 
CCT TCG CTT CAA AAA ATG GAA C 3’.  Conditions used for the reaction are as follows:  
1 cycle at 95ºC for 10min, 45 cycles at  95ºC for 10sec, 62ºC for 10sec, 72ºC for 10sec, 1 
cycle at 95ºC for 30sec, 65ºC for 1min, and 99ºC for acquisition. 
Collection of SMM and transduction of HAE cultures.  Lumenal mucopurulent 
material from excised human CF lungs was harvested at the North Carolina Cystic Fibrosis 
Center as previously described  (Ribeiro et al., 2005a; Ribeiro et al., 2005b; Martino et al., 
2009).   To ensure a homogenous stimulus, SMM was pooled from several patients.  For 
treatment prior to infection, SMM (20µl) was added to the apical surface of fully 
differentiated HAE cultures in Millicells for 24hr.  Prior to virus administration, SMM-
treated wells and non-treated control wells were washed and hydrated two times with PBS.  
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An AAV variant (HAE-2) previously isolated from directed evolution in HAE cultures (Li et 
al., 2009b) was used in these studies.  Approximately 5x1010  particles of HAE-2 packaging 
either eGFP or Luc were applied to the apical surface of HAE cultures in PBS for 4hr.  Virus 
was washed from the apical surface and GFP or Luc expression was assayed 1week post-
infection. 
 
Results 
Subcellular barriers to infection act at multiple levels to prevent viruses, bacteria, and 
parasites from commandeering host cells for their own purposes.  We hypothesize that if a 
cell is already under threat from an existing infection, disease, or abundance of misfolded 
protein, then these barriers are likely to be less effective.  As previously reported, proteasome 
inhibitors, heatshock, and genotoxic agents affect events of subcellular processing to enhance 
transduction of rAAV2 in a cell-type and serotype-specific manner (Duan et al., 2000; 
Hansen et al., 2000; Ding et al., 2003; Hauck et al., 2004).  Here we have assessed whether 
manipulating stress pathways, with a specific focus on processing of misfolded proteins, will 
increase transduction of AAV vectors. 
Subcellular stress pathways in trafficking and transduction.  During infection 
with AAV2, the most commonly characterized serotype, capsids accumulate at a perinuclear 
region within the first 2hr after internalization (Zadori et al., 2001).  We have tracked the 
localization of capsids by confocal microscopy in HeLa cells and identified this perinuclear 
region to be near the MTOC (Fig 25A), considered to be an area rife with misfolded protein 
proteolysis.  rAAV2 capsids (20,000vg/cell) were administered to HeLa cells and prepped for  
  106 
 
 
Fig 25. Subcellular stress pathways in trafficking and transduction.  A.  Confocal 
immunofluorescence microscopy depicts rAAV2 capsids (i, green) trafficking near the 
microtubule organizing center (ii - γ-tubulin, red) during infection in HeLa cells, a region 
known for misfolded protein proteolysis.  B. Luciferase assay of transduction indicating 
several treatments that influence misfolded protein processing or trafficking positively 
impact rAAV2 transduction.  rAAV2 capsids (10,000vg/cell) were administered concurrently 
with either vehicle controls (DMSO or EtOH), or ALLN (40mM), MG132 (2mM), Radicicol 
(10mM), 3-methyladenine (10mM), or administered directly after treating with L-canavanine 
(10mM, 12hr), or during heatshock (4hr at 42.5oC).  Luciferase activity was measured 24hr 
post-infection.  
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immunofluorescence using a monoclonal antibody that detects intact capsids (Mab A20, 
green) and a marker of the MTOC, γ-tubulin (red). 
Since components of several degradation pathways intersect at the MTOC, we tested 
pharmacological and physical stressors that impact the ubiquitin-proteasome system, 
chaperone-mediated degradation, and autophagy for their ability to enhance AAV 
transduction in HeLa cells.  The vehicle controls, dimethyl sulfoxide (DMSO) and ethanol 
(EtOH) did not significantly influence expression in a luciferase assay of transduction for 
AAV2.  As reported previously, the proteasome inhibitors ALLN and MG132 increased 
transduction between 30 and 40-fold.  The Hsp90 inhibitor, radicicol, known to perturb 
chaperone activity and induce a heatshock-like response (Hadden et al., 2006), potently 
increased transduction by roughly 100-fold.  A specific inhibitor of autophagy, 3-
methyladenine (Seglen and Gordon, 1982; Mizushima et al., 2008), was found to augment 
transduction by at least 20-fold.  L-canavanine is a naturally occurring amino acid analogue 
of arginine, and when added exogenously to cells will induce widespread protein misfolding.  
This occurs as it is incorporated into newly synthesized proteins and increases the burden on 
the ubiquitin-proteasome system (Chen and Piper, 1995).  After pre-treatment with L-
canavanine, AAV transduction was increased 5 to 10-fold.  Heatshocking HeLa cells during 
the first 4hr of infection was also found to increase transduction (Fig 25B), as previously 
documented (Ferrari et al., 1996).  
rAAV2 exploits expression of misfolded ΔF508 CFTR.  Because each of these 
stress-inducing agents has been found to positively impact AAV2 transduction and yet also 
negatively influence misfolded protein processing, we hypothesized that overexpression of a 
misfolded protein alone could predispose cells for more efficient AAV infection.  Therefore  
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Fig 26. rAAV2 exploits expression of misfolded ΔF508 CFTR.  A.  Images of GFP-
positive cells after administration of rAAV2 (2,000vg/cell: eGFP transgene) to control wt 
BHK-21 cells (panel i), stable BHK-21 cells expressing CFTR (ii), or ΔF508 CFTR (iii).  
Heatshock (42.5oC, first 2hr of infection) potentiates transduction in each case (panels iv, v, 
and vi).  B. Luciferase assay of transduction of rAAV2 (2,000vg/cell: Luc transgene) in 
control cells, cells expressing CFTR, or ΔF508.  C.  Corresponding luciferase assay of 
transduction following heatshock. 
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we tested whether AAV2 could exploit expression of ΔF508 CFTR, in BHK-21 cells.  Stable 
lines of control wt BHK-21 cells, BHK-21 cells expressing CFTR, or BHK-21 cells 
expressing ΔF508, were infected with rAAV2 packaging either eGFP (Fig 26A) or Luc (Fig 
26B & C) transgenes.  Expression levels of both reporters indicate that infection is 
significantly more efficient in ΔF508-expressing cells.  Interestingly, heatshock potentiates 
transduction in all cell types (Fig 26A panels iv, v, and vi; Fig 26C), suggesting either that 
the transduction enhancement due to the misfolded protein in ΔF508 cells is not saturated, or 
that heatshock increases transduction through a separate mechanism, unrelated to misfolded 
protein processing.  It should be noted we also tested CHO and HEK-293 cell lines that 
expressed wt CFTR or ΔF508 CFTR and observed higher AAV2 transduction in ΔF508 lines, 
similar to what was observed in BHK-21 cells (data not shown). 
 ΔF508-expressing cells are transduced at greater numbers and at higher 
intensity than controls.  Because its difficult to gain an appreciation for the number of cells 
transduced and the relative intensity of transduction per cell from the assays just discussed, 
we performed flow cytometry analysis of GFP expression.  More ΔF508-expressing cells 
were transduced than control cells or CFTR-expressing cells after AAV2 administration (Fig 
27C: 80.17% GFP positive +/-0.57%, compared to Fig 27A: 47.71% +/-5.8% and Fig 27B: 
51.58% +/-0.72%, respectively).  This pattern was similar for a range of MOIs, from 
100vg/cell, 1000vg/cell, to 10000vg/cell.  Additionally, the mean fluorescence intensity 
(MFI) of gene expression was noted to be most intense in ΔF508 cells; this was most obvious 
at high MOI (Fig 27D).  When weighting the frequency of transduction with the intensity of 
gene expression (Fig 27E), transduction in ΔF508-expressing cells was roughly 1 log order  
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Fig 27. Flow cytometry analysis of GFP expression after transduction of rAAV2.  Plots 
show percent of GFP-positive cells after infection with rAAV2 (10,000vg/cell: eGFP 
transgene) in control cells (A), cells expressing CFTR (B), or ΔF508 (C).  +/- indicates 
standard deviation from three independent experiments.  D.  Mean fluorescence intensity 
(MFI) of GFP expression in GFP-positive cells acquired after administration of 100, 1,000, 
or 10,000vg/cell.  E.  Bar graph represents weighted transduction in different cell lines over 
the same range of MOIs.  Data is shown on a log scale using MFI multiplied by the 
percentage of GFP-positive cells to derive the z-axis levels. 
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higher than that in control BHK-21 cells or CFTR-expressing cells, a fold increase in 
transduction that mirrored what was observed by luciferase assay (Fig 26B).   
Cell-surface attachment of rAAV2 to control, CFTR, and ΔF508 cells occur at 
similar rates.  rAAV2 could be exploiting ΔF508 expression at a number of steps in the 
infectious pathway.  To test whether this is due to an increase in cell surface attachment we 
performed a binding assay with rAAV2.  Equal numbers of control wt BHK-21 cells (purple 
diamonds), cells expressing CFTR (red squares), or ΔF508 (blue triangles) were plated in 
24well plates and cooled to 4oC to inhibit endocytosis.  rAAV2 was administered to the cell 
medium (10,000vg/cell) at 4oC and subsequently the DNA was harvested after 5, 10, 20, or 
60min.  Vector genome amounts were quantified by qPCR and no significant difference was 
observed in rate binding (Fig 28), indicating that rAAV2 likely exploits expression of ΔF508 
CFTR at some time after  cellular attachment. 
 Analysis of expression levels after transfection of TR reporter plasmids.  
Because our hypothesis is that rAAV2 exploits subcellular stress and expression of misfolded 
proteins at the level of virus trafficking or processing, it is important to establish whether 
expression levels of the gene product are increased independently of an effect on the capsid.  
To determine whether ΔF508 expression influences steps late in transduction of the 
transcription, translation, or reporter protein stability, we exogenously introduced TR-eGFP 
or TR-Luc plasmids by transfection and quantified expression levels by flow cytometry or 
luciferase assay 24hr later.  No significant difference in transfection efficiency was detected 
when comparing eGFP expression in control cells, cells expressing CFTR, or ΔF508 (Fig 29, 
panels A-C), and the MFI was within the same order of magnitude for those cells that were 
eGFP-positive (Fig 29D).  Results from luciferase assays again closely mirrored those from  
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Fig 28. Cell surface binding of rAAV2. Equal numbers of control wt BHK-21 cells (purple 
diamonds), cells expressing CFTR (red squares), or ΔF508 (blue triangles) in 24well plates 
were cooled to 4oC to inhibit endocytosis.  rAAV2 was applied (10,000vg/cell) for the 
indicated times and the DNA was harvested for qPCR quantification of vector genomes.  
Error bars represent standard deviations from three independent samples. 
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flow cytometry, as we measured similar levels of luciferase activity among the three cell 
lines after transfection of TR-Luc (Fig 29E).  Therefore we conclude that rAAV2 virions are 
able to exploit cells expressing ΔF508 CFTR at a point between receptor binding and gene 
expression during transduction. 
Localization of rAAV capsids in control, CFTR, or ΔF508 cells.  To explore the 
possibility that ΔF508 CFTR has an observable effect on the trafficking profiles of rAAV2 
capsids, we followed their localization by confocal immunofluorescence during infection.  At 
no time point after administration was there a clear distinction between localization of 
capsids (green) in control cells, CFTR cells, and ΔF508-expressing cells (16hr time point 
shown, Fig 30A).  BHK-21 cells that were not infected with virus were processed identically 
to other samples and demonstrate no background antibody staining (Fig 30A, panel i).  
Capsid staining displayed the characteristic perinuclear ring in all cell types, with various 
amounts of punctate or aggregated capsid signal surrounding the nucleus (blue).  At this level 
of resolution there does not appear to be a significant difference in capsid trafficking among 
these cell types, but the possibility remains that capsids could be processed differently in 
ΔF508 cells which could result in expedited delivery of the transgene to the nucleus.  
If wt CFTR or mutant ΔF508 CFTR is recognized by ER quality control as being 
misfolded they are extracted into the cytoplasm and subject to ERAD through the 
ubiquitin/proteasome system (Ward et al., 1995).  With this in mind, we analyzed z-stacked 
confocal slices of viral infection utilizing 3D volume-imaging software to determine if 
rAAV2 virions colocalize with CFTR (Fig 30B, panel ii, red) or ΔF508 (panel iii, red) in 
BHK-21 cells.   We did not detect any obvious colocalization between capsids and CFTR or  
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Fig 29. Analysis of expression levels after transfection of TR reporter plasmids. Flow 
cytometry data indicating percent GFP-positive cells 24hr after transfection of TR-eGFP in 
control cells (A), cells expressing CFTR (B), or ΔF508 (C).  +/- indicates standard deviation 
from three independent experiments.  D.  Mean fluorescence intensity (MFI) of GFP 
expression in GFP-positive cells after transfection.  E.  Luciferase assay of reporter 
expression in control cells, CFTR-expressing cells, or ΔF508-expressing cells, 24hr after 
transfection with a TR-Luc plasmid.  Error bars represent standard deviations from three 
samples. 
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Fig 30. Localization of rAAV capsids in control, CFTR, or ΔF508 cells.  A. Confocal 
immunofluorescence staining of capsids (green) 16hr post-infection (50,000vg/cell) do not 
highlight obvious differences in subcellular trafficking at this level of resolution.  B. Single 
cell 3D composites were rendered using volume imaging software on z-stacked images taken 
after co-staining capsids with CFTR (panel ii, red) or ΔF508 (iii, red).   Absence of yellow 
color suggests no direct interaction between rAAV and wt or mutant CFTR, yet does not rule 
out that they could be degraded through the same pathway. 
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ΔF508, but this does not rule out the possibility that components of their trafficking pathways 
converge upstream of their degradation at a separate subcellular location.  
Effect of low temperature conditioning on processing of ΔF508 and transduction 
of rAAV2.  Classical biochemistry experiments demonstrated 15 years ago that ΔF508 
CFTR folding and trafficking defects can be rescued by growing cells at low temperature 
(Denning et al., 1992; French et al., 1996).  If the repercussions of excess misfolded protein 
in the cell benefits rAAV2, then experimentally reducing the misfolded protein burden 
should mitigate the transduction enhancement we observe.  In this light, we infected cells 
with AAV2 packaging TR-Luc two days after conditioning cells at 27oC and compared the 
results to a control infection performed at 27oC without pre-conditioning.  After two days of 
low-temp conditioning at 27oC, a considerable amount of ΔF508 protein is complexly 
glycosylated (Fig 31A), which is indicative of its ability to traffic similar to wt CFTR at this 
temperature.  Although overall levels of infection efficiency at 27oC are dramatically lower 
than what is observed at 37oC, transduction in ΔF508 cells at 27oC was still 3 to 4-fold higher 
than in control cells (Fig 31B, white bars).  In contrast, after low-temp conditioning there was 
no difference in transduction levels among control, CFTR, and ΔF508 cells (Fig 31B, black 
bars), suggesting that AAV2 exploits expression of ΔF508 only in cases where it is 
misfolded.  
Comparative analysis of mutant CFTR processing with rAAV2 transduction.  In 
addition to performing rescue experiments, we explored whether the increase in transduction 
efficiency due to expression of ΔF508 was a generalized phenomenon that could be 
reproduced with other misfolded proteins.  A variety of mutant CFTR proteins and related 
ABC transporters were generously provided by the Riordan and Gentzsch labs and enabled  
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Fig 31. Effect of low temperature conditioning on processing of ΔF508 and transduction 
of rAAV2.  A. Western blot showing immature form of CFTR and ΔF508 (black arrow) and 
mature glycosylated form (arrowhead).  Following low temperature conditioning (2d, 27oC), 
a significant amount of DF508 becomes complexly glycosylated. Western courtesy of 
Martina Gentzsch.  B. Luciferase assay of transduction after low temp conditioning, and a 
comparative control at 27oC.  Cells were infected with rAAV2 (10,000vg/cell) as indicated 
and luciferase activity was measured 24hr later.   
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us to determine that this effect was not unique to ΔF508.  The G551D (glycine to aspartic 
acid) mutant version of CFTR is folded properly, traffics to the plasma membrane, but does 
not display an operative chloride ion channel (Yang et al., 1993).  When rAAV2 was 
administered to cell lines expressing G551D CFTR, we did not observe a significant 
difference in transduction from control or CFTR-expressing cells (Fig 32B).  Two other 
CFTR mutants that we tested do not traffic to the membrane.  D572N CFTR misfolds, is 
rapidly cleared from the cell, and cannot be rescued even at low temperature (Gentzsch et al., 
2007).  AAV2 is able to exploit expression of D572N CFTR, but its unclear if there is an 
effect in cells expressing the truncated 1410X CFTR, another mutant that is not delivered to 
the plasma membrane.  It is interesting that the level of transduction enhancement 
corresponds to the lack of mature glycosylated forms of CFTR shown by western (Fig 32A). 
Related ABC transporter proteins MRP1 and an analogous mutant ΔF728-MRP1 do not share 
the misfolding and degradation pattern of ΔF508 CFTR (Buyse et al., 2004) and do not 
render cells more sensitive to rAAV2 transduction.  Aside from ΔF508 CFTR, many of these 
proteins have not been studied in detail and it is difficult to draw firm conclusions from this 
result alone, but together these data suggest that AAV is able to exploit cells that express 
misfolded proteins. 
Transduction of rAAV in a model of physiological subcellular stress with HAE 
cultures.  Despite being an established system for studying misfolded proteins, 
overexpression of ΔF508 in vitro cannot accurately represent the physiological condition of 
the airway epithelium in cystic fibrosis, since in vivo ΔF508 is not expressed at high levels.  
The subcellular status of HAE in cystic fibrosis displays an increase in sensitivity to Ca2+- 
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Fig 32. Comparative analysis of mutant CFTR processing with rAAV2 transduction.  A. 
Western blot of proteins expressed in BHK-21 cell lines depicting level of glycosylation of 
CFTR, and mutants ΔF508 (misfolded), G551D (properly folded), D572N (misfolded), 
1410X (unclear effect). Related ABC transporter proteins MRP1 and an analogous mutant 
DF728-MRP1 are also shown. Western courtesy of Martina Gentzsch.  B.  Luciferase assay 
of transduction in these cell lines following administration of rAAV2 (10,000vg/cell). 
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mediated inflammation, ER expansion, and activation of the UPR (Ribeiro et al., 2005a; 
Ribeiro et al., 2005b; Martino et al., 2009).  This can be reproduced in normal HAE cultures 
derived from excised lungs by apical administration of the infectious/inflammatory stimulus, 
SMM.  We have used SMM to model the physiological state of HAE cultures under stress 
and tested whether these conditions improve transduction of rAAV.  For these experiments 
we have used an AAV variant (HAE-2) that was isolated from an AAV capsid library 
generated by DNA shuffling and selected through directed evolution on HAE cultures (Li et 
al., 2009b).   SMM or a PBS control was applied to the apical surface of fully-differentiated 
HAE cultures grown at an air-liquid interface.  24hr following SMM treatment we 
administered virus carrying either TR-eGFP or TR-Luc transgenes and transduction 
efficiency was analyzed 1week later.  GFP expression was considerably higher in wells that 
were treated with SMM (Fig 33A, panels i, ii, and iii), compared to controls (panels iv, v, and 
vi).  Although the difference in luciferase activity between cultures treated with PBS and 
SMM was not as great as that for GFP, transduction in SMM-treated samples was still 2-fold 
higher than controls (Fig 33B) and found to be statistically significant (p-value < 0.05). 
 
Discussion 
With these studies we have described how recombinant AAV vectors can exploit 
subcellular stress due to misfolded proteins. In support of our hypothesis, rAAV2 
transduction was found to be roughly a log order higher in cells expressing misfolded ΔF508 
CFTR than in control cells (Figs 26 & 27).  A variety of drug treatments and physical 
stressors have been known to increase transduction of AAV, but to our knowledge this is the 
first time it has been shown that cells are predisposed for AAV transduction due to  
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Fig 33. Transduction of rAAV in a model of physiological subcellular stress with HAE 
cultures.  SMM was applied to the apical surface of HAE cultures as a physiological inducer 
of subcellular stress in HAE known to result in misfolded protein responses, ER expansion, 
and Ca2+-mediated inflammation.  24hr after application, SMM was removed and the 
cultured infected with an AAV variant isolated from directed evolution on HAE.  The data 
shown are representative from three independent experiments.  A. One week after infection 
with virus packaging an eGFP transgene, GFP images were acquired for PBS control wells 
(panels i, ii, and iii) and wells treated with SMM (iv, v, and vi).  B.  From wells treated with 
rAAV packaging a Luc transgene, a luciferase assay was performed.  Error bars represent 
standard deviations from three separate infections. 
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expression of misfolded proteins.  Here we have documented by immunofluorescence that 
rAAV capsids traffic to the MTOC during infection (Fig 25A), a location where misfolded 
proteins are targeted for degradation (Wigley et al., 1999).  We speculate that AAV and other 
viruses are treated by the cell as misfolded proteins.  Our findings allude to a convergence of 
pathways and suggest common components are enlisted to process misfolded proteins and 
protect against infection.  
It is interesting to note that heatshock, which potently activates the UPR (Davenport 
et al., 2008), further potentiates transduction in BHK-21 control cells, CFTR-expressing 
cells, and ΔF508-expressing cells (Fig 26).  This finding could mean two things: AAV’s 
exploitation of ΔF508 CFTR could occur through a pathway separate from that activated by 
heatshock, or if they operate through the same pathway then either one independently does 
not fully saturate the system.  Both are reasonable explanations for this observation.  The 
effect of heatshock on transduction may simply result from increased metabolism in the cell, 
which could expedite virus uptake, transit, and provide increased activation energy for 
uncoating if it is dependent on thermodynamics.  We have also observed that transduction is 
increased after low temperature conditioning if virus is introduced to cells as they are 
returned to normal growth temperatures (data not shown), which supports the idea that 
heatshock increases transduction by affecting metabolism.  Similarly, AAV transduction is 
reported to be enhanced following hypothermia (Iwatate et al., 2003) in organs such as the 
heart.  Alternatively, it is equally likely that the misfolded protein pathway is not saturated by 
expression of ΔF508 or heatshock and together they synergistically increase transduction.  
We observe a greater effect on expression intensity with higher MOI (Fig 27, panels D & E), 
which is indicative of a saturation phenomenon.  In this same vein, we have found that 
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proteasomes function at the same rate in ΔF508 cells as in control cells, according to a 
luciferase assay of proteasome activity (Promega, data not shown).  By using proteasome 
inhibitors transduction can be further enhanced in each cell type, similar to heatshock.  
Further research is required to determine if all of these treatments can be harnessed 
cooperatively to improve gene delivery and whether any effects on metabolism or protein 
processing are saturable. 
It is clear that the enhancement of rAAV2 transduction afforded by ΔF508 expression 
is not due to effects on virus binding (Fig 28), transcription, or translation of the reporter (Fig 
29).  By process of elimination, this has enabled us to narrow our focus to steps in virus 
trafficking or processing in attempt to identify where ΔF508 expression confers an infectious 
advantage to rAAV2.  Although we were unable to pinpoint the specific step in the 
transduction pathway that mediates this effect using immunofluorescence microscopy, we 
have tracked capsids to a perinuclear region during infection (Fig 30).  In select ΔF508 cells 
it appears that capsids aggregate in punctate structures more readily than in BHK-21 control 
cells or CFTR cells.  We also observed that capsid localization was more distal from the ER 
in a population of ΔF508-expressing cells, but these subtle differences did not warrant further 
exploration since at this level of resolution there was no obvious trafficking phenotype 
apparent in ΔF508-expressing cells.  Unfortunately these experiments are subject to the same 
limitations that plague other trafficking studies, in that high particle numbers must be 
administered to obtain significant fluorescent signal.  Thus, we are unable to identify the 
infectious virions from among the many particles in bulk-flow.  Nonetheless, with these 
experiments we have established that there is no significant colocalization between intact 
capsids and wt CFTR or ΔF508 CFTR (Fig 30B).  This suggests AAV2 is either able to 
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exploit expression of misfolded proteins indirectly, or the capsid has lost A20 antibody 
reactivity in regions near CFTR or ΔF508. 
Throughout its biogenesis and degradation, ΔF508 CFTR interacts with a multitude 
of proteins in the cell.  Overexpression of ΔF508 or other misfolded proteins may saturate 
these interactions and sequester these proteins away from their designated functions. AAV 
transduction may be enhanced if these proteins would otherwise impede virus trafficking.  
Proteins known to play a role in ΔF508 processing include the chaperones calnexin, Hsp90, 
and the Hsc-Hsp40/Hsp70 complexes (Riordan, 2005). In one report, Hsp90 has been shown 
to inhibit AAV infection (Zhong et al., 2004b), and indeed we see that the Hsp90 inhibitor 
radicicol potently increases transduction (Fig 25).  Many cellular chaperones have been 
reported to influence infection of a wide variety of viruses, but in using siRNA and plasmid 
transfection screens we have not been able to confirm that any of these proteins significantly 
impact AAV transduction (data not shown).  However, preliminary results from our 
colleagues working with Dr. Tal Kafri implicate Hsp27 and HDAC6, two proteins involved 
in misfolded protein trafficking, also play a role to inhibit viral transduction. 
Beyond testing transduction in an overexpression in vitro model of subcellular stress, 
we have documented that AAV has an infectious advantage in stressed HAE cultures (Fig 
33).  SMM, which was used as the inflammatory stimulus in these studies, causes 
upregulation of the secretory pathway, expansion of the ER, and activation of the UPR.  
These subcellular effects are not only mimicking what is observed in cystic fibrosis, but also 
found with other diseases associated with misfolded proteins.  It will be of great interest to 
the gene therapy community if exploitation of misfolded proteins by AAV is a generalized 
phenomenon applicable to Parkinson’s disease (a-synuclein), amyotrophic lateral sclerosis 
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(superoxide dismutase-1), hereditary emphysema (α-1-antitrypsin), familial 
neurohypophyseal diabetes insipidus (arginine vasopressin), and many other protein folding 
disorders (Gregersen et al., 2006).  Even more striking, would be to discover that there is a 
viral component to these diseases, and that the presence of the misfolded protein renders the 
cells more susceptible to infection. 
Over the course of eukaryotic cell evolution, a series of cellular defense systems have 
been enlisted to defend against a wide variety of pathogens.  Clearly innate defense 
mechanisms have been streamlined to maximize their efficiency and are tuned to operate 
with redundancy toward many different targets.  An example of this flexibility can be found 
in pattern recognition receptors in the innate immune system: TLRs (toll-like receptors), 
cytosolic NLRs [NOD (nucleotide binding and oligomerization domain)-like receptors], 
RLRs [RIG-I (retinoic acid-inducible gene 1)-like receptors], and CLRs (C-type lectin 
receptors).  These receptors are built from different combinations of seven simple structural 
elements and possess the ability to sense a multitude of different bacteria, viruses, and fungi 
(Palsson-McDermott and O'Neill, 2007).  Similar to this strategy, we speculate that cells 
have evolved mechanisms for handling and degrading misfolded proteins in concert with 
those mechanisms for protection against foreign invaders.  In fact, a link between innate 
immunity and misfolded protein processing has recently been demonstrated in C. elegans, 
where the apoptotic receptor, CED-1, and a network of UPR genes were shown to be 
required for proper defense to pathogen infection (Haskins et al., 2008).  In this light, 
exploitation of subcellular stress is a property that is relevant to the natural survival of AAV 
and will be crucial to consider when optimizing the virion for gene therapy or targeting 
diseased cells with these vectors. 
  
 
CHAPTER 5 
CONCLUSIONS AND FURTHER EXPLORATIONS 
 
Summary of results 
AAV is a remarkably elegant virus that has evolved to coexist with its host in a non-
pathogenic state and only replicate in times of cellular stress.  Properties of the AAV virion 
make it an attractive vector for gene therapy applications, but much remains to be learned 
concerning its fundamental biology.  In this dissertation we have sought to elucidate steps 
during subcellular trafficking as rAAV2 traverses from the cell surface to the nucleus.  
Notably, we have demonstrated that rAAV2 can enter the nucleus as an intact virion.  We 
have also explored through confocal immunofluorescence and biochemical fractionation how 
changing cellular parameters can direct nucleolar accumulation or mobilization to the 
nucleoplasm.  Our results from Chapter 2 suggest virions that accumulate in nucleoli remain 
infectious and are sequestered there in stable form.  These data prompt us to speculate that 
mobilization from the nucleolus to nucleoplasmic sites enables capsid transition from a stable 
environment to one where uncoating can occur (Fig 14).  When taking the helper-dependent 
nature of AAV into consideration, this model is particularly striking.  We hypothesize the 
virus has evolved to utilize nucleolar proteins for sequestration in a stable compartment and 
exploit nucleolar disruption during mitosis, genotoxic stress, or coinfection to trigger genome 
release under favorable conditions. 
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In studies for Chapter 2 we employed multiple techniques to substantiate our 
conclusions.  We tracked the subcellular trafficking profile of rAAV2 through indirect 
immunofluorescence microscopy and detected accumulation of intact capsids in the 
nucleolus.  These nucleolar-associated virions were found to retain infectivity in secondary 
infection assays after isolating nucleoli biochemically.  Moreover, disruption of nucleoli by 
genotoxic agents or siRNA-knockdown of nucleolar proteins mobilizes virions and increases 
transduction.  One of the major limitations to our experimental approach is that 
immunofluorescence detection of capsids requires high particle numbers.  Like many 
immunofluorescence studies, sensitivity of detection is a major issue.  Future work that will 
optimize single-particle tracking similar to that performed by the Brauchle group 
(Seisenberger et al., 2001) will likely enable researchers to map the course of an individual 
infectious virus from the cell surface to the nucleus.  Currently, we have been able to detect 
capsid proteins in nucleoli post-infection at MOIs of 1000vg/cell through biochemical 
analyses.  Although we have not empirically visualized rAAV2 in nucleoli at lower MOIs, 
transduction studies down to 200vg/cell strongly argue for identical effects on nucleolar 
accumulation and nucleoplasmic mobilization at lower MOIs.   
As mentioned several times throughout this dissertation, studying events in AAV 
trafficking is becoming increasingly popular since in the last few years, several groups have 
shown nuclear delivery of the genome is a major barrier to gene therapy (Duan et al., 2000; 
Hansen et al., 2000; Douar et al., 2001; Xiao et al., 2002; Zhong et al., 2004a; Sonntag et al., 
2006).  Thus, for Chapter 3 we employed rational mutagenesis of AAV2 to more clearly 
understand the trafficking profile of the virus through testing how capsid elements direct 
steps in infection.  Specifically, we generated mutations in the unique N-terminal regions of 
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capsid proteins VP1 and VP2 and examined their effect on subcellular trafficking, 
transduction, and sensitivity to proteasome-mediated enhancement.  We have reported that 
these mutants assemble into capsids, package DNA at levels similar to wild type, endocytose 
into cells, and once in the cell, traffic to a perinuclear region in the vicinity of the Golgi 
apparatus.  These mutants display differences in their patterns of localization and 
transduction.  Mutations in BR1- reduce infectivity and result in abnormally concentrated 
Golgi localization.  Mutations in BR2- and BR3- have an even greater negative effect on 
infectivity and capsids display more diffuse cellular localization.  Remarkably, one mutant 
(BR3+K) is able to carry its genome to the nucleus, but is 10 to 100-fold less infectious than 
rAAV2 in HEK-293 and HeLa cells.  We hypothesize that the BR3+K capsid is unable to 
uncoat, either due to a high affinity to the nucleolus (which is provides a stable environment 
for the virion (Johnson and Samulski, 2009)), or to the extra positive charge prohibiting DNA 
release.  Taken together, our results highlight the complex functional duality of the capsid.  
The capsid proteins form a shell to protect the genome, they determine receptor binding 
preferences, direct steps in subcellular trafficking, and ultimately must be flexible enough to 
release the genome in an appropriate environment.    
With this work we have also touched on a general phenomenon of how AAV exploits 
conditions of subcellular stress.  We have focused on subcellular stress associated with 
expression of misfolded proteins, since diseases such as cystic fibrosis, alpha-antitrypsin 
deficiency, and Parkinson’s disease have all been linked to misfolded proteins and have been 
targeted in AAV clinical trials.  In support of our hypothesis, we found rAAV2 transduction 
to be roughly a log order higher in cells expressing misfolded ΔF508 CFTR than in control 
cells (Figs 26 & 27).  We have also determined that perinuclear accumulation of AAV during 
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infection is oriented toward the MTOC (Fig 25A).  In this location, with the abundance of 
proteasomes, late endosomes, lysosomes, and autophagosomes, we speculate AAV is marked 
for degradation similar to misfolded proteins (Wigley et al., 1999).  Polyubiquitination of 
misfolded proteins is a hallmark signal that leads to their proteasomal degradation.  
Researchers at the University of Iowa have demonstrated that AAV can be ubiquitinated 
during in vitro reactions and during infection (Yan et al., 2002).  This finding lends support 
to our hypothesis that cellular mechanisms used to clear misfolded proteins likely operate 
with dual function on AAV and other viruses.  Indeed, recent evidence from C. elegans 
points to a link between the ER stress response and innate immunity (Haskins et al., 2008).  
Our findings from Chapter 4 allude to a convergence of cellular pathways that handle 
aberrantly folded proteins and incoming AAV capsids.  Importantly, our results underscore 
the gravity with which the subcellular environment can influence infection efficiency, and 
encourage a thorough evaluation of these factors when considering specific disease targets 
for gene therapy. 
 
Supporting evidence and tangential experiments 
The mechanisms that govern transduction efficiency in vitro and in vivo are beginning 
to be elucidated for AAV.  In some cases a particular serotype will transduce much more 
efficiently in vivo compared to infection efficiency in tissue culture.  AAV8 is a prototypical 
example; it is heralded as one of the best capsids for targeting liver tissue in vivo and capable 
of transducing ~100% of mouse hepatocytes after portal vein or tail vein injection (Nakai et 
al., 2005).  In contrast, AAV8 does not efficiently transduce cells in tissue culture.  To 
determine if our panel of mutant virions transduced differently in vivo than in HEK-293 and  
  130 
 
Fig 34. BR3+K is able to transduce liver in vivo and HepG2 cells in culture.  A. rAAV2 
or mutant virions (1010 vg) were administered by tail vein injection to female balb/c mice that 
were approximately two months old.  1 week and 2 weeks post-injection, luciferin was 
administered intraperitonealy and bioluminescent luciferase activity was visualized on an 
IVIS 100.  B. Regions of interest were identified using Living Image software and photons 
per second per cm2 were quantified for 3 or 4 mice from each group.  Group averages and 
standard deviations are displayed on the graph.  C.  A luciferase assay of transduction was 
performed in HepG2 cells similar to those done in HEK-293 and HeLa cells.  Transduction 
profiles for all recombinant virions except BR3+K are similar between HEK-293, HeLa, 
HepG2, and liver tissue in vivo.  We observe BR3+K to transduce at least as well as rAAV2 
in HepG2 cells and liver tissue in vivo. 
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HeLa cells we administered 1010 vg by tail vein injection to female balb/c mice.  At 1 week 
and 2 weeks post-injection, we visualized bioluminescence of the luciferase reporter in the 
liver of these mice (Fig 34A).  Transduction profiles closely matched those observed in vitro 
except for mutant BR3+K, which produced transgene expression as high as rAAV2 (Fig 
34B). 
One explanation for this effect is that species-specific restriction factors present in 
human cells prevent delivery of BR3+K genomes.  An example of species-specific restriction 
can be seen in retroviruses, where HIV-1 infection can be blocked in human cell lines with 
rhesus monkey TRIM5α, which blocks infection of HIV-1 but not simian immunodeficiency 
virus, in Old World monkeys (Stremlau et al., 2004).  The possibility of species-specific 
restriction of BR3+K was eliminated when we discovered these mutant virions transduced 
HepG2 cells in culture, which are transformed liver cells of human origin.  We observe 
BR3+K to transduce at least as well as rAAV2 in HepG2 cells and liver tissue in vivo, 
prompting the idea that infection is restricted in a cell-specific manner. 
In line with our hypothesis that AAV exploits conditions of cellular stress, numerous 
pharmacologicals that impact the subcellular stress response have been used to potentiate 
transduction of rAAV.  We have tested whether the drug treatments used in Chapters 2 and 4 
will rescue the panel of mutant virions we generated for Chapter 3 in hopes of gaining a 
greater understanding of how these mutants are deficient and also where these drugs act to 
influence infection.  Here we show mutant virions respond in a variety of ways to the 
proteasome inhibitor MG132, the Hsp90 inhibitor radicicol, the autophagy inhibitor 3-
methyladenine, and the genotoxic agent hydroxyurea (HU) (Fig 35).  In addition to the 
unique  
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Fig 35. Mutant virions display differential responses to pharmacologicals.   A luciferase 
assay of transduction was performed to compare the effects of various drug treatments on 
mutant virions.  As shown in Chapter 3, the proteasome inhibitor MG132 potentiates 
transduction of rAAV2, BR1-, and BR2+K.  The Hsp90 inhibitor, radicicol, affects 
transduction in a similar pattern.  A specific inhibitor of autophagy, 3-methyladenine, was the 
only treatment found to increase transduction of BR2-.  The genotoxic agent, hydroxyurea, 
which acts as an ADP ribosylation factor inhibitor, only had significant effects on rAAV2, 
but mildly increased transduction of BR1-, BR2-, and BR2+K.  
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characteristics of BR3+K being largely non-responsive to enhancement, the most interesting 
of these effects are on the BR2- mutant, which will be discussed later.  
Our conclusions from Chapter 2 mention separate pathways in the nucleus can be 
taken by rAAV2:  a pathway that results in nucleolar accumulation and a pathway that leads 
to nucleoplasmic mobilization.  Capsids can be driven to accumulate in the nucleolus if 
continuously administered at high particle numbers or infection occurs in the presence of 
proteasome inhibition.  Capsids can be routed to the second pathway after pretreating cells 
with HU, resulting in mobilization to the nucleoplasm.  Taken together with our studies on 
mutant virions we can see how capsid components intersect with these two pathways, 
specifically in the case of BR3+K. 
To build on these findings, we have infected HeLa cells with rAAV2 or BR3+K for 
16hr (20,000vg/cell) and prepped samples for confocal immunofluorescence to determine if 
HU will mobilize mutant virions to the nucleoplasm.  Z-stacked sections were processed for 
3D rendering using Volocity software as described in previous chapters to depict capsids 
(green), nucleolin (red), and nuclei (blue) (Fig 36).  As the channels for the nucleus and 
nucleolus are digitally subtracted (panels ii through iv) we can identify rAAV2 and BR3+K 
virions in the nucleolus when infection was performed in the presence of MG132 (Fig 36, 
white arrows).  However, only rAAV2 capsids are affected by HU pre-treatment and are 
found to mobilize to the nucleoplasm (Fig 36, white arrowhead). This raises questions about 
the specifics of how nuclear trafficking may or may not lead to productive infection.  
Proteasome inhibitors will drive accumulation of BR3+K virions in the nucleolus, but do not 
increase transduction.  Thus, nuclear entry is not sufficient for successful transduction, and 
suggests the capsid must transition to the nucleoplasm in order to complete genome delivery.  
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Fig 36. HU treatment does not mobilize BR3+K capsids to the nucleoplasm.  To 
visualize whether mutant BR3+K capsids could be mobilized into the nucleoplasm in 
response to HU, we fixed and stained infected HeLa cells for indirect immunofluorescence of 
capsids (green), nucleolin (red), and nuclei (blue).  Roughly 40 confocal sections that span 
5µm were stacked and rendered in 3-dimensions using Volocity software (i).  The blue 
channel representing the nucleus was digitally gated (ii, iii), to reveal the nuclear interior.  
Along with increasing the zoom, the red channel was gated (v) to show nucleolar 
accumulation (white arrows) or nucleoplasmic mobilization (white arrowhead) of vector. 
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For several years now, subcellular trafficking of AAV has been studied upstream of 
nuclear entry.  Although the details are not yet in focus, a general route has been established 
from virus binding, to endocytosis, to perinuclear accumulation that depends on activation of 
Rac1 and phosphatidylinositol-3 kinase (Sanlioglu et al., 2000).  In our studies a significant 
amount of rAAV capsids were detected in the vicinity of the Golgi apparatus, which has been 
documented in other studies (Bantel-Schaal et al., 2002; Pajusola et al., 2002). The majority 
of VP1/VP2 exposure can be colocalized using Mab A69 with Golgi markers (data not 
shown).  It should be noted that the Mab A1, which specifically detects VP1 N-termini, could 
not be used for immunofluorescence in HeLa cells due to extremely high background 
staining of mitochondria in uninfected cells. 
In our studies we have not determined the specific vesicular compartment where VP1 
exposure occurs.  Research on CPV suggests VP1 exposure is triggered in an endosome, 
since blocking endosomal maturation or formation of the Golgi with drug treatments does not 
prevent capsids from translocating VP1 (Vihinen-Ranta et al., 2000).  So a likely scenario is 
that VP1 translocates to the capsid exterior in an endosomal compartment and then default 
sorting signals eventually result in delivering the endosomal contents to the Golgi apparatus 
or other compartment.  The fact that VP3only and 75HD/AN particles are found to traffic to 
the Golgi means this sorting event is not dependent on an active PLA2 domain.  However, 
Golgi membranes are known to be a primary target for endogenous cytosolic PLA2 activity 
(Ghosh et al., 2006).  PLA2 propensity to cleave phospholipids into arachadonic acid is 
typically regulated by both intracellular Ca2+ levels and phosphorylation of residues near the 
catalytic domain of the PLA2.  Not surprisingly, the N-terminus of VP1 contains several 
potential phosphorylation sites and a GXG calcium binding site (Fig 6).  Finding capsids 
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localized with exposed VP1 N-termini at the Golgi could be interpreted as the virus 
attempting to target an area where the chance of PLA2-mediated membrane disruption is 
high.  Future studies looking at how AAV trafficking and viral-associated PLA2 activity is 
sensitive to calcium flux would prove valuable.  In addition we are beginning to probe the 
significance of Golgi localization using siRNA-mediated knockdown of specific proteins 
involving in sorting in and out of the Golgi.  Two potential candidates that affect AAV 
transduction in preliminary siRNA screens are KDEL-R3 and Cop-β, which are involved in 
retrograde transport from the Golgi to the ER (data not shown). 
In the same vein, we have discovered that a bacterial toxin from pseudomonas 
aeruginosa, exotoxin A (ExoA) will dramatically potentiate nucleolar accumulation of 
rAAV2 (Fig 37).  Using confocal immunofluorescence microscopy we found that ExoA is 
similar to MG132 in that a significant percentage of capsids (green) are shunted to the 
nucleolus (red) during infection.  After internalization ExoA traffics through Rab9 
independent and dependent pathways to reach the Golgi (Smith et al., 2006).  From there the 
toxin exploits retrograde transport to reach the ER (Jackson et al., 1999), but in the process 
can enable translocation of other macromolecules into the cytoplasm (Liao et al., 2005; Mere 
et al., 2005).  ExoA inhibits protein translation, so we have not been able to demonstrate a 
corresponding effect on transduction, but in light of its trafficking patterns we can infer that 
AAV undertakes a similar route through the Golgi to reach the cytosol.  
 
Implications and future directions 
Discovering how viruses transition from the cell surface to delivering their genetic 
material inside the host is a central aspect of virology research that has led to many advances  
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Fig 37. Exotoxin A potentiates nucleolar accumulation of virions.  Using indirect 
immunofluorescence we demonstrate that the bacterial toxin, ExoA (10µM), potentiates 
nucleolar accumulation of rAAV.  Intact capsids (green) are shown to colocalize with 
nucleolin (red) in the nucleolus. 
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in cell biology.  In evolutionary terms, a virus would derive great benefit from doing little to 
alarm the host cell and only propagate during favorable conditions.  Although AAV is non-
pathogenic, it is impossible for the cell to become aware of that property a priori, and so a 
natural course of action would be to treat the virus as a threat.  In this light, a virus has 
garnered evolutionary intelligence if it has adapted to lie dormant in a subcellular 
compartment such as the nucleolus and only mobilize to a productive nucleoplasmic region 
when gene delivery has a high probability of success.  This concept resonates particularly 
well with AAV, because as a dependovirus it can only replicate in the presence of a helper 
virus or when a subcellular stress response has been elicited.   
An unanswered question in AAV trafficking is whether capsids either avoid or exploit 
autophagy.  The two primary modes of degradation in mammalian cells are the ubiquitin 
proteasome system and the lysosome/autophagosome system, the first degrades proteins with 
short half-lives and the second generally degrades proteins that do not experience rapid 
turnover.  Dr. John Engelhardt was the first to convincingly demonstrate that the proteasome 
system influences AAV biology (Duan et al., 2000), but since capsids are not readily turned 
over in certain cells (Stieger et al., 2009), it seems plausible they are even more likely to be 
affected by autophagy.  We have demonstrated in Chapter 4 of this dissertation that 3-
methyladenine, an inhibitor of autophagy, can potently increase transduction of AAV2 in 
HeLa cells by at least 10-fold (Fig 1).   
Here we show that by stimulating autophagy with the microtubule depolymerizing agent 
vinblastine, we can restrict perinuclear accumulation of rAAV2 (Fig 38).  
Immunofluorescence microscopy depicts an increase in the autophagosome marker, Atg7, in 
response to vinblastine treatment.  These autophagosomes (red) are located proximal to 
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Fig 38. Vinblastine stimulates autophagy and restricts perinuclear accumulation of 
rAAV2.  Confocal immunofluorescence of infection in HeLa cells depicts perinuclear 
accumulation of most incoming capsids (green).  Vinblasine, a microtubule-stabilizing agent 
that induces autophagy, restricts perinuclear targeting of capsids (white arrows) and 
upregulates expression of the autophagosome marker, Atg7 (red). 
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rAAV capsids (green) and are pulled away from the nucleus.  Thus far we have not 
developed a clear picture of how autophagic degradation may influence AAV trafficking and 
infection, but there are clues from the BR2- mutant virion.  As depicted in this chapter, BR2- 
is rescued in the presence of 3-methyladenine and transduces at levels similar to untreated 
rAAV2 (Fig 35).  Research in cell biology has suggested that the ubiquitin proteasome 
system and autophagy are linked (Ding et al., 2007); inhibition of the proteasome will lead to 
a corresponding activation of autophagy to compensate for the loss of degradative capacity.  
This phenomenon is observed in the transduction profile of BR2-.  Transduction of BR2- 
increases when autophagy is inhibited with 3-methyladenine, and decreases when the 
proteasome is inhibited with MG132 (decrease is insignificant in HEK-293 cells but ~80% in 
HepG2 cells, data not shown).  Oddly enough, both treatments increase transduction of 
rAAV2, which suggests a certain promiscuity of subcellular trafficking preferences could 
exist with wild-type virus.    
A central focus of this work was on pharmacological modulation of AAV trafficking 
and transduction.  We can conclude that proteasome inhibitors influence transduction through 
an effect on capsid trafficking or genome processing.  Partially defective mutants such as 
BR2- and BR3+K display low basal levels of transduction but are not potentiated by MG132, 
indicating proteasome inhibition has little effect on transcription, translation, or reporter 
protein stability.  An issue this dissertation does not address is how effectiveness of 
proteasome inhibitors or other drugs could be dependent on the capsid/genome structural 
relationship or the number of capsids present within the cell.  It has previously been shown 
that non-infectious AAV packaging larger-than-wild-type genomes can be rescued with 
proteasome inhibitors (Grieger and Samulski, 2005).  Proteasome inhibitors have been shown 
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to have differential effects on AAV serotypes 1, 2, 5, 7, and 8 that all were packaged with 
AAV2 ITRs (Wu et al., 2006; Yan et al., 2006).  This has been interpreted as a capsid-
specific transduction enhancement, but from these publications we cannot rule out the 
possibility that proteasome inhibitors also act at the level of genome processing or depend on 
capsid/genome connections.   
One of the most striking results obtained from this work was the identification of 
BR3+K as a cell-type specific uncoating mutant.  BR3+K is capable of entering the nucleus 
of HeLa cells similar to rAAV2.  Proteasome inhibitors will potentiate nucleolar 
accumulation of BR3+K virions, but do not potentiate transduction. On the other hand, 
adenovirus can augment transduction of BR3+K at the same ratios as wild type rAAV2.  
From this we can deduce proteasome inhibitors operate upstream of uncoating to improve 
transduction. Interestingly, we have also discovered that proteasome inhibitors block Ad-
mediated transduction enhancement (data not shown).  It is known that the ubiquitin 
proteasome system is required for the E1b-E4OFR6 complex to function properly during Ad 
infection (Corbin-Lickfett and Bridge, 2003), which futher supports our conclusions that Ad-
mediated enhancement of rAAV2 and BR3+K is dependent on E4ORF6 activity.  
Aside from pharmacological stressors and the favorable conditions created during 
coinfection, we have reported that subcellular stress associated with misfolded proteins can 
significantly enhance rAAV2 transduction.  Misfolded protein processing is in constant flux 
as the cell attempts to balance the system between refolding, degradation, and aggregation-
prone states (Ding and Yin, 2008).  Exacerbating the system leads to a myriad of 
consequences.  Misfolded protein disorders have been associated with induction of cell 
stress, proteasome inhibition, chaperone sequestration, transcription/cell cycle factor 
  142 
sequestration, calcium overload, oxidative stress, glutamate overload, mitochondrial 
dysfunction, and cell death (Gregersen et al., 2006).  While we have not identified which of 
these outcomes directly impacts AAV biology, we have narrowed the focus on events in 
subcellular trafficking after empirically excluding effects on cell surface attachment, 
transcription, and translation.  For further study we recommend testing a wide range of 
misfolded proteins associated with disease to help determine if this effect depends on specific 
cellular factors.  Preliminary results with misfolded alpha antitrypsin and huntingtin’s 
proteins suggest exploitation of misfolded proteins could be a generalized phenomenon.  
Although beyond the scope of this dissertation, it would not be surprising to find a 
pathogenic viral component to be partially responsible for the progression of misfolded 
protein disorders.  Notably, it has been postulated that a correlation exists between viral 
infections and progression of amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s 
disease and prion transmission (Leblanc et al., 2006; Perry et al., 2007).  
In summary, with these studies we have refined our understanding of AAV2 
trafficking dynamics and have identified cellular parameters that mobilize virions in the 
nucleus and significantly influence AAV infection.  Additionally, the BR3+K mutant and 
other vectors we have generated in this study should prove valuable as we continue to dissect 
the trafficking profile of AAV with new molecular tools.  Furthermore, we have described 
how exploitation of subcellular stress is a property that is relevant to the natural survival of 
AAV and ultimately will be a crucial factor to consider when targeting diseased cells with 
these vectors. 
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